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cost-effectiveness, in different patient groups, of the
use of 64-slice or higher computed tomography (CT)
angiography, instead of invasive coronary angiography
(CA), for diagnosing people with suspected coronary
artery disease (CAD) and assessing people with 
known CAD. 
Data sources: Electronic databases were searched
from 2002 to December 2006. 
Review methods: Included studies were tabulated and
sensitivity, specificity, positive and negative predictive
values calculated. Meta-analysis models were fitted
using hierarchical summary receiver operating
characteristic curves. Summary sensitivity, specificity,
positive and negative likelihood ratios and diagnostic
odds ratios for each model were reported as a median
and 95% credible interval (CrI). Searches were also
carried out for studies on the cost-effectiveness of 
64-slice CT in the assessment of CAD.
Results: The diagnostic accuracy and prognostic studies
enrolled over 2500 and 1700 people, respectively. The
overall quality of the studies was reasonably good. In
the pooled estimates, 64-slice CT angiography was
highly sensitive (99%, 95% CrI 97 to 99%) for patient-
based detection of significant CAD (defined as 50% or
more stenosis), while across studies the negative
predictive value (NPV) was very high (median 100%,
range 86 to 100%). In segment-level analysis compared
with patient-based detection, sensitivity was lower
(90%, 95% CrI 85 to 94%, versus 99%, 95% CrI 97
to 99%) and specificity higher (97%, 95% CrI 95 to
98%, versus 89%, 95% CrI 83 to 94%), while across
studies the median NPV was similar (99%, range 95 to
100%, versus 100%, range 86 to 100%). At individual
coronary artery level the pooled estimates for sensitivity
ranged from 85% for the left circumflex (LCX) artery
to 95% for the left main artery, specificity ranged from
96% for both the left anterior descending (LAD) artery
and LCX to 100% for the left main artery, while across
studies the positive predictive value (PPV) ranged from
81% for the LCX to 100% for the left main artery and
NPV was very high, ranging from 98% for the LAD
(range 95 to 100%), LCX (range 93 to 100%) and right
coronary artery (RCA) (range 94 to 100%) to 100% for
the left main artery. The pooled estimates for bypass
graft analysis were 99% (95% CrI 95 to 100%)
sensitivity, 96% (95% CrI 86 to 99%) specificity, with
median PPV and NPV values across studies of 93%
(range 90 to 95%) and 99% (range 98 to 100%),
respectively. This compares with, for stent analysis, a
pooled sensitivity of 89% (95% CrI 68 to 97%),
specificity 94% (95% CrI 83 to 98%), and median PPV
and NPV values across studies of 77% (range 33 to
100%) and 96% (range 71 to 100%), respectively.
Sixty-four-slice CT is almost as good as invasive CA in
terms of detecting true positives. However, it is
somewhat poorer in its rate of false positives. It seems
likely that diagnostic strategies involving 64-slice CT will
still require invasive CA for CT test positives, partly to
identify CT false positives, but also because CA provides
other information that CT currently does not, notably
details of insertion site and distal run-off for possible
coronary artery bypass graft (CABG). The high
sensitivity of 64-slice CT avoids the costs of unnecessary
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Systematic review of the clinical effectiveness and 
cost-effectiveness of 64-slice or higher computed tomography
angiography as an alternative to invasive coronary angiography 
in the investigation of coronary artery disease
G Mowatt,1* E Cummins,2 N Waugh,2 S Walker,3 J Cook,1 X Jia,1 GS Hillis4
and C Fraser1
1 Health Services Research Unit, Institute of Applied Health Sciences, University of Aberdeen, UK
2 Department of Public Health, University of Aberdeen, UK
3 Radiology Department, Aberdeen Royal Infirmary, UK
4 Cardiology Department, Aberdeen Royal Infirmary, UK
* Corresponding authorCA in those referred for investigation but who do not
have CAD. Given the possible, although small,
associated death rate, avoiding these unnecessary CAs
through the use of 64-slice CT may also confer a small
immediate survival advantage. This in itself may be
sufficient to outweigh the very marginally inferior rates
of detection of true positives by strategies involving 64-
slice CT. The avoidance of unnecessary CA through the
use of 64-slice CT also appears likely to result in overall
cost savings in the diagnostic pathway. Only if both the
cost of CA is relatively low and the prevalence of CAD
in the presenting population is relatively high (so that
most patients will go on to CA) will the use of 64-slice
CT be likely to result in a higher overall diagnostic cost
per patient.
Conclusions: The main value of 64-slice CT may at
present be to rule out significant CAD. It is unlikely to
replace CA in assessment for revascularisation of
patients, particularly as angiography and angioplasty 
are often done on the same occasion. Further 
research is needed into the marginal advantages and
costs of 256-slice machines compared with 64-slice 
CT, the usefulness of 64-slice CT in people with
suspected acute coronary syndrome, the potential of
multislice computed tomography to examine plaque
morphology, the role of CT in identifying patients
suitable for CABG, and the concerns raised about
repetitive use, or use of 64-slice or higher CT
angiography in younger individuals or women of
childbearing age.
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Background
Coronary artery disease (CAD) is a major cause of
mortality and ill-health. Coronary angiography
(CA) is the gold standard for diagnosing CAD.
However, CA is an invasive and expensive
procedure, with a small (0.1–0.2%) risk of major
complications such as death, myocardial infarction
and stroke. A primary non-invasive technique for
the diagnosis of CAD is therefore highly desirable.
The emergence of multislice computed
tomography (MSCT) in the past decade and the
introduction of 64-slice systems in 2004 have
overcome many of the image quality issues that
affected conventional CT systems. The technical
factors that enhance image quality in 64-slice CT
also result in a higher radiation dose, although the
use of electrocardiogram (ECG)-dependent dose
modulation can reduce this by 30–50%. 
Objectives
This review aims to assess the clinical effectiveness
and cost-effectiveness, in different patient groups,
of the use of 64-slice or higher CT angiography,
instead of invasive CA, for diagnosing people 
with suspected CAD and assessing people with
known CAD. 
Methods
Electronic searches were undertaken to identify
published and unpublished reports. Searches were
restricted to the years 2002 onwards and to
English-language reports. The date of the last
searches was December 2006. 
The types of studies considered were randomised
controlled trials, non-randomised comparative
studies or case series in which adults received 
64-slice or higher CT angiography, with invasive
CA or long-term follow-up as the reference
standard. Myocardial perfusion scintigraphy (MPS)
was considered as a comparator test. Diagnostic
accuracy studies had to report the absolute
numbers of true and false positives and negatives,
or sensitivity and specificity. Prognostic studies had
to provide information on the likelihood of future
cardiac events. 
One reviewer screened the titles (and abstracts if
available) of all reports identified by the search
strategy. Two reviewers independently extracted
details from the included full-text studies and
assessed their quality using a modified version of
the QUADAS instrument. 
The results of the individual studies were
tabulated and sensitivity, specificity, positive and
negative predictive values calculated. Separate
summary receiver operating characteristic (SROC)
curves were derived for various levels of analysis.
Meta-analysis models were fitted using hierarchical
summary receiver operating characteristic
(HSROC) curves. A symmetric SROC model was
used. Summary sensitivity, specificity, positive and
negative likelihood ratios and diagnostic odds
ratios (DORs) for each model were reported as a
median and 95% credible interval (CrI). 
Searches were also carried out for studies on the
cost-effectiveness of 64-slice CT in the assessment
of CAD.
Results
Twenty-one diagnostic accuracy studies reported as
full-text papers and 20 reported as abstracts, along
with one prognostic study reported as a full-text
paper and four reported as abstracts, met the
inclusion criteria for the review. The diagnostic
accuracy and prognostic studies enrolled over
2500 and 1700 people, respectively. As measured
by the modified QUADAS checklist, the overall
quality of the full-text diagnostic accuracy studies
was reasonably good. 
In the pooled estimates, 64-slice CT angiography
was highly sensitive (99%, 95% CrI 97 to 99%) for
patient-based detection of significant CAD
(defined as >50% or 50% stenosis), while across
studies the negative predictive value (NPV) was
very high (median 100%, range 86 to 100%). In
the 13 full-text studies included in the pooled
estimates, in terms of patient-based detection, 11
(2%) of 718 patients could not be assessed owing
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to unevaluable CT scans (median across studies
0%, range 0 to 6%). Three studies reported that
all vessels smaller than 1.5 mm were excluded
from analysis. 
In segment-level analysis compared with patient-
based detection, sensitivity was lower (90%, 95%
CrI 85 to 94%, versus 99%, 95% CrI 97 to 99%)
and specificity higher (97%, 95% CrI 95 to 98%,
versus 89%, 95% CrI 83 to 94%), while across
studies the median NPV was similar (99%, range
95 to 100%, versus 100%, range 86 to 100%). At
individual coronary artery level the pooled
estimates for sensitivity ranged from 85% (95%
CrI 69 to 94%) for the left circumflex (LCX) artery
to 95% (95% CI 84 to 99%) for the left main
artery, specificity ranged from 96% for both the
left anterior descending (LAD) artery (95% CrI 91
to 98%) and LCX (95% CrI 92 to 99%) to 100%
(95% CrI 99 to 100%) for the left main artery,
while across studies the positive predictive value
(PPV) ranged from 81% (range 56 to 100%) for
the LCX to 100% (range 90 to 100%) for the left
main artery and NPV was very high, ranging from
98% for the LAD (range 95 to 100%), LCX (range
93 to 100%) and right coronary artery (range 94
to 100%) to 100% (all five studies) for the left
main artery. The pooled estimates for bypass graft
analysis were 99% (95% CrI 95 to 100%)
sensitivity, 96% (95% CrI 86 to 99%) specificity,
with median PPV and NPV values across studies of
93% (range 90 to 95%) and 99% (range 98 to
100%), respectively. This compares with, for stent
analysis, a pooled sensitivity of 89% (95% CrI 68
to 97%), specificity 94% (95% CrI 83 to 98%), and
median PPV and NPV values across studies of 77%
(range 33 to 100%) and 96% (range 71 to 100%),
respectively. 
None of the studies reporting the diagnostic
accuracy of 64-slice CT included MPS as a
comparator. In two systematic reviews of single-
photon emission computed tomography (SPECT)
MPS, sensitivity was reported as a median of 81%
across studies (range 63 to 93%) or pooled
estimate of 87% [fixed-effect model, 95%
confidence interval (CI) 86 to 88%], while
specificity was reported as a median of 65% across
studies (range 10 to 90%) or pooled estimate of
64% (fixed-effect model, 95% CI 60 to 68%). 
Three of the five prognostic studies included low-
risk patients with suspected acute coronary
syndrome and all reported that 64-slice CT
angiography had very good NPV in short-term
(mostly 30-day) follow-up. Of the other two
studies, one reported that in the year following 
the introduction of 64-slice CT the rates of
increase in diagnostic catheterisation volume and
percutaneous coronary interventions had not been
significantly affected, while the other reported 
that in the 6 months following the introduction 
of 64-slice CT invasive CA was avoided in 398
(82%) of 486 patients who would have received 
the test. 
Cost-effectiveness
No studies of the cost-effectiveness of 64-slice CT
in assessing CAD were found. However, some of
the reviews and previous health technology
assessments did identify some of the cost-
effectiveness issues that are likely to arise. Other
studies examined the cost-effectiveness of other
investigations against angiography, such as
exercise testing and positron emission tomography
scanning, and these provided useful background.
Sixty-four-slice CT appears to be as good as but
cheaper than MPS for the diagnosis of CAD.
Consequently, 64-slice CT is likely to be a cost-
effective replacement for MPS in diagnosing CAD.
Sixty-four-slice CT is almost as good as invasive
CA in terms of detecting true positives. However,
it is somewhat poorer in its rate of false positives.
Consequently, diagnostic strategies involving 
64-slice CT angiography will result in a number of
false positives (not in terms of whether CAD is
present, but in terms of quantifying the degree of
stenosis). It seems likely that diagnostic strategies
involving 64-slice CT will still require invasive CA
for CT test positives, partly to identify CT false
positives, but also because CA provides other
information that CT currently does not, notably
details of insertion site and distal run-off for
possible coronary artery bypass graft (CABG).
The high sensitivity of 64-slice CT avoids the costs
of unnecessary CA in those referred for
investigation but who do not have CAD. Given the
possible although small associated death rate,
avoiding these unnecessary CAs through the use of
64-slice CT may also confer a small immediate
survival advantage on the presenting population.
This in itself may be sufficient to outweigh the
very marginally inferior rates of detection of true
positives by strategies involving 64-slice CT.
The avoidance of unnecessary CA through the use
of 64-slice CT also appears likely to result in
overall cost savings in the diagnostic pathway.
Only if both the cost of CA is relatively low and the
prevalence of CAD in the presenting population is
relatively high (so that most patients will go on to
Executive summaryCA) will the use of 64-slice CT be likely to result in
a higher overall diagnostic cost per patient.
Conclusions
Implications for practice
The proportion of CA that could be replaced by
64-slice CT is currently uncertain. Reduction in
CA would be mainly at the diagnostic end of the
pathway, in both elective assessment of chest pain
of possibly anginal origin, and assessment of
suspected acute coronary syndromes in some
patients with normal or equivocal ECGs and
negative troponin tests. In the emergency
situation, some hospital admissions might be
avoided. However, to do so, 64-slice CT would
need to be readily available, ideally on a 24-hour
basis, which is unlikely to be the case in most
hospitals. Some perfusion studies could also be
replaced by 64-slice CT angiography.
In summary, the main value of 64-slice CT may at
present be to rule out significant CAD. It is
unlikely to replace CA in assessment for
revascularisation of patients, particularly as
angiography and angioplasty are often done on
the same occasion.
One issue is whether to acquire 64-slice CT
systems or wait until 256-slice systems become
available. Evidence on 256-slice CT is currently
sparse and mostly commercial in origin. However,
it is unlikely that performance would be less good,
and if the cost difference between 64- and 256-
slice machines were small, it could be argued that
the NHS should bypass 64-slice machines in
favour of 256-slice ones. However, there must
come a time when the extra data do not provide
additional clinical benefit, although it is as yet
unclear when that point will be reached.
Recommendations for research
The following areas should be addressed by
further research.
• The marginal advantages and costs of 256-slice
machines compared with 64-slice CT.
• The usefulness of 64-slice CT in people with
suspected ACS. This review identified only a few
studies, mostly reported as abstracts, containing
small numbers of patients, most of whom were
low risk and would be expected to have
relatively low event rates. 
• The potential of MSCT to examine plaque
morphology.
• The role of CT in identifying patients suitable for
CABG. CT can identify stenoses, but research is
needed into its ability to identify distal insertion
sites and adequacy of run-off. Such research
could be done by conducting CT in a large group
of patients before CABG (with preceding invasive
CA), with assessment of suitability for CABG by
observers unaware of the invasive CA results and
arterial findings at CABG.
• Concerns raised about repetitive use, or use of
64-slice or higher CT angiography in younger
individuals or women of childbearing age.
Health Technology Assessment 2008; Vol. 12: No. 17
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The primary aim of this review is to assess the
clinical effectiveness and cost-effectiveness, in
different patient groups, of using 64-slice or
higher computed tomography (CT) angiography,
instead of invasive coronary angiography (CA), for
diagnosing people with suspected coronary artery
disease (CAD) and assessing people with known
CAD. However, a further consideration is whether
64-slice CT could replace some myocardial
perfusion scanning.
The disease
CAD is a major cause of mortality and ill-health in
the UK. It presents in different ways, with the
most common being angina and myocardial
infarction (MI). The underlying cause is a 
process called atherosclerosis, which leads to
narrowing of the coronary arteries, restricting 
the blood flow to the heart muscle. During
exercise, if the blood flow to the heart muscle
cannot increase enough, angina occurs. This leads
to treatment and/or referral for cardiological
assessment.
The diagnosis of angina is usually made on
clinical history and simple examinations such as
electrocardiogram (ECG) or exercise ECG testing.
Treatment options include:
● symptomatic measures such as nitrates, 
-blockers and calcium antagonists
● antithrombotic drugs such as aspirin,
dipyridamole and clopidrogel, to reduce the
chance of a coronary thrombosis forming on the
atheromatous plaque
● lipid-lowering drugs such as statins, to lower the
risk of MI and reduce or prevent progression of
atherosclerosis
● angioplasty with or without (but nowadays,
usually with) stenting; angioplasty is now often
referred to as percutaneous coronary
intervention (PCI)
● coronary artery bypass graft (CABG) surgery
● general diet and lifestyle advice.
PCI and CABG may be used for two purposes:
first, to relieve symptoms when medical therapy
fails to achieve that and, secondly, in some groups,
to reduce the chance of a heart attack (MI). About
twice as many people now have angioplasty as
CABG. Increasingly, angioplasty is done at the
same time as the initial angiography.
Before either CABG or angioplasty, the state of
the arteries is examined by coronary angiography.
This involves passing a fine catheter into each
artery in turn, injecting a dye and visualising the
arteries by X-ray. A limiting factor in these
processes is that angiography facilities (catheter
laboratories) are limited. 
Angiography is used to assess the extent of the
CAD, identify significant stenoses (narrowings)
that may be the culprit lesions causing angina and
provide information on prognosis, in terms of
likelihood of future infarction and its severity.
Some patterns of disease such as left main or left
anterior descending (LAD) artery stenosis carry a
higher risk of death. The information from
angiography is used to decide whether to proceed
to angioplasty or CABG, and if the former, which
stenoses to dilate.
One of the constraints on angiography is space in
angiography rooms; another is cardiologist time.
Both will be under greater pressure if immediate
angioplasty becomes routine, as suggested by the
findings of a previous HTA review.1
The technology
CT has been developing rapidly in recent years.
Four-slice machines appeared in 1998, 16-slice in
2001 and 64-slice machines at the end of 2004.
The newer multidetector machines can produce
more images in less time, thereby increasing
throughput and decreasing the cost per patient. 
A previous HTA review2 is now well out of 
date. A recent HTA review3 examined the role 
of electron-beam computed tomography (EBCT)
in screening for CAD, but did not address the use
of the newer forms of CT in investigation of
suspected or symptomatic CAD.
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Chapter 1
BackgroundImaging of the heart is technically challenging
because of continuous motion during the cardiac
cycle. CA is the gold standard for the diagnosis of
CAD owing to its high temporal and spatial
resolution. However, it is an invasive and
expensive procedure, with a small (0.1–0.2%) risk
of major complications such as death, MI and
stroke.4 Previously, magnetic resonance imaging
(MRI) and EBCT were considered non-invasive
cardiac imaging modalities of choice, owing to
their high temporal resolution, but neither has
been used in routine clinical practice because of
limited availability in specialist centres. A primary
non-invasive technique for the diagnosis of CAD is
therefore highly desirable.
The emergence of multislice computed
tomography (MSCT) in the past decade and the
introduction of 64-slice systems in 2004 have
overcome many of the image quality issues that
plagued conventional CT systems. This newest
generation of CT systems acquires 64 × 0.6-mm
slices in a single tube rotation of just 330 ms.5
Coupled with hard and software advances, 64-slice
CT has become a viable proposition in non-
invasive imaging of cardiac vascular anatomy and
pathology. 
CT image quality depends on the patient’s ability
to suspend respiration. With 64-slice CT, the
major benefit of the increased number of slices
acquired and the improved temporal resolution
(time required to acquire data for one image) is a
shorter overall scan time. Currently, this has been
reduced to 8 seconds.6 Image acquisition is
completed within a single breath-hold, which
reduces respiratory motion and improves image
quality. The spatial resolution (the number of
pixels of information that make up a digital
image) of 64-slice CT is also superior to
conventional CT. This allows better assessment of
smaller coronary arteries such as the distal LAD
and left circumflex (LCX) arteries. In addition,
there is less blooming artefact, the main cause of
false-positive results where partial volume
averaging effects of high-density calcific material
overestimate the degree of stenosis, and therefore
64-slice CT allows better assessment of calcified or
stented vessels.7
Following the acquisition of data the images are
reconstructed with a slice thickness of 0.75 mm, a
50% overlap between slices and a pixel matrix of
512 × 512. Although the thinner slice improves
the resolution of three-dimensional data sets and
the quality of reformatted images, it comes at the
cost of increased image noise, which can
significantly limit the diagnostic assessment of the
coronary arteries in patients with a body mass
index (BMI) of greater than 30. 
Heart rate also significantly influences the length
of coronary artery visualised without motion
artefact. Sixty-four-slice CT angiography uses ECG
gating techniques to capture data at points in the
cardiac cycle when cardiac motion is minimised,
usually in the mid to late diastolic phase.6 The
ECG signal is monitored and used prospectively to
trigger imaging or retrospectively to reconstruct
data from continuous acquisitions. However,
despite this technique motion artefact remains a
major technical problem with heart rates above 
70 beats per minute. In both studies and clinical
practice -blockers have been used to reduce the
heart rate, lengthen the period of diastole and
therefore minimise cardiac motion. In patients
with a contraindication to -blockade (e.g. chronic
obstructive pulmonary disease), calcium channel
blockers can be used as an alternative.
Image quality also depends on the volume of
contrast material within the coronary tree at the
time of imaging. CT angiography relies on the
intravenous administration of iodinated contrast
material, unlike conventional angiography in
which contrast is administered directly into the
coronary arterial tree. To ensure adequate contrast
enhancement, the contrast material is injected
intravenously and a bolus tracking technique used
to synchronise its arrival in the coronary arteries
with initiation of the examination. CT
angiography is performed with less iodinated
contrast material (average 80–100 ml) than
conventional angiography; however, the absolute
contraindication of hypersensitivity to iodinated
contrast agent remains in addition to the relative
contraindications of renal insufficiency, multiple
myeloma and phaeochromocytoma. CT
angiography, however, avoids the major
complications associated with arterial puncture,
plaque embolisation, serious bleeding and vessel
dissection, and provides highly detailed
information about the aorta, pulmonary artery
and veins, lungs and mediastinum, which may
prove useful in clinical practice for excluding
other causes of chest pain such as pulmonary
thromboembolism and thoracic aortic dissection.
The technical factors that enhance image quality
in 64-slice CT, namely high spatial and temporal
resolution, also affect the radiation dose received.
To obtain diagnostic image quality with the narrow
slice width and reduced scan time of 64-slice CT,
the number of photons received by the detector
Background
2array must be increased. This occurs by increasing
the tube current from 400–650 mAs typically used
in 16-slice CT to 500–950 mAs in 64-slice CT. This
results in an increased radiation exposure and
increased effective dose. A recent study by
Hausleiter and colleagues8 estimated the effective
dose to be 11.0 (SD 4.1) mSv for 64-slice CT. Use
of ECG-dependent dose modulation can reduce
the radiation dose by 30–50% during systole, when
the acquired data add little to coronary imaging.
This radiation exposure is comparable to 160
posterior–anterior (PA) chest films or three to four
times the average yearly effective dose of natural
background radiation (2.5 mSv). Alternative
methods to reduce radiation dose include
reducing tube kilovoltage; however, this is often to
the detriment of image quality and the high
radiation doses received remain an important
consideration of this choice of imaging modality.
Previous reports
Reviews
There have been some recent reviews, but the pace
of publication in this field means that they quickly
become out of date.
Stein and colleagues,9 in a high-quality review
published in 2006, found only one study of 64-
slice CT, because their literature search was up to
March 2005. The conclusions of their review were
that:
● MSCT had high sensitivity for detecting
significant stenosis
● sensitivity increased with number of detectors
● specificity also increased with increasing
number of detectors
● with a higher number of detectors, more
segments could be examined
● there was higher sensitivity for stenoses in
proximal and mid-segments of arteries.
Significant stenosis was defined as being 50% or
greater narrowing of the artery. This definition is
presumably based on assessment for
revascularisation. However, CT may be used for
other purposes. One could be to confirm or rule
out the presence of CAD, in which case much
lesser degrees of atherosclerosis and stenosis
would be relevant. Another could be to identify
high-risk plaques (i.e. those that are most likely to
provide the focus for a coronary thrombosis).
High-risk plaques may show little or no stenosis.
Hence, the sensitivity required will vary according
to the purpose of CT.
The term ‘segments’ refers to the part of the
artery, and is based on definitions by the American
Heart Association (AHA). Proximal includes the
parts of the arteries from their origins to the first
main branches, where the artery is widest. Distal
includes the sections after the largest branches
have come off, and where the artery is
progressively narrowing. The higher up (or more
proximal) a stenosis, the more dangerous it is,
because blockage would deprive a large part of the
heart muscle of its blood supply. Blockage of a
distal artery is less dangerous, partly because a
much smaller portion of muscle is affected, and
partly because at that level, there may be collateral
circulation from the distal branches of the other
coronary arteries. Hence, sensitivity at the distal
level could be seen as less important, but
awareness of the extent of distal disease is still
useful since it may predict the success of relieving
or bypassing a proximal stenosis.
The Technology Evaluation Center (TEC), which
is a joint service to Blue Cross/Blue Shield and
Kaiser Permanente in the USA, published another
high-quality review of cardiac CT in 2005.10
Searches were up to April 2005, and no studies of
CT with more than 16 slices were found. The
review assumed that negative CT would avoid the
need for invasive CA, and that positive CT would
be followed by angiography. It is possible that the
latter assumption may not apply with 64-slice CT.
CT failed to meet the TEC criteria, and in
particular criterion 2, which states that the
technology should improve health outcomes.
However, the report envisaged a more persuasive
case once 64-slice CT arrived.
The TEC report notes some weaknesses of the
literature. One is that results are often presented
in terms of number of arteries or segments
examined, rather than being based on patients.
Clinical decisions need the whole picture for the
patient. Secondly, results are often presented only
for ‘evaluable’ segments of arteries, which can give
a misleadingly good impression of the technology.
Thirdly, studies were often done in high-risk
patients, not representative of the groups in which
it may be used in future, such as those with only
suspected CAD.
The TEC report concluded that CT should not be
recommended because the criteria were not yet
met. One issue dealt with, albeit briefly, in the TEC
report, was the potential of CT to examine plaques.
As the report points out, plaque morphology is
important and if CT can assess the composition of
plaques and identify the lipid-rich unstable
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A report from the Andalusian Agency for
Healthcare Technology Assessment11 drew on the
TEC report, but added a review of some more
recent papers on 16-slice CT. Using patient-based
analysis (rather than artery-based), the 16-slice
studies reviewed gave sensitivities ranging from 86
to 97%, specificities from 49 to 87%, positive
predictive values (PPVs) of 84 to 90% and negative
predictive values (NPVs) of 53 to 95%. If the main
role of CT is to rule out the need for CA, then for
16-slice machines the low NPV is a problem. 
CT is very quick, and faster than CA, and so
probably much less expensive, as well as being less
invasive, although the radiation dose is higher
than the average 4–8-mSv exposure quoted by the
TEC report10 or the below 5% exposure quoted by
a British Cardiovascular Society Working Group
report12 for invasive angiography. The radiation
dose is also higher with 64-slice than 16-slice
(about 11 versus 6 mSv)8 but there are ways of
reducing the dose such as ECG-dependent dose
modulation and reduced tube voltage.8
Studies of 16-slice CT
While not strictly relevant to this review, which is
more concerned with 64-slice CT, past reviews or
studies of 16-slice can at least provide a baseline
impression, on the assumption that 64-slice will be
better.
Hoffman and colleagues13 compared 16-slice CT
with invasive CA in 103 patients with known or
suspected CAD, and produced patient-based
results for the sensitivity of detection of stenoses of
50% or more. Only 6% of images were not good
enough for diagnosis, mainly because of fast heart
rates. Segment-based sensitivity and specificity
were high at 95% and 98%, and NPV was 99%.
However, in the patient-based analysis, in 27% 
of cases there was incomplete coverage of the
whole coronary tree. In those with complete
coverage, CT identified 84% of those without
significant stenosis, as judged by invasive CA, 
and identified 97% of those with stenoses suitable
for revascularisation.
Kefer and colleagues14 compared both 16-slice CT
and MRI with CA in 52 patients with a high
probability of significant arterial disease. CT was
better than MRI, but both overestimated non-
significant stenosis and underestimated significant
(> 50%) stenosis. Sensitivity of CT was better in
larger vessels such as the left main and LAD, but
not so good in small branches of the LCX and
right coronary artery (RCA).
Kuettner and colleagues15 reported good results
with a more modern 16-slice CT machine, but did
not include CA, so there was no reference
standard.
More useful background comes from a good
Canadian Coordinating Office for Health
Technology Assessment (CCOHTA) review16 of the
clinical effectiveness (economics reported
separately). The review notes that there are several
manufacturers of MSCT: GE Medical Systems in
the USA, Philips in The Netherlands, Siemens in
Germany, and Shimadzu and Toshiba in Japan.
Much of the research comes from those countries.
The CCOHTA report was on all uses of CT. It
noted the rapid growth of CT in Canada, from
200 scanners in 1991 to 338 in 2004; a growth
rate of 70%. In January 2004, there were 11 CT
machines (publicly funded) per million
population.
The CCOHTA review16 identified five existing
reviews,17–21 but none of these covered 64-slice CT
(the latest references were from 2003), and most
received low-quality scores using a modification of
the Oxman and Guyatt criteria. The CCOHTA
review concluded that MSCT was “promising but
not yet superior to coronary angiography”.
Another thorough review from Canada,22 this time
from the Ontario Health Technology Advisory
Committee, in April 2005, was again a little too
early to provide data on 64-slice CT, since only
two abstracts could be found. It provides a good
review of 16-slice studies, and concluded that 16-
slice CT was not good enough to rule out the
presence of CAD.
Gaspar and colleagues23 provide both a brief
review and the results of their own experience of
using a variety of CT scanners in over 1000
patients. They provide one of the few accounts of
using a 40-slice scanner, noting that it had high
sensitivity of 95% on an arterial basis, but lower at
90% on a patient basis. Calcifications rendered
some segments unevaluable. CT was useful in
showing significant CAD in 29% of patients with a
negative or non-diagnostic exercise tolerance test
(ETT).
Gaspar and colleagues23 also give details of their
assessment of the value of CT in four specific
applications:
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4● in plaque characterisation, where they
concluded that MSCT was better than CA for
detecting non-obstructive but high-risk plaques
● evaluation of in-stent restenosis with both 
40-slice and 64-slice CT, where they reported
that stent lumens were visible in 200 stents of
13 different designs, and that in-stent restenosis
could be detected with 85% sensitivity, 97%
specificity and 95% NPV
● CABG, where 64-slice is more useful than 
16-slice CT
● acute chest pain diagnosis, where 64-slice CT
changed diagnosis or management in almost
half of 42 patients. Among those discharged
because CT was low risk or negative, there were
no adverse cardiac events in 30-day follow-up.
Berman and colleagues24 provide a wide-ranging
review of the place of non-invasive imaging tests. It
is not a systematic review, and is a little out of date
(it was submitted in July 2005) and hence does not
include all the 64-slice studies now available; it
relies mainly on 16-slice studies. However, it
includes useful thinking about the place of the
different technologies in a number of scenarios,
including situations similar to both the diagnostic
and assessment scenarios included in this review. 
Among other things, Berman and colleagues24
consider the relative places of single-photon
emission computed tomography (SPECT),
myocardial perfusion scintigraphy (MPS) and CT
angiography (CTA). In patients being investigated
for symptoms that may be due to CAD, they suggest
that the choice of investigation should depend on
the pretest likelihood of CAD. Very low-risk patients
are not investigated further. High-risk patients are
sent for MPS, looking for functional changes in
myocardial muscle with a view to revascularisation.
Intermediate risk patients go for CT angiography,
and if abnormal for CA with a view to angioplasty.
They argue that in the intermediate group (who on
risk scoring might have from 10 to 20% risk of a
cardiac event in the next 10 years), that,
“Although existing guidelines recommend exercise
testing without imaging for these patients, because
CTA provides a far more sensitive test for CAD in this
population, we consider it more useful than the
exercise ECG in selecting patients for aggressive
medical management and for additional testing. It is
likely that the definitive ability to rule out CAD will
become a principal driving force in the application of
coronary CT.”
One question that needs to be considered is the
threshold for ruling out CAD. Most people being
investigated for suspected angina will be middle
aged. What proportion of such people in the UK
will have entirely normal coronary arteries?
However ‘ruling out CAD’ is short-hand for ‘ruling
out CAD as a cause of symptoms’, which implies
that it is not complete absence of CAD which is
required, but rather absence of sufficient stenosis
to cause angina. That then raises a need to define
‘sufficient’. Whether a stenosis can cause angina
will depend not just on the percentage narrowing
of the lumen, but on other factors such as the
length of the stenosis, the difference in pressure
across it and the demands placed on the heart by
the level of exercise.
Berman and colleagues24 anticipate that CT
angiography can replace some MPS, and that the
rapid growth of MPS activity in the USA will slow
considerably.
NHS Quality Improvement Scotland issued an
evidence note in 2005,25 in which it was concluded
that 16-slice CT was not yet as good as CA for
detecting stenosis, and that it was too early to pass
judgement on 64-slice CT. The cost of a 64-slice
scanner was estimated to be over £1 million, with
annual maintenance, and perhaps cardiovascular
imaging software, costs to be added. But it also
concluded [probably based on the Medical
Services Advisory Committee (MSAC) review] that
the cost of the multislice procedure might be less
than half that of CA.
More recently, a working group convened by the
American College of Cardiology Foundation, with
representatives from other relevant organisations,
produced recommendations on appropriate uses of
cardiac CT (and cardiac MRI).26 The appropriate
indications for CT angiography included:
● evaluation of chest pain where there was
intermediate pretest probability of CAD and
either an uninterpretable ECG or inability to
exercise; or after an uninterpretable or
equivocal stress test
● evaluation of suspected coronary anomalies in
symptomatic CAD
● acute chest pain with intermediate pretest
probability of CAD, no ECG changes and
enzymes negative
● evaluation of coronary arteries in patients with
new onset heart failure to assess aetiology.
At almost the same time, another statement on CT
angiography was issued by a different group of
American societies, led by the AHA.27 There was
only one author in common. The statement noted
the rapid development of CT and commented
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times have preceded the critical evaluation of
clinical application.”
The statement included the following
recommendations or conclusions:
● CT angiography is useful for the assessment of
obstructive coronary disease in symptomatic
patients, perhaps especially for ruling out
stenosis in patients with low or intermediate
pretest likelihood of disease. “A ‘normal’ CT
coronary angiogram allows the clinician to rule
out the presence of haemodynamically relevant
coronary artery stenosis with a high degree of
reliability.”
● There is insufficient evidence at present for its
use in follow-up of stent placement.
● The use of CT to study non-calcified plaque is
promising but premature.
● CT angiography is not recommended for
detecting CAD in asymptomatic people.
● Serial imaging for assessment of progression of
coronary calcification is not recommended.
● “The use of cardiac CT angiography for non-
invasive assessment of lumen stenosis in
symptomatic individuals has the potential to
significantly alter the management of CAD and
current diagnostic testing patterns.”
The authors concluded that CT angiography
could reduce the need for invasive CA.
Neither of the working group statements mentions
the possible use of CT angiography to identify
patients whose pattern of disease is such that they
are not suitable for angioplasty, but should go
straight to CABG. That might be another way of
reducing CA needs.
There is great interest in the USA in 64-slice CT,
as a recent commentator28 noted: 
“The advent of the 64-slice scanner and its ability to
spin an x-ray tube around a body at 30 mph,
capturing the heart in a 10-second breath-hold, has
clearly unleashed a surge of excitement and ambition.
For radiology, this may well be the holy grail. For
cardiology, it foretells tectonic change and the
potential for some professional and technical
obsolescence. Surely there are plenty of cardiologists
out there who would like to vaporise the 64-slice.”
Decision problem
Key question: Could CT be used to reduce CA
requirements, for the diagnosis and assessment 
of CAD?
Subsidiary questions – technical:
● How well does 64-slice CT identify stenoses in
coronary arteries?
● Can 64-slice CT identify vulnerable plaques
which do not cause significant stenoses?
Can 64-slice CT replace some angiography by: 
● Excluding significant CAD in people with
symptoms suggestive of angina but where there
is uncertainty about the diagnosis? The essential
feature would be a high NPV.
● Excluding significant CAD in people with acute
chest pain? Again this would require a high
NPV.
● Identifying cases where CAD is present but does
not require revascularisation (at present), i.e. to
rule out further procedures, at least for the
present? This might be followed by ‘watchful
waiting’ with repeat CT angiography at
intervals.
● Identifying cases where revascularisation by
CABG rather than PCI is indicated, i.e.
enabling some patients to go direct to CABG
without prior angiography?
In both the last two cases, ability to detect non-
stenotic but unstable plaques would also be of
value, since these are more likely sites of coronary
thrombosis than rigid calcified plaques.
An additional question is whether CT angiography
could replace some perfusion studies. This is not
within the original remit of this review, but since
we need to consider the pathways by which 
people reach CT or CA, it can be dealt with in
passing.
Possible patient subgroups include:
● Those with definite coronary heart disease
being assessed with a view to revascularisation.
The options for this group include medical
treatment only, angioplasty or CABG. Given the
trend to do angioplasty at the same time as CA,
CT may not have a large role in this group,
unless it could identify those in whom CABG is
required.
● Those in whom there is diagnostic uncertainty
after resting and exercise ECG testing. At
present, people may be referred for MPS, and
CT may replace some of this. One possibility
could be that in those with a low pretest
probability of heart disease, CT could be used,
whereas in those with a high probability, CA
would be used. If CT was negative, patients
would not go for CA.
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6● Disease-specific groups: in people with diabetes,
the pattern of atherosclerosis is different (more
diffuse so often less amenable to angioplasty).
There may be a role for CT in identifying
patients who will require CABG rather than
angioplasty. One possibility may be that people
with diabetes would have CT to decide whether
to proceed to CA with an intention of
angioplasty, or to go directly to CABG.
● People admitted with chest pain, but who do
not have convincing evidence of acute coronary
syndrome (ACS) (and have normal ECG and
troponins). This may represent quite a large
group and there may be a place for CT. Exercise
testing is another option.
One issue is what to use as the reference standard,
and this may vary according to whether the
purpose is to detect stenosis, in which case
angiography would be the gold standard, or
vulnerable plaques, when angiography may miss
some lesions, and where the gold standard may be
long-term follow-up. However, it is likely that
people with vulnerable plaques will also have
stenoses elsewhere, which would trigger
intervention.
False positives could be defined as lesions not
needing revascularisation but which are so treated;
but once treated it would not be possible to
identify which were false positives. So the use of a
reference standard would be to identify false
negatives; that is, those in whom CT or CA
suggests that there is no disease requiring
treatment, but who go on to suffer an event such
as MI or angina. Long-term follow-up would be
the best reference standard here, but the duration
of follow-up requires thought. Too long a follow-
up would make it difficult to distinguish false
negatives from true negatives in whom disease has
developed de novo.
False negatives could be divided into two groups:
● those in whom the severity of arterial disease is
underestimated, and who are therefore not sent
for revascularisation
● those in whom disease is missed altogether.
Sensitivity and specificity may differ for stenotic
and non-stenotic lesions, and also perhaps for
different arteries. CT may be better for detecting
lesions in, for example, left main or LAD arteries
than in LCX, because of their locations; or for
proximal rather than distal lesions. 
If CT could reveal vulnerable plaques, one
problem would be knowing what treatments to
use. The data on the benefits of revascularisation
all relate to degrees of stenosis. So uncertainties
about treatment of vulnerable plaques may reduce
the value of CT information.
The analysis will focus on the diagnostic and
prognostic assessment pathways (Figures 1–5). It is
assumed that treatments such as revascularisation
are of proven benefit, and that the key outcome
for the review is allocation to appropriate
treatment. 
Figure 1 shows the investigation pathway for non-
urgent investigation. A resting ECG may show
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Symptoms
? CAD Resting ECG
Exercise test
b
Positive
Go to Assessment 
pathway
Equivocal
c
High probability CAD
Further test
Low probability CAD Reassurance and 
discharge
Negative
CT
MPS
Not possible
d
Further test
Confirm CAD
a Go to Assessment pathway
Normal or
equivocal
MPS
CT
FIGURE 1 Investigation pathway – non-acute. aFor example, evidence of previous MI; bexercise test plus clinical finding; cincludes
unable to exercise enough, non-specific ECG changes; de.g. left bundle branch block (LBBB).evidence of a previous infarction, but more often
the patient will progress through the usual
pathway of exercise testing on a treadmill. If the
diagnosis is confirmed, patients go forward for
prognostic assessment. If the exercise test is
equivocal, or negative but with a high probability
of CAD, then further testing may be carried out,
and options include CT and MPS. 
Figure 2 shows the pathway for urgent
investigation when someone attends an emergency
facility with acute chest pain of suspected cardiac
origin. If clinical assessment suggests that the pain
is cardiac, ECG and troponin testing will be done.
If these confirm that the pain is cardiac in origin,
appropriate care will follow. But with both tests,
especially in the early hours after MI, false
negatives can occur. The physicians have to decide
whether patients should be admitted for
observation and repeated tests, or reassured and
discharged. After admission, some will be shown
not to have pain of cardiac origin; these could be
regarded as a form of ‘false positives’ in the
assessment process. Conversely, some of those
discharged may truly have had pain of cardiac
origin: the ‘false negatives’. Some may have a
recurrence and be admitted, but others may die at
home from an MI. If CT were available in the
emergency situation, it might have a role in
excluding CAD and avoiding the need for
admission for observation. Conversely, it might
also lead to some people being admitted who
would otherwise have been incorrectly 
discharged.
Figure 3 starts with a positive diagnosis of CAD,
following which treatment for angina will be given.
If symptoms are not relieved, revascularisation will
be considered for symptomatic relief. If symptoms
are relieved, then revascularisation may still be
considered if CABG would improve the prognosis.
Good performance on an exercise test suggests a
good prognosis, and that CABG is unlikely to be
indicated. 
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Acute chest
pain, ?
cardiac
Clinical
assessment
ECG
troponin
Option
Admit for observation
Cardiac
Not cardiac – discharge
CT
Cardiac origin confirmed Coronary care
ECG and
troponin
negatives True negative
False negative
Cardiac origin
Not cardiac
Death
Recurrence
FIGURE 2 Diagnosis of acute chest pain
Symptomatic
CAD
Intensification 
of therapy
Symptoms relieved
Symptoms not relieved
b Assess for RV
Exercise
test
a
Good prognosis
Poor prognosis
Reassurance, lifestyle
measures and medical 
treatment
Assess for RV
FIGURE 3 Prognosis pathway. aPerfusion scanning would be another option; the aim is to assess for inducible ischaemia; bmay include
a few false positives who do not have CAD; RV, revascularisation.Figure 4 concerns those patients in whom
revascularisation is being considered, and the
question here is whether CT could be used to rule
out the need for CABG. 
Figure 5 shows what happens after
revascularisation. Symptoms may be permanently
relieved, or may recur. If they recur, that could be
due to a graft being narrowed or occluded, or a
new lesion arising in another artery. CT may be an
alternative to invasive angiography.
One aspect will be the degree of reassurance from
negative results. Would negative CT provide the
same level of reassurance as negative CA or
perfusion studies? Answering that question would
require data on (untreated) follow-up after each
investigation.
A last question is whether CT could assist with the
planning of angiography/PCI sessions by
identifying which patients would need PCI as well
as angiography. This may make planning of
sessions easier and improve the efficiency of use of
catheter laboratories.
Terminology
For the purposes of this review, confirming the
diagnosis in people with symptoms that may be
due to CAD means determining whether there is
sufficient CAD to cause the symptoms. Most
people of the age at which symptoms present may
have some evidence of CAD, so ‘sufficient CAD’
means the presence of one or more stenoses that
result in enough arterial narrowing to limit blood
flow. The consensus among cardiologists is that
stenosis has to be about 70% or more of the lumen
to be flow limiting and cause symptoms. However,
50% is another accepted cut-off and errs on the
side of not missing anything that may be flow
limiting. CT angiography will often detect CAD
with lesser degrees of narrowing, and while these
patients will not be referred for revascularisation,
they would be considered for lifestyle advice and
statin therapy.
Screening for asymptomatic CAD
This review does not cover screening for
asymptomatic disease. The patient groups
included here are suspected of having coronary
disease, or known to have it. Screening for
asymptomatic disease by CT is usually done by
looking for calcium deposits in the coronary
arteries, and was the subject of a previous report
by Waugh and colleagues.3
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Assessment for
revascularisation Options
Angiography followed by PCI
Combined angiography and PCI
CT
‘Positive’ Angiography + PCI as above
a
‘No RV needed’
Correct
False negatives
b No RV
FIGURE 4 Assessment for revascularisation. aIn theory, there could be false positives if CT overestimated the degree of stenosis; 
ba false negative would be someone in whom CT underestimated stenosis sufficiently to rule out RV in a patient with over 50% stenosis.
Revascularisation
No recurrence of symptoms
Symptoms recur
Assessment for patency
or new stenosis
Angiography
CT
FIGURE 5 Assessment following revascularisationMethods for reviewing test
performance
Search strategy
Electronic searches were undertaken to identify
published and unpublished reports evaluating the
performance of 64-slice or higher CT angiography
for the diagnosis and assessment of CAD. Searches
were restricted to the years 2002 onwards and to
English-language reports. Abstracts from recent
conference proceedings were also searched.
The main databases searched were: MEDLINE
(2002 to November week 3 2006), EMBASE (2002
to week 49 2006), BIOSIS (2002 to December
2006), Science Citation Index (SCI, 2002 to
December 2006), Medline In-Process (14
December 2005), Cochrane Controlled Trials
Register (CCTR, The Cochrane Library, Issue 4,
2006), Cochrane Database of Systematic Reviews
(CDSR, The Cochrane Library, Issue 4, 2006),
Database of Abstracts of Reviews of Effects (DARE,
December 2006), HTA Database (December 2006)
and Health Management Information Consortium
(HMIC, 2002 to May 2006). In addition, recent
conference proceedings and reference lists of all
included studies were scanned to identify
additional potentially relevant studies. Full details
of the search strategies used are documented in
Appendix 1.
Inclusion and exclusion criteria
Types of studies
The types of studies considered were randomised
controlled trials (RCTs) or prospective/retrospective
non-randomised comparative studies or case series
in which some or all patients received both MSCT
angiography using 64-slice or higher machines
and invasive CA.
Index and comparator tests 
The index test was multislice CT angiography
using 64-slice or higher machines. MPS was
considered as a comparator test.
Reference standard
Two reference standards were considered, either
invasive CA or long-term follow-up of participants.
The latter was chosen because it would provide
some indication of the numbers of patients with
false-negative results on diagnostic 64-slice CT
angiography who as a consequence were deemed
not to require invasive CA but who then went on
to suffer a cardiac event.
Participants
The participants were adults undergoing CT
angiography using 64-slice or higher machines for
the detection of CAD. Analysis was planned on the
following patient subgroups, if evidence was
available:
● patients in whom there was diagnostic
uncertainty, or who were unable to perform
exercise testing
● patients with definite heart disease being
assessed with a view to revascularisation
● patients with suspected ACS
● patients with previous PCI including stenting
● patients with previous CABG
● patients with diabetes
● women, in case CT was less useful in smaller
arteries.
Outcomes
Diagnostic accuracy studies had to report the
absolute numbers of true positives, false positives,
false negatives and true negatives, or sensitivity
and specificity for CT angiography.
Prognostic studies had to provide information on
the likelihood of future cardiac events. Assessment
studies had to illustrate the pattern of CAD and
suitability for revascularisation. Post-
revascularisation studies were examined to assess
the accuracy of 64-slice or higher CT angiography
for detecting stenosis in stents or grafts.
Data extraction strategy
One reviewer screened the titles (and abstracts if
available) of all reports identified by the search
strategy. Full-text copies of all studies deemed to
be potentially relevant were obtained and two
reviewers independently assessed them for
inclusion. Any disagreements were resolved by
consensus or arbitration by a third party.
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Chapter 2
Assessment of test performance for diagnosis and 
assessment of coronary artery diseaseA data extraction form was developed and piloted.
Two reviewers independently extracted details
from full-text studies of study design, participants,
index, comparator and reference standard tests,
and outcome data. Any disagreements were
resolved by consensus or arbitration by a third
party. Abstracts were not data extracted.
Quality assessment strategy
Quality assessment was performed using QUADAS,
a quality assessment tool developed for use in
systematic reviews of diagnostic studies.29 QUADAS
was developed through a formal consensus
method and was based on empirical evidence. The
original QUADAS checklist contained 14
questions. The QUADAS tool was adapted to make
it more applicable to evaluating the
methodological quality of studies reporting tests
for diagnosing and assessing CAD (see Appendix
2 for an example of the modified checklist). 
Questions 1, 3, 4, 5, 6, 7, 10, 11, 12, 13 and 14 of
the original QUADAS tool were retained (questions
1–11 in the modified version). Three questions in
the original QUADAS tool that related to the
quality of reporting rather than methodological
quality were omitted from the modified version
(questions 2, 8 and 9). These questions related to
the description of the selection criteria, the
execution of the index test and the execution of
the reference standard test. Three questions were
added to the modified checklist on whether an
established cut-off point was used (question 12),
whether data on observer variation were reported
and within an acceptable range (question 13) and
whether data were presented for appropriate
subgroups of patients (question 14). 
Two reviewers (GM, XJ) independently assessed
the quality of all included studies using the
modified version of QUADAS. Each of 14
questions was checked as ‘Yes’, ‘No’ or ‘Unclear’.
Each item was worded so that a rating of ‘Yes’ was
always optimal in terms of methodological quality.
Any disagreements were resolved by consensus or
arbitration by a third party. Abstracts were not
quality assessed.
Data analysis
Study level
The results of the individual studies were
tabulated and sensitivity, specificity, positive and
negative predictive values calculated. If reported
in a given study, a separate 2 × 2 table was derived
for patient level, all segments, individual arteries,
stents and bypass grafts. The confidence intervals
for the sensitivity and specificity of individual
studies were calculated using the F distribution
method30 in MetaDiSc software.31
Data synthesis
Summary receiver operating characteristic (SROC)
curves were produced for each test where three or
more studies reported sufficient data. A separate
SROC curve was derived for patient-level analysis,
all segments, left main, LAD overall, LAD
proximal, LCX overall, RCA overall, stents and
bypass grafts where possible. The primary meta-
analysis method was the hierarchical summary
receiver operating characteristic (HSROC)
model,32 which was fitted using WinBUGS 1.4
using non-informative priors.33 Fitting the full
(asymmetric) HSROC model was initially
attempted, but owing to numerical non-
convergence a symmetric SROC model was used.
This model takes proper account of the diseased
and non-diseased sample sizes in each study, and
allows estimation of random effects for the
threshold and accuracy effects. The SROC curves
from the HSROC models were produced on the
corresponding SROC plots. For each model,
summary sensitivity, specificity, positive and
negative likelihood ratios and diagnostic odds
ratios (DORs) were reported as a median and 95%
credible interval (CrI). Credible intervals are the
Bayesian equivalent of confidence intervals. 
If numerical difficulties were encountered with the
HSROC symmetric model and there was no
evidence of heterogeneity, sensitivity and
specificity were pooled using the weighted average
method.34 Similarly, pooled likelihood ratios and
DORs were calculated using the DerSimonian and
Laird random-effects method.35 Where a study
had an empty cell, a correction of 0.5 was added
to all four cells. These analyses were carried out
using MetaDiSc software;31 corresponding 95%
confidence intervals (CIs) (rather than CrIs) were
reported. Heterogeneity of sensitivity and
specificity was assessed separately using the I2
statistic in MetaDiSc software.31 This measure
describes the percentage of the variability in effect
estimates that is due to heterogeneity rather than
sampling error (chance). A value greater than 50%
may be considered to represent substantial
heterogeneity.36 Results reported were for the
HSROC model unless otherwise stated. 
Results
Number of studies identified
The results of the searches are summarised in
Table 1. The numbers retrieved from the searches
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additional reports found after excluding those
identified from the MEDLINE/EMBASE multifile
search.
A total of 1211 reports was identified from the
various searches, of which 275 reports (135 full-
text papers; 140 abstracts) were selected for full
assessment. Table 2 details the numbers of these
that were included and excluded. Figure 6 shows a
flow diagram outlining the screening process, with
reasons for exclusion of full-text papers. 
Number and type of included studies
Appendix 3 lists the 45 studies, published in 74
reports, that were included in the review of
effectiveness. Forty-one studies, published in 68
reports,37–104 met the inclusion criteria for studies
of diagnostic accuracy. The primary reports were
published in full-text papers for 21 and only as
abstracts for 20. All used 64-slice CT angiography
apart from the study by Motoyama and
colleagues,68 reported as an abstract, in which a
prototype 256-slice CT machine was used. Five
studies, published in seven reports,55,105–110
provided information on the prognostic usefulness
of 64-slice CT. The study by Hoffmann and
colleagues55 provided information on both
diagnostic accuracy and prognostic usefulness of
64-slice CT. Of the five studies reporting
prognostic usefulness, the primary reference was a
full-text report for one and abstracts for the
remaining four. 
Number and type of excluded studies 
A list of potentially relevant studies identified by
the search strategy, for which full-text papers were
obtained, but which subsequently failed to meet
the inclusion criteria, is given in Appendix 4.
These studies were excluded because they failed to
meet one or more of the inclusion criteria in terms
of types of studies, participants, test, reference
standard or outcomes (see also Figure 6). 
Characteristics of the included studies
Appendix 5 shows the characteristics of the
included studies. Only full-text studies were
formally data extracted. Table 3 shows summary
information for the full-text diagnostic accuracy
studies.
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TABLE 1 Search results
Database No. retrieved
MEDLINE/EMBASE/MEDLINE In-Process multifile search (after deduplication in Ovid) 580
SCI 257
BIOSIS 197
CENTRAL 0
HMIC 23
CDSR 0
DARE  3
HTA Database 13
NRR 7
CCTR 1
Clinical Trials 1
ISI Proceedings 59
Conference Papers Index 24
Selected from screening conference abstracts 46
Total retrieved 1211
NRR, National Research Register.
TABLE 2 Papers selected for full assessment
Full-text papers Abstracts
Included in the report 22 52
Retained for background information 13 0
Excluded – did not meet inclusion criteria 96 88
Unobtainable papers 4
Total 135 140The 21 full-text studies reporting diagnostic
accuracy enrolled 1333 participants, with 1176
included in the analysis. Fourteen studies gave no
details of when they took place. The remaining
eight studies46,52,55,56,58,59,85,101 took place 
during the period from July 200456,58 to 
February 2006.85 Eight studies took place in
Germany,56,58,71,77,86,89,93,94 four in the
USA,49,55,85,101 three in The Netherlands,65,66,100
two in Switzerland,59,79 and one each in France,52
Japan46 and Malaysia,75 while one study involved
centres in Italy and The Netherlands.83 All but
one of the full-text studies used Siemens Sensation
64 CT equipment. Schuijf and colleagues,100 in a
study set in The Netherlands, used a Toshiba
Multi-Slice Aquilion 64 system.
Two studies gave no details of participant
gender.58,93 In the remaining 19 studies, of 1168
people included in the analysis, 822 (70%) were
men and 346 (30%) were women. Across studies
the median age of the participants was 61 years
(range of means 54 to 69 years). 
The 20 diagnostic accuracy studies reported as
abstracts enrolled and analysed at least 1158
participants. In three studies reporting when they
took place this was during the period from
November 2004 to July 2005.60,61,76 Five studies
took place in Germany,37,39,53,99,102 four in the
USA,48,60,61,97 three each in Japan45,68,76 and The
Netherlands,62,82,84 two in Israel,95,96 and one each
in Brazil,78 China103 and Turkey.72 Eight
studies,37,39,45,48,62,72,76,103 set in Germany (two),
Japan (two), the USA, The Netherlands, Turkey
and China (one each), used Siemens Sensation 64
machines. Two studies,60,61 set in the USA, used
GE Healthcare Light-Speed VCT machines,
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1211 titles/abstracts identified for screening
275 selected for full assessment
936 excluded
74 reports of 45 
studies included
201 reports excluded
88 abstracts
113 full-text reports:
Letters, comments, editorials, case reports, reviews: 28 
4-slice: 9
8-slice: 1
16-slice: 9
32-slice: 1
40-slice: 3
Number of slices not stated or clearly stated not 64-slice: 27
Results not presented separately for 64-slice: 2
Did not meet inclusion criteria in terms of outcomes reported: 5
Did not meet inclusion criteria in terms of reference standard test: 3
Not relevant to review question: 8
Retained for background information: 13
Unobtainable: 4
FIGURE 6 Flow diagram outlining the screening processtwo,95,96 set in Israel, used Philips Brilliance 64
machines and the study by Motoyama and
colleagues,68 set in Japan, used a Toshiba
prototype 256-slice machine. Seven
studies53,78,82,84,97,99,102 gave no details of the CT
equipment manufacturer.
In six studies giving details of gender,37,39,45,95,96,102
of 592 people included in the analysis, 362 (61%)
were men and 230 (39%) were women. The
median age of the participants across six studies
giving details of age was 60 years (range of means
58 to 68 years).37,39,45,95,96,102
The five studies reporting the prognostic
usefulness of 64-slice CT enrolled at least 1785
participants, with 1778 included in the analysis. In
two studies reporting when they took place, this
was during the calendar year 2005105 and from
May to July 2005.55 Four studies took place in the
USA55,105–107 and one in Israel.110 In three studies
giving details of gender,55,106,110 of 629 people
included in the analysis, 370 (59%) were men 
and 259 (41%) were women. The median age 
of the participants across three studies giving
details of age was 56 years (range 54 to
62 years).55,106,110
Fryback and Thornbury111 suggested a useful
hierarchy for describing studies of diagnostic
technologies (Table 4). All of the studies reporting
diagnostic accuracy, including those reported as
abstracts, were classed as level 2 (diagnostic
accuracy) on the Fryback and Thornbury scale.111
The study by Hoffmann and colleagues55 reported
both diagnostic accuracy and prognostic
usefulness, and was classed as level 2 for the
former and level 3 (diagnostic thinking) for the
latter. The remaining four studies105–107,110
reporting prognostic usefulness were classed as
level 4 (therapeutic).
The Australian Medical Services Advisory
Committee112 provides a useful diagram that
Health Technology Assessment 2008; Vol. 12: No. 17
15
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
TABLE 3 Patient details, indication for CT and technique used (full-text diagnostic accuracy studies, n = 21)
Patients
Enrolled 1333
Analysed 1176
Gender
Male 822 (70%)
Female 346 (30%)
NR 146
Age
Median (range of means) across 21 studies 61 (54 to 69) years
Indication for CT angiography
Suspected CAD  499 (49%) 
Known history of CAD  219 (21%)
Preoperative scanning prior to valve surgery or CABG 120 (12%)
To assess implanted stents  89 (9%)
Other  95 (9%)
NR 292
Use of -blocker to reduce heart rate
Already on -blocker treatment 140 (32%)
-Blocker treatment given  184 (42%)
-Blocker treatment not given  113 (26%)
NR 877
64-Slice CT angiography
Heart rate during scan: mean of means (range of means) across 16 studies 63 (58–72) beats per minute 
Total 64-slice CT scan time: range of mean scan times (seconds) 11.2–21.4 seconds
Radiation dose: range of means across 12 studies  Men and women: 6–14 mSv
Men: 7.45–15.2 mSv
Women: 10.2–21.4 mSv
Information was reported by some studies for those enrolled and by others for those analysed.
NR, not reported.illustrates the pathway linking the use of a
diagnostic test to health outcomes (Figure 7), with
the effectiveness of a test depending on whether
the overall accuracy of testing is improved by
including the index test (as a replacement or
additional test), its impact on therapeutic
decisions and the effectiveness of the therapies
selected.112 Four55,106,107,110 of the five studies
reporting prognostic usefulness provided
information on patient outcomes. 
Quality of the included studies
Figure 8 summarises the quality assessment for the
full-text diagnostic studies, while the quality
assessment results for each individual study are
shown in Appendix 6.
The overall quality of the included full-text studies
was reasonably good. In all studies the reference
standard (either invasive CA or long-term follow-
up) was considered likely to classify CAD correctly,
partial verification bias was avoided in that all
patients who received 64-slice CT angiography
also received a reference standard test, differential
verification bias was avoided in that patients
received the same reference standard regardless of
the index test result, incorporation bias was
avoided in that the index test did not form part of
the reference standard, and an explanation of
study withdrawals was provided. The question on
partial verification bias was checked ‘Yes’ for two
studies,55,56 in which only some patients received
both index and reference standard tests, as it was
only the results for the patients who received both
tests that were included in the review.
In 95% of studies an established cut-off point was
used to define a positive test result (e.g. stenosis 
> 50%). In 86% of studies uninterpretable test
results were reported. In 85% of studies the period
between 64-slice CT and the reference standard
test was less than 6 months, a period considered
short enough to be reasonably sure that the target
condition had not changed between the two tests.
In 85% of studies test review bias was avoided in
that those interpreting 64-slice CT data were
blinded to the results of the reference standard
test. In 71% of studies diagnostic review bias was
avoided in that those interpreting the reference
standard test were blinded to the results of 
64-slice CT. 
In 48% of studies the participants belonged to
specific groups (e.g. studies in which all patients
had LBBB,52 were being referred for cardiac valve
surgery,65 or had previously undergone PCI86,89 or
CABG.77,94
In 67% of studies participant subgroup analysis
was reported or the whole participant group was
Assessment of test performance for diagnosis and assessment of coronary artery disease
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TABLE 4 Hierarchy of diagnostic efficacy
Level Data  products
1 Technical Technical imaging quality
2 Diagnostic accuracy Sensitivity, specificity, PPV, NPV
3 Diagnostic thinking Likelihood ratio
4 Therapeutic Changes in treatment of patients
5 Patient outcome Improvement in morbidity and/or mortality
6 Societal Cost–benefit analysis
Clinical
presentation Testing Diagnosis Treatment Outcomes
Test
accuracy
Treatment
decisions
Treatment
effectiveness
Test safety: adverse events associated with the test, subsequent diagnosis and treatment
FIGURE 7 Causal pathway and determinants of the clinical effectiveness of a diagnostic test. From Guidelines for the assessment of
diagnostic technologies.112 Copyright Commonwealth of Australia reproduced by permission.in effect considered to be a subgroup (e.g. the
study by Ghostine and colleagues52 in which all
participants had LBBB), while 57% gave details of
observer variation in interpreting study results,
and in 48% of studies clinical review bias was
avoided in that those interpreting 64-slice CT data
were blinded to the patients’ clinical history. 
Studies reporting the diagnostic
accuracy of 64-slice CT angiography
Overview
This section reports the diagnostic accuracy 
of 64-slice CT angiography on the following 
levels of analysis: patient, segment, left main
artery, LAD artery, proximal LAD artery, LCX
artery, RCA, stents/stented segments and CABG.
For each of these levels of analysis figures are
included showing, for 64-slice CT angiography
compared with invasive CA as the reference
standard, sensitivity and specificity of the
individual studies, SROC curves and pooled
estimates for sensitivity, specificity, positive and
negative likelihood ratios and DOR. In all of the
studies included in the pooled estimates the cut-
off for a positive result was greater than 50% or at
least 50% stenosis. Only full-text studies reported
diagnostic accuracy at artery level. Appendix 7
shows the studies that reported data that allowed
their inclusion in the pooled estimates for
different levels of analysis. Individual study results
are given in Appendix 8. 
Patient-level analysis for the detection of CAD
Although segmental analysis is useful to 
validate the accuracy of the test, patient-level 
data are more useful in determining 
management. Eighteen studies (13 full
text46,52,55,65,66,71,77,79,83,85,93,94,100 and five 
studies reported as abstracts39,62,95–97) enrolling 
at least 1313 people, with 1286 included in the
analysis, provided sufficient information to 
allow their inclusion in the pooled estimates for
patient-level analysis. Across studies, the median
prevalence of CAD at this cut-off was 58% 
(range 23 to 96%). 
Figure 9 shows the sensitivity and specificity, with
95% CIs, for the 18 studies. Sensitivity ranged
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Spectrum representative
Reference standard likely to classify CAD
Period between tests short enough
Partial verification bias avoided
Differential verification bias avoided
Incorporation bias avoided
Test review bias avoided
Diagnostic review bias avoided
Clinical review bias avoided
Uninterpretable results reported
Withdrawals explained
Established cut-off used
Observer variation reported
Participant subgroup analysis
0% 20% 40% 60% 80% 100%
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Unclear
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FIGURE 9
P
atient-level analysis: sensitivity
, specificity
, SROC curve and pooled estimates. FN, false negative; FP
, false positive; TN, 
true negative; TP
, true positive. from 94%100 to 100%,55,62,65,66,77,79,83,94–97 with a
pooled sensitivity of 99% (95% CrI 97 to 99%).
Specificity ranged from 50%62 to 100%,55 with a
pooled specificity of 89% (95% CrI 83 to 94%).
Across studies the median PPV was 93% (range 64
to 100%), while the median NPV was 100% (range
86 to 100%).
The study reported as an abstract by Malagutti
and colleagues62 demonstrated noticeable
heterogeneity in terms of specificity. In this study
all patients (n = 52) had previously undergone
CABG surgery. The low specificity was due to the
fact that, of two patients classed as having no
significant (>50% luminal narrowing) CAD on
invasive CA, one received a positive test result on
64-slice CT (false positive). The false-positive
result may be due to the fact that, as reported by
the study authors, overestimation of stenosis
severity occurred more often in calcified segments.
However, overall there was no evidence of
substantial statistical heterogeneity in terms of
sensitivity (I2 = 0.1%) or specificity (I2 = 31.7%).
In the 13 full-text studies included in the pooled
estimates,46,52,55,65,66,71,77,79,83,85,93,94,100 11 (2%) of
718 patients could not be assessed because of
unevaluable CT scans (median across studies 0%,
range 0 to 6%).
Patient subgroups
Suspected and known CAD
Most studies contained a mixture of patients with
suspected and known CAD and did not report the
results of 64-slice CT angiography for these
groups separately. However, four studies (three full
text71,85,93 and one abstract97) reported patient-
level analysis (n = 245) and six studies (two full
text85,93 and four abstracts37,82,97,99) reported
segment-level analysis (n > 5085) for those with
suspected CAD (Table 5). Two full-text studies71,83
reported patient-level analysis (n = 64) and three
full-text studies58,75,83 reported segment-level
analysis (n = 2623) for those with known CAD
(Table 5).
In terms of patient-level analysis, better sensitivity,
PPV and NPV, but worse specificity, were reported
for those with known CAD. The lowest NPV (93%)
was reported by Nikolaou and colleagues71 in a
subgroup analysis of 39 patients with suspected
CAD, but no explanation of the reasons for the
false-negative results in this group was provided.
For segment-level analysis, better sensitivity was
reported for those with suspected CAD and better
PPV for those with known CAD, while specificity
and NPV were similar for both groups.
The study by Nikolaou and colleagues71 reported
patients with suspected and known CAD in
subgroup analysis but only provided information
on unevaluable scans for the whole patient
population, while the studies by Beck and
colleagues,37 Pugliese and colleagues82 and Savino
and colleagues97 did not report whether any of the
scans were unevaluable. In the remaining studies,
64-slice CT scans for three (1%) of 209 patients
and 240 (9%) of 2779 segments were unevaluable
for those with suspected CAD, compared with four
(4%) of 94 patients and 217 (8%) of 2853
segments for those with known CAD.
In conclusion, 64-slice CT is highly sensitive for
detecting significant CAD in cases of diagnostic
uncertainty, and the high NPV suggests that if 
64-slice CT is negative, then patients may not
need to be referred for further investigation by
invasive CA. 
Acute chest pain
Three studies (one full text55 and two
abstracts39,84) reported patient-level analysis
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TABLE 5 Studies reporting data separately for those with suspected and known CAD
No. of  Median %  Median %  Median %  Median % 
studies (range) sensitivity (range) specificity (range) PPV (range) NPV
Suspected CAD
Patients (n = 245) 4 96 (95–100) 87 (82–91) 86 (76–93) 96 (93–100)
Segments (n > 5085) 6 92 (82–100) 97 (95–99) 68 (55–95) 99 (98–100)
Known CAD
Patients (n = 64) 2 100 (both) 83 (75–90) 91 (85–96) 100 (both)
Segments (n = 2623) 3 85 (79–99) 96 (96–97) 78 (72–80) 98 (97–100)
The study by Pugliese and colleagues82 reported sensitivity, specificity, PPV and NPV values for segment-level analysis for
people with suspected CAD, but did not report the number of segments analysed.(n = 232) for 64-slice CT angiography for patients
admitted to hospital with acute chest pain. Across
these studies the median (range) values were 100%
(97 to 100%) for sensitivity, 100% (79 to 100%) for
specificity, 100% (87 to 100%) for PPV and 100%
(94 to 100%) for NPV for detecting 50% or greater
stenosis. In the studies by Hoffmann and
colleagues55 and Pugliese and colleagues84 the
values for sensitivity, specificity, PPV and NPV
were all 100%. None of the studies gave
information on whether any of the scans were
unevaluable.
Details of three prognostic studies,55,95,107
including that by Hoffmann and colleagues, that
went beyond the Fryback stage 2 classification
(diagnostic accuracy, sensitivity and specificity of
the images) are given in the section on prognostic
usefulness of 64-slice CT angiography later in this
chapter. 
In conclusion, 64-slice CT angiography, if it were
available 24 hours per day, might have a role to
play in the assessment of acute chest pain and
might allow some patients to be reassured and
discharged, leading to a reduction in hospital
admissions with associated cost savings. 
PCI and CABGs
Details of studies reporting patient-level analysis
on patients who have previously undergone PCI or
CABG are included in the sections on stents and
CABGs later in this chapter.
Diabetes
One study, reported as an abstract,48 provided
information on the accuracy of 64-slice CT
angiography for detecting greater than 70%
stenosis in three groups of high-risk patients, one
of which was patients with diabetes (number not
stated), reporting 87% sensitivity, 94% specificity,
87% PPV and 94% NPV.
Women
No study reported the diagnostic accuracy of 64-
slice CT angiography separately for women. 
Other
In the study by Ghostine and colleagues52 all of
the study participants (n = 66) had LBBB
(limiting the diagnostic yield from an exercise
ECG). In patient-level (n = 66) and segment-level
(n = 990) analysis, respectively, Ghostine and
colleagues52 reported 97 and 72% sensitivity, 95
and 99% specificity, 93 and 91% PPV, and 97%
NPV (both) for 64-slice CT angiography for
detecting greater than 50% stenosis. In this study
all scans at both patient and segment level were
evaluated.
In the study by Meijboom and colleagues65 all of
the study participants had been referred for
cardiac valve surgery. In this setting, exclusion of
significant CAD may obviate the need for invasive
investigation. Likewise, in some cases, knowledge
of the severity of CAD may influence the decision
on whether or not to operate. In patient-level
(n = 70) and segment-level (n = 1003) analysis,
respectively, Meijboom and colleagues65 reported
100 and 94% sensitivity, 92 and 98% specificity, 82
and 65% PPV, and 100% NPV, (both) for 64-slice
CT angiography for detecting 50% or greater
stenosis. In this study all scans at both patient and
segment level were evaluated.
Segment-level analysis 
Seventeen studies (14 full
text46,52,58,59,65,66,71,75,79,83,85,93,94,100 and three
abstracts76,97,99) enrolling at least 1102 people,
with 1078 included in the analysis, provided
sufficient information to allow their inclusion in
the pooled estimates for segment-level analysis
(n = 14,199). Figure 10 shows the sensitivity and
specificity, with 95% CIs, for the 17 studies.
Sensitivity ranged from 72%52 to 100%,99 with a
pooled sensitivity of 90% (95% CrI 85 to 94%).
Specificity ranged from 76%94 to 99%,52,76 with a
pooled specificity of 97% (95% CrI 95 to 98%).
Across studies the median PPV was 76% (range 44
to 93%), while the median NPV was 99% (range 95
to 100%).
There was evidence of substantial statistical
heterogeneity across the studies in terms of both
sensitivity (I2 = 80.1%) and specificity 
(I2 = 95.1%). The study by Ropers and
colleagues94 was most noticeable in contributing to
the heterogeneity in terms of specificity. In this
study all of the participants (n = 50) had
previously undergone CABG surgery. One reason
suggested by the authors for the low specificity was
that the prevalence of severe calcifications led to
an overestimation of stenosis severity and
consequently a high level of false-positive results.94
Thirteen full-text
studies46,52,58,59,65,66,71,75,83,85,93,94,100 reported that
997 (8%) of 12,476 segment scans could not be
evaluated (median across studies 9%, range 0 to
18%). In the study by Ehara and colleagues46 82
(8%) of 966 segments were not evaluated owing to
poor image quality, caused by irregular heart
rhythm (29), sinus tachycardia above 90 beats per
minute (bpm) (15), calcification (24), vessel motion
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Proximal, mid and distal segments
Five studies46,52,59,75,83 reported the sensitivity and
specificity of 64-slice CT angiography for
detecting 50% or greater stenosis in proximal, mid
and distal segments of the RCA and LAD, and
proximal and distal segments of the LCX (Table 6;
see also Appendix 8). Sensitivity tended to be
higher for proximal segments compared with
distal segments, while in terms of specificity the
results were more variable.
Coronary artery calcification
Three full-text studies65,75,85 reported the accuracy
of 64-slice CT angiography for detecting 50% 
or greater stenosis in segments affected by
different degrees of calcification (n = 3269
segments). The results of these studies are
summarised in Table 7 (see also Appendix 8 for
individual study results).
In the study by Meijboom and colleagues65 all of
the study participants (n = 70) had been referred
for cardiac valve surgery. The presence of coronary
calcium appeared to be associated with
overestimation of the severity of stenoses, with no
false positives in the 338 segments with an
Agatston score (AS) 0–10, but seven (2%) false
positives in the 465 segments with an AS 11–400,
five (3%) false positives in the 146 segments with
an AS 401–1000 and six (11%) false positives in
the 54 segments with an AS above 1000 (see
Appendix 8 for details of true and false positives
and negatives).
All participants (n = 134) in the study by Ong and
colleagues75 had ischaemic heart disease and were
classed as having either minimal to mild
calcification (AS < 142) or moderate to heavy
calcification (AS  142). Again the presence of
coronary calcium appeared to be associated with
overestimation of stenosis severity, with 12 (2%)
false positives in the 700 segments with an AS
below 142 and 33 (5%) false positives in the 631
segments with an AS of 142 or above (see
Appendix 8 for details of true and false positives
and negatives).
In the study by Raff and colleagues85 all of the
study participants (n = 70) had suspected CAD.
Patients were ranked by total AS, with segment
calcium rated as: 0 = not calcified (none); 
1 = calcium present, no image impairment (mild);
2 = calcium covering less than 50% of lumen
(moderate); and 3 = calcium covering more than
50% of lumen in all planes including in cross-
section (severe). There were 14 (2%) false positives
in 709 segments with a calcium rating of none,
five (6%) false positives in 89 segments rated as
mild, six (13%) false positives in 48 segments
rated as moderate and 16 (18%) false positives in
88 segments rated as severe (see Appendix 8), with
the presence of severe coronary calcium associated
with overestimation of stenosis severity. Raff and
colleagues85 reported that 64-slice CT
angiography was highly accurate in the presence
Assessment of test performance for diagnosis and assessment of coronary artery disease
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TABLE 6 Sensitivity and specificity for proximal, mid and distal segments
Study RCA artery LAD artery LCX artery
Proximal Mid Distal Proximal Mid Distal Proximal Distal
Sensitivity (%)
Ehara, 200646 96 93 82 95 100 67 95 84
Ghostine, 200652 50 70 67 94 84 –a 100 60
Leschka, 200559 100 95 67 100 93 50 100 88
Ong, 200675 97 60 83 91 97 100 80 60
Pugliese, 200683 100 100 100 100 90 100 100 100
Specificity (%)
Ehara, 200646 92 92 95 90 93 100 90 75
Ghostine, 200652 98 95 100 100 100 100 95 100
Leschka, 200559 100 91 97 100 88 97 90 94
Ong, 200675 97 93 98 91 92 99 93 95
Pugliese, 200683 96 96 92 96 91 100 100 100
a In the study by Ghostine and colleagues,52 for the analysis of the distal segment of the LAD artery, sensitivity [True
positive/(True positive + False negative)] could not be calculated as there were no true positives and no false negatives.of moderate calcification, but that extreme
calcification reduced specificity and NPV.
In these studies in terms of segment-level analysis,
sensitivity, specificity and PPV varied according to
the degree of calcification, with lower values
associated with increased coronary calcification,
while the NPV values all remained high (range 94
to 100%).
Raff and colleagues85 also reported patient-level
analysis (n = 70). Study participants were classed
as those having AS 0–100 (n = 35), AS 101–400
(n = 17) and AS 401–1804 (n = 18). There was
one false positive in each of the three groups (see
Appendix 8). Sensitivity and PPV values remained
high at over 90% for all three categories, while
specificity declined as the severity of calcification
increased and NPV markedly declined in the
group with the most severe coronary calcification. 
In the study by Meijboom and colleagues65 all
1003 segments were evaluated. Ong and
colleagues75 reported that 48 (6%) of 748
segments with AS below 142 were not evaluable,
compared with 95 (13%) of 726 segments with AS
of 142 or above. In the study by Raff and
colleagues85 130 (12%) of 965 segments were not
evaluated, but a breakdown was not provided by
calcium rating, and none of the 70 participants
was excluded from patient-level analysis owing to
unevaluable CT scans.
Other studies reporting segment-level analysis
cited coronary calcification as a cause of
unevaluable CT scans.45,46,93,94,99,100,102 Although
in the study by Ghostine and colleagues52 no
segment was excluded from analysis owing to
calcification, the authors stated that heavily
calcified segments accounted for nine missed
lesions and 12 underestimated lesions (35% and
46%, respectively, of 26 false negatives), as well as
four overestimated lesions (57% of seven false
positives).
The only study included in the review not to use
64-slice CT technology was that of Motoyama 
and colleagues.68 In this study ten patients
underwent CT angiography using a Toshiba
prototype 256-slice machine, with segments of 
2 mm or less in diameter excluded from analysis.
Of the 101 segments greater than 2 mm in
diameter remaining, none was subsequently
excluded owing to motion artefact. In segment-
based detection of significant (> 50% stenosis)
CAD, when segments with severe calcification
(number not stated) were excluded from analysis,
sensitivity, specificity, PPV and NPV were 100%,
96%, 73% and 100%, respectively, compared with
100%, 90%, 61% and 100% when segments with
severe calcification were assumed as having
significant stenosis.68
Hence, the presence of coronary artery
calcification reduces the accuracy of CT
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TABLE 7 64-Slice CT stenosis detection in segments affected by calcification
Study and type of classification Score No. Sens. % Spec. % PPV % NPV %
Segments
Meijboom, 200665 0–10 338 100 100
AS 11–400 465 100 98 68 100
401–1000 146 94 96 76 99
>1000 54 75 88 33 98
Ong, 200675
AS <142 AS 700 93 98 84 99
142 AS 631 82 93 79 94
Raff, 200585
Calcium rating
None 709 77 98 66 99
Mild 89 87 93 72 97
Moderate 48 92 83 65 97
Severe 88 93 72 64 95
Patients
Raff, 200585
AS 0–100 35 94 95 94 95
101–400 17 100 88 90 100
401–1804 18 93 67 93 67
AS, Agatston score; Sens., sensitivity; Spec., specificity.angiography. This limitation is of most relevance
for those with advanced CAD and so least relevant
at the diagnostic end of the pathway.
Left main artery analysis
Five full-text studies46,52,59,71,75 enrolling 408
people, with 406 included in the analysis, reported
analysis of the left main coronary artery (n = 393).
Figure 11 shows the sensitivity and specificity, with
95% CIs, for the five studies. Sensitivity ranged
from 90%46 to 100%,52,59,71,75 with a pooled
sensitivity of 95% (95% CI 84 to 99%). All five
studies reported a specificity of 100%, with a
pooled specificity of 100% (95% CI 99 to 100%).
Across studies the median PPV was 100% (range
90 to 100%), while all five studies reported a NPV
of 100%.
There was no evidence of statistical heterogeneity
for either sensitivity (I2 = 0.0%) or specificity 
(I2 = 0.0%).
In the studies by Ghostine and colleagues,52
Leschka and colleagues59 and Nikolaou and
colleagues71 all left main artery scans were
evaluated (n = 201). Ehara and colleagues46
reported that five (7%) of 69 left main artery CT
scans were not evaluated owing to poor image
quality, caused by irregular heart rhythm (two),
calcification (two) and vessel motion (one). Ong
and colleagues75 reported that six (4%) of 134 left
main scans were not evaluated, without providing
further details. 
LAD artery analysis
Seven full-text studies46,52,59,65,71,75,83 enrolling 
513 people, with 511 included in the analysis,
reported analysis of the LAD artery (n = 1685).
Figure 12 shows the sensitivity and specificity, with
95% CIs, for the seven studies. Sensitivity ranged
from 78%71 to 100%.65 The pooled sensitivity was
92% (95% CrI 83 to 97%). Specificity ranged 
from 90%65 to 100%.52 The pooled specificity was
96% (95% CrI 91 to 98%). Across studies the
median PPV was 86% (range 63 to 100%), while
the median NPV was 98% (range 95 to 100%).
There was evidence of substantial statistical
heterogeneity for both sensitivity (I2 = 55.8%),
most obviously due to the relatively low sensitivity
(78%) reported by Nikolaou and colleagues,71 and
specificity (I2 = 83.0%), due to the very high
specificity (100%) and extremely narrow
confidence intervals (95% CI 99 to 100%) 
reported by Ghostine and colleagues.52 The
reason for the relatively low sensitivity reported by
Nikolaou and colleagues71 compared with other
studies was unclear. In the study by Ghostine and
colleagues52 all 288 arteries classified as not
having a stenosis greater than 50% on invasive CA
were likewise classified by 64-slice CT (no false
positives). 
In the studies by Ghostine and colleagues,52
Leschka and colleagues,59 Meijboom and
colleagues65 and Pugliese and colleagues83 all
scans were evaluated (n = 702). Ehara and
colleagues46 reported that 32 (9%) of 345 CT 
LAD scans were not evaluated owing to poor
image quality, caused by irregular heart rhythm
(13), sinus tachycardia above 90 bpm (five),
calcification (12) and vessel motion (two).
Nikolaou and colleagues71 reported that 29 (9%)
of 340 CT LAD scans were unevaluable, with
reasons mostly cardiac motion artefacts or small
vessel calibre in distal segments. Ong and
colleagues75 reported that 43 (11%) of 402 LAD
scans were not evaluated, without providing
further details.
Proximal LAD artery analysis
Five full-text studies46,52,59,75,83 enrolling 371
people, with 369 included in the analysis, reported
analysis of the proximal segment of the LAD
artery (n = 358). Figure 13 shows the sensitivity
and specificity, with 95% CIs, for the five studies.
Sensitivity ranged from 91%75 to 100%,59,83 with a
pooled sensitivity of 97% (95% CrI 87 to 99%).
Specificity ranged from 91%75 to 100%,52,59 with a
pooled specificity of 97% (95% CrI 90 to 99%).
Across studies the median PPV was 95% (range 85
to 100%), while the median NPV was 98% (range
90 to 100%).
There was evidence of substantial statistical
heterogeneity in terms of specificity (I2 = 65.7%),
but not sensitivity (I2 = 21.8%).
In the studies by Ghostine and colleagues,52
Leschka and colleagues59 and Pugliese and
colleagues83 all scans were evaluated (n = 168).
Ong and colleagues75 reported that nine (7%) of
134 scans were not evaluated, without providing
further details. Ehara and colleagues46 did not
report the number of LAD proximal scans that
were unevaluable. 
LCX artery analysis
Seven full-text studies46,52,59,65,71,75,83 enrolling 513
people, with 511 included in the analysis, reported
analysis of the LCX artery (n = 1351). Figure 14
shows the sensitivity and specificity, with 95% CIs,
for the seven studies. Sensitivity ranged from
59%52 to 100%,65 with a pooled sensitivity of 85%
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921.9 (174.3 to 9283)(95% CrI 69 to 94%). Specificity ranged from
92%59 to 100%,65 with a pooled specificity of 96%
(95% CrI 92 to 99%). Across studies the median
PPV was 81% (range 56 to 100%), while the
median NPV was 98% (range 93 to 100%).
There was evidence of substantial statistical
heterogeneity in terms of both sensitivity
(I2 = 67.5) and specificity (I2 = 71.4). The study
by Ghostine and colleagues52 was most noticeable
in contributing to the heterogeneity in terms of
sensitivity. In this study all participants had LBBB
and the authors reported that heavily calcified
segments had contributed to 21 out of a total of
26 false positive results for all segments. However,
the effect of calcification on sensitivity at
individual artery level was not reported.
In the studies by Ghostine and colleagues,52
Leschka and colleagues,59 Meijboom and
colleagues65 and Pugliese and colleagues83 all
scans were evaluated (n = 560). Ehara and
colleagues46 reported that 34 (12%) of 276 CT
LCX scans were not evaluated owing to poor
image quality, caused by irregular heart rhythm
(nine), sinus tachycardia above 90 bpm (eight),
calcification (eight), vessel motion (two),
inadequate breath-hold (two), low-contrast
opacification (four) and anomaly (one). Nikolaou
and colleagues71 reported that 47 (14%) of 340 CT
LCX scans were unevaluable, with reasons mostly
cardiac motion artefacts or small vessel calibre in
distal segments. Ong and colleagues75 reported
that 12 (4%) of 268 scans were not evaluated,
without providing further details.
RCA analysis
Seven full-text studies46,52,59,65,71,75,83 enrolling 513
people, with 511 included in the analysis, reported
analysis of the RCA (n = 1567). Figure 15 shows
the sensitivity and specificity, with 95% CIs, for the
seven studies. Sensitivity ranged from 52%52 to
100%,65 with a pooled sensitivity of 87% (95% 
CrI 77 to 95%). Specificity ranged from 95%46,83
to 99%,52 with a pooled specificity of 97% (95%
CrI 92 to 98%). Across studies the median 
PPV was 82% (range 74 to 91%), while the 
median NPV was 98% (range 94 to 100%).
There was evidence of substantial statistical
heterogeneity in terms of sensitivity (I2 = 78.7%),
but not specificity (I2 = 29.1%). The study by
Ghostine and colleagues52 was most noticeable in
contributing to the heterogeneity and, as for the
LCX artery, underestimation of heavily calcified
segments may have contributed to the relatively
lower sensitivity reported.
In the studies by Ghostine and colleagues,52
Leschka and colleagues,59 Meijboom and
colleagues65 and Pugliese and colleagues83 all
scans were evaluated (n = 691). Ehara and
colleagues46 reported that 11 (4%) of 276 CT RCA
scans were not evaluated owing to poor image
quality, caused by irregular heart rhythm (five),
sinus tachycardia above 90 bpm (two), calcification
(two), inadequate breath-hold (one) and low-
contrast opacification (one). Nikolaou and
colleagues71 reported that 21 (8%) of 272 CT RCA
scans were unevaluable, with reasons mostly
cardiac motion artefacts or small vessel calibre in
distal segments. Ong and colleagues75 reported
that 42 (10%) of 402 scans were not evaluated,
without providing further details. 
Stents or stented segment analysis
Six studies (four full text58,86,89,100 and two
abstracts45,72) reported the accuracy of 64-slice CT
angiography for detecting 50% stenosis in
patients who had undergone PCI.
Figure 16 shows the sensitivity and specificity, with
95% CIs, for the six studies reporting the analysis
of stents or stented segments (n = 317). Sensitivity
ranged from 50%58 to 100%,100 with a pooled
sensitivity of 89% (95% CrI 68 to 97%). Specificity
ranged from 56%58 to 100%,100 with a pooled
specificity of 94% (95% CrI 83 to 98%). Across
studies the median PPV was 77% (range 33 to
100%), while the median NPV was 96% (range 71
to 100%).
There was no evidence of substantial statistical
heterogeneity in terms of sensitivity (I2 = 30.1%),
but there was in terms of specificity (I2 = 74.5%).
The study by Leber and colleagues58 was most
noticeable in contributing to the heterogeneity.
The data from this study were based on the
analysis of a small number of stented segments
(n = 13), in which four of nine stents without any
restenosis on invasive CA were diagnosed as
having greater than 50% restenosis on 64-slice CT.
The authors stated that the misclassification was
due to artefacts caused by the dense stent
material.58
Two studies (one full text89 and one abstract45)
involving 113 participants reported patient-level
data. Across these two studies the median (range)
values were 86% (83 to 89%) for sensitivity, 67%
(46 to 87%) for specificity, 41% (10 to 71%) for
PPV and 96% (both) for NPV. 
Three studies (two full text86,89 and one abstract45)
reported that 59 (21%) of 276 scans of stents or
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119.9 (22.9 to 799.9)stented segments could not be evaluated (median
across studies 12%, range 2 to 42%), while no
studies gave information on unevaluable scans at
patient level. Rixe and colleagues89 noted that
stent type had an influence on evaluability,
reporting that of the 31 stents with a diameter of
3.0 mm or larger that were classified as
unevaluable, 30 were of the BxSonic (n = 20) or
Cypher type (n = 10), both of which share the
same strut system with a strut thickness of
0.14 mm. In comparison, only one of nine Taxus
stents, which have a strut thickness of 0.13 mm,
was classified as unevaluable.89 In addition, Rixe
and colleagues89 noted that stent diameter was a
significant influence on evaluability, stating that
3.5 mm was a threshold below which the rate of
evaluable stents was very low. Rist and colleagues86
also reported that the single case of poor image
quality concerned a small (2.5-mm diameter)
stent, which was uninterpretable owing to
extensive metallic streak artefacts. They noted that
the cases in which image quality was considered
poor or moderate typically involved patients fitted
with small-diameter stents in distal segments of
the coronary arteries.86
In conclusion, although the 64-slice CT
performance for identifying in-stent restenosis was
reasonably good, it may vary according to the
type, diameter and location of the stent.
CABG analysis
Four studies (two full text77,94 and two abstracts53,62)
reported the accuracy of 64-slice CT angiography
to detect 50% or greater stenosis in people who
had previously undergone CABG surgery. 
Figure 17 shows the sensitivity and specificity, with
95% CIs, for the analysis of CABGs (n = 543).
Sensitivity ranged from 97%53 to 100%,94 with a
pooled sensitivity of 99% (95% CrI 95 to 100%).
Specificity ranged from 89%77 to 98%,53 with a
pooled specificity of 96% (95% CrI 86 to 99%).
Across studies the median PPV was 93% (range 90
to 95%), while the median NPV was 99% 
(range 98 to 100%).
There was no evidence of substantial statistical
heterogeneity in terms of either sensitivity
(I2 = 0.0%) or specificity (I2 = 41.4%).
Three studies (two full text77,94 and one abstract62)
involving 133 participants reported patient-level
data. Across these studies the median (range)
values were 100% (all three studies) for sensitivity,
71% (50 to 89%) for specificity, 94% (92 to 98%)
for PPV and 100% (all three studies) for NPV.
Only the studies by Pache and colleagues77 and
Ropers and colleagues94 provided information on
unevaluable scans, reporting that all bypass grafts
(n = 231) were evaluable. The study by Pache and
colleagues77 reported that none of the 50
participants had to be excluded from patient-level
analysis owing to unevaluable CT scans.
In conclusion, the performance of 64-slice CT
angiography was very good for assessing graft
patency.
Diagnostic accuracy of SPECT
Some patients in whom there is diagnostic
uncertainty may be referred for a myocardial
perfusion scan. Depending on their relative
diagnostic performance, a potential use of 64-slice
CT angiography may be to replace some perfusion
scanning. In this review, primary studies of
perfusion imaging were not formally searched for.
Rather, the following information on the
diagnostic accuracy of SPECT MPS was derived
from two systematic reviews by Mowatt and
colleagues113 and Fleischmann and colleagues114
and a critique of the Fleischmann review by Kymes
and colleagues115 (Table 8) identified from a search
of the literature for review articles on perfusion
imaging.
The review by Mowatt and colleagues113
included studies comparing SPECT with stress
ECG for the detection of CAD and in which
invasive CA was the reference standard test. In 14
studies involving 3032 patients, ten studies used a
cut-off of 50% or greater stenosis for a positive
result, one used a cut-off of 60% or greater
stenosis and one a cut-off of 70% or greater
stenosis. Results were not pooled owing to
heterogeneity among studies. Across studies the
median sensitivity and specificity for SPECT was
81% (range 63 to 93%) and 65% (range 10 to
90%), respectively.113
Fleischmann and colleagues114 compared the
diagnostic accuracy of exercise SPECT versus
exercise echocardiography, with invasive CA as the
reference standard test. Studies performed
exclusively in patients after MI, after PCI or
CABG, or with unstable coronary syndromes were
excluded. A positive SPECT result was as defined
by the individual study authors (e.g. a fixed or
reversible perfusion defect or a perfusion defect at
rest or after exercise), with a cut-off for significant
CAD also as defined by the individual study
authors (e.g. 50% or 70% stenosis). In pooled
data for SPECT weighted by sample size from 27
studies involving 3237 patients, sensitivity was 87%
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2049 (406.9 to 13890)(95% CI 86 to 88%) and specificity 64% (95% CI
60 to 68%).114
Kymes and colleagues115 critiqued the
Fleischmann review, noting that the included
studies were significantly heterogeneous
(p < 0.001). Kymes and colleagues115 reanalysed
the same 27 studies and reported (using a fixed-
effect model) a pooled sensitivity of 88% (95% CI
86 to 89%) and pooled specificity of 64% (95% CI
60% to 67%). Kymes and colleagues115 also
reported (using a random-effects model) a pooled
sensitivity of 87% (95% CI 83 to 90%) and pooled
specificity of 69% (95% CI 60 to 77%). Within each
meta-analysis they also presented pooled data for
studies stratified for sources of heterogeneity. 
When these results are compared with the 99%
(95% CrI 97 to 99%) sensitivity and 89% (95% CrI
83 to 94%) specificity in the pooled estimates for
64-slice CT angiography for patient-based
detection of significant CAD, this indicates that
there could potentially be a role for 64-slice CT to
replace some perfusion imaging.
Studies reporting the prognostic
usefulness of 64-slice CT angiography
Five studies (one full text55 and four
abstracts95,105–107) provided information on the
prognostic usefulness of 64-slice CT angiography. 
Acute chest pain
The study by Hoffmann and colleagues55 involved
103 patients admitted to the hospital emergency
department between May and July 2005 for chest
pain and who had negative initial cardiac
biomarkers and a non-diagnostic ECG on
presentation. The aims of the study included 
an examination of whether 64-slice CT
angiographic patterns of CAD – any coronary
atherosclerotic plaque and significant stenosis –
were associated with risk of ACS and whether they
provided incremental value to standard
cardiovascular risk factors and standard clinical
risk assessment. Sixty-four-slice CT data were not
used to define ACS.
Of the 103 patients, 14 were diagnosed with ACS
(five with an acute MI and nine with unstable
angina pectoris). Hoffmann and colleagues55
reported that in multivariate logistic regression
analyses both initial models containing either
traditional risk factors or the categorised clinical
estimates of probability of ACS did not predict
ACS [likelihood ratio (LR) 8.41, p = 0.13, and LR
1.94, p = 0.38]. Adding the extent of coronary
atherosclerotic plaque on 64-slice CT as a
continuous variable provided incremental
information and improved both the model with
traditional risk factors (LR, 23.27, p = 0.0007)
and the model with the categorised clinical
estimates of probability of ACS (LR, 19.1,
p = 0.0003).55
In 81 of 89 patients who were diagnosed as not
having an ACS during hospitalisation, telephone
follow-up was conducted at a mean of 5.2 months
(SD 0.3) after hospital discharge, with no patient
having suffered a major cardiovascular event.55
Hoffmann and colleagues55 concluded that the
absence of coronary artery plaque or significant
stenosis on 64-slice CT had an excellent NPV for
the subsequent diagnosis of ACS, potentially
identifying a group of patients who could be sent
home safely on the basis of CT findings. 
Gallagher and colleagues,107 in a prospective study
set in the USA, compared the accuracy of 64-slice
CT with that of stress myocardial perfusion
imaging (MPI) in low-risk chest pain patients
admitted to the emergency department, with all
patients receiving rest/stress MPI and 64-slice CT.
Patients with a positive MPI scan (inducible
ischaemia or submaximal heart rate response)
and/or a positive CT scan (calcium score >400,
stenosis >50%, or uninterpretable images due to
severe calcification or motion artefacts) were
considered for invasive CA, while patients with
negative results were discharged. Telephone
follow-up at 30 days and chart review aimed to
identify major adverse cardiac events. They
reported that 64-slice CT and MPI were both
negative in 52 of 93 patients, who were
Assessment of test performance for diagnosis and assessment of coronary artery disease
34
TABLE 8 Sensitivity and specificity of SPECT for detecting significant CAD
Study No. of  No. of  Measure Sensitivity % Specificity %
studies patients
Mowatt, 2004113 14 3032 Median (range) 81 (63 to 93) 65 (10 to 90)
Fleischmann, 1998114 27 3237 Pooled, fixed effect (95% CI) 87 (86 to 88) 64 (60 to 68)
Kymes, 2000115 27 3237 Pooled, fixed effect (95% CI) 88 (86 to 89) 64 (60 to 67)
Pooled, random effects (95% CI) 87 (83 to 90) 69 (60 to 77)subsequently discharged without undergoing
invasive CA. During the 30-day follow-up period
13 patients with positive scans on 64-slice CT
and/or MPI underwent invasive CA. Of seven
patients with coronary stenoses greater than 50%
on invasive CA, six required revascularisation.107
There were no additional 30-day adverse cardiac
events. Gallagher and colleagues107 concluded 
that the accuracy of 64-slice CT for the detection
or exclusion of ACS or significant coronary
stenosis in low-risk emergency department chest
pain patients was comparable with that of stress
MPI.
Rubinshtein and colleagues,95 in a study set in
Israel, aimed to examine the role of 64-slice CT in
assessing 40 patients presenting to the emergency
department with chest pain of uncertain cause.
Diagnosis, decision to hospitalise and intended
management (intensive therapy/early intervention
versus medical management) were made and
recorded. Following 64-slice CT, change in
diagnosis, need for early intervention and/or
hospitalisation were noted. 
Following 64-slice CT the diagnosis of ACS was
revised in 14 (50%) of 28 patients, hospitalisation
cancelled in 15 (44%) of 34 patients and early
invasive CA postponed in 16 (67%) of 24, but
advanced in one (6%) of 16 patients.95 At 30-day
follow-up there were no adverse cardiac events in
the 15 patients discharged on the basis of negative
or low-risk CT findings. Rubinshtein and
colleagues95 stated that 64-slice CT had resulted in
the primary diagnosis, decision to hospitalise and
decision concerning early intervention being
altered in nearly half of the patients, and that the
decision to discharge patients from the emergency
department based on 64-slice CT results had
proved to be efficient and safe.
In conclusion, the evidence from the few studies
reporting prognostic usefulness of 64-slice CT
angiography suggests that it can affect the way in
which people presenting with ACS are managed
and reduce the need for some hospital admissions
and invasive CAs. However, this is based on only
three studies involving 236 low-risk patients, two
of which were reported as abstracts and had a
follow-up of only 30 days. 
Elective investigation of CAD
The aim of the study by Auseon and colleagues105
was to determine, in a university hospital in the
USA, the impact of the first year (2005) of use of
64-slice CT on invasive coronary angiographic
procedures in diagnosing and treating
atherosclerotic heart disease. The findings from
1056 64-slice CT examinations were recorded
along with subsequent invasive CAs and cardiac
surgeries. The annual throughput of patients in
the cardiac catheterisation laboratories was
tabulated and assessed for change after the
introduction of 64-slice CT.105
Auseon and colleagues105 reported that from 2000
to 2004 there was an average yearly increase of
8.7% in diagnostic cardiac catheterisation volume
and 15.2% in percutaneous interventions.
Following the introduction of 64-slice CT in 2005,
diagnostic catheterisation volume increased by 7%
and percutaneous interventions by 15%. The
authors concluded that in its first year of use 64-
slice CT had a significant impact on the diagnosis
and treatment of atherosclerotic heart disease,
stating that after the introduction of 64-slice CT
only 94 (9%) of 1056 patients went on to receive
invasive CA, 24 of whom required a cardiovascular
operative procedure. However, the annual rates of
increase in diagnostic catheterisation volume and
percutaneous interventions were not significantly
affected.105
The aim of the study by Danciu and colleagues106
was to review the initial experience with 64-slice
CT in a single 20-physician cardiology group in
the USA. All records of studies performed during
the first 6 months of 64-slice CT usage were
reviewed. Charts were abstracted for demographic
data, referral patterns and indications, prior
cardiac testing, results of 64-slice CT and clinical
decisions based on these. Short-term follow-up was
obtained in all patients. Records of 486 patients
were included, of whom 58% were men, 56% had
hypertension, 67% dyslipidaemia, 15% diabetes
mellitus and 29% prior CAD. The indications for
64-slice CT were abnormal stress test (47%),
unexplained symptoms after stress test (35%), high
risk for CAD (10%), cardiomyopathy (3%) and
other (5%), including congenital heart disease and
post-transplant.106
Danciu and colleagues106 reported that CT ruled
out CAD in 30% of patients without prior known
disease. Invasive CA was recommended in 88
patients (18%) and avoided in 398 patients (82%).
Sixty-four-slice CT missed six moderate, but not
severe, stenoses and overestimated six lesions.
During 300 patient-years of follow-up, two
hospitalisations for minor CAD-related issues were
noted in the medically treated patients.106 The
authors concluded that the use of 64-slice CT
angiography could potentially avoid an invasive
procedure in up to 80% of cases in a patient
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64-Slice CT angiography image quality
Twenty-five studies (17 full-
text46,49,52,56,58,59,66,71,75,79,83,86,89,93,94,100,101 and
eight abstracts39,45,68,72,76,82,97,99,102) reported
information on 64-slice CT image quality. Table 9
shows, for different levels of analysis, the median
rate (range) across studies providing information
on image quality for those scans classed as poor
quality. This was 6% (0 to 8%) for patient-level
analysis, 3% (0 to 13%) for segment analysis, 7% (0
to 42%) for stent analysis and 0% for bypass graft
analysis. In some studies images classed as poor
quality were still included in the analysis. Factors
affecting image quality included the presence of
motion artefacts, poor contrast-to-noise ratio,
luminal calcification, small vessel diameter and
stents.
64-Slice CT angiography interobserver
variation
According to Altman,116 kappa values less than
0.20 indicate poor agreement, those between 0.21
and 0.40 fair agreement, between 0.41 and 0.60
moderate agreement, between 0.61 and 0.80 good
agreement, and between 0.81 and 1.00 very good
agreement. Ten full-text
studies46,55,56,59,65,66,71,79,83,86 reported the results of
kappa analysis for interobserver variation in
assessing 64-slice CT scans (Table 10). The median
kappa score across these studies was 0.74 (range
0.53 to 0.95). None of the studies reported as
abstracts provided information on interobserver
variation. In conclusion, there appeared to be
good overall interobserver agreement for 64-slice
CT, with the exception of analysis of stents.
However, as none of the studies reported the
degree of uncertainty around these values the true
level of agreement is somewhat unclear.
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TABLE 9 Studies reporting poor-quality 64-slice CT images
Unit of analysis No. of studies Poor-quality scans, median (range) % 
across studies
Patients
Full-text studies 4 6 (6 to 7)
Abstracts 3 2 (0 to 8)
Total 7 6 (0 to 8)
Segments
Full-text studies 9 4 (0 to 13)
Abstracts 5 3 (0 to 11)
Total 14 3 (0 to 13)
Stents
Full-text studies 2 22 (2 to 42)
Abstracts 2 6 (0 to 12)
Total 4 7 (0 to 42)
Bypass grafts
Full-text studies 1 0
TABLE 10 64-Slice CT interobserver variation in detecting significant stenosis
Study Unit of analysis Kappa
Ehara, 2006a46 Segment 0.95
Hoffmann, 200655 Patient 0.82
Johnson, 200756 Patient 0.81
Leschka, 200559 Unclear whether patient or segment 0.95
Meijboom, 200665 Segment 0.71
Mollet, 200566 Unclear whether patient or segment 0.73
Nikolaou, 200671 Patient 0.81
Plass, 200678 Unclear whether patient or segment 0.93
Pugliese, 2006a83 Unclear whether patient or segment 0.73
Rist, 200686 Stent 0.53Summary
Twenty-one diagnostic accuracy studies reported as
full-text papers and 20 reported as abstracts, along
with one full-text study reporting prognostic
usefulness and four studies reported as abstracts,
met the inclusion criteria for the review. The
diagnostic accuracy and prognostic studies
enrolled over 2500 and 1700 people, respectively.
As measured by the modified QUADAS checklist,
the overall quality of the full-text diagnostic
accuracy studies was reasonably good. In all
studies the reference standard was considered
likely to classify CAD correctly and all patients
who received 64-slice CT angiography also
received the same reference standard regardless of
the 64-slice CT result. In 85% of studies those
interpreting 64-slice CT data were blinded to the
results of the reference standard test and 71% of
studies vice versa. In 48% of studies the
participants belonged to specific groups, for
example those with LBBB, or who had undergone
previous PCI or CABG, or who had been referred
for cardiac valve surgery. 
Table 11 summarises, across different levels of
analysis, the results of those diagnostic accuracy
studies meeting the inclusion criteria for the review
that reported true and false positives and negatives
or provided information enabling these data to be
calculated, thereby allowing them to be included
in the pooled estimates. These studies used 64-slice
CT angiography with the aim of detecting 50% or
greater stenosis in people with suspected or known
CAD, with invasive CA used as the reference
standard. The median prevalence of CAD across
these studies at this cut-off was 58% (range 23 to
96%). The pooled sensitivity (95% CrI) for the
different levels of analysis ranged from 85% (69 to
94%) for the LCX artery to 99% (97 to 99%) for
both patient-level analysis and CABG analysis (95
to 100%), with left main artery analysis and
proximal LAD analysis also showing values of 95%
or higher. Pooled specificity ranged from 89%
(95% CrI 83 to 94%) for patient-level analysis to
100% (95% CI 99 to 100%) for left main artery
analysis, with all of the other levels of analysis
apart from stents showing values of 95% or higher.
The median PPV (range) at 76% (44 to 93%) was
lowest for segment-level analysis and at 100% (90
to 100%) highest for left main artery analysis, with
proximal LAD analysis also showing a high value
at 95% (85 to 100%). Median NPVs for all levels of
analysis (apart from stents, 96%, range 71 to
100%) showed values of 98% or higher.
The studies were heterogeneous in terms of their
participants. In some studies the participants were
all suspected CAD, in others they were all known
CAD, or a mixture of suspected/known CAD, or
with previous CABG or had LBBB. The
prevalence of significant CAD (50% stenosis) in
the studies included in the pooled estimates
ranged from 23 to 96%. However, as assessed by
the I2 statistic, there was no evidence of substantial
statistical heterogeneity in terms of sensitivity or
specificity across studies reporting patient-level
analysis, left main artery analysis or bypass graft
analysis, no evidence of substantial statistical
heterogeneity in terms of sensitivity across studies
reporting proximal LAD artery or stents/stented
segments analysis, or in terms of specificity across
studies reporting RCA analysis.
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TABLE 11 Summary of diagnostic accuracy results for different levels of analysis 
Level of analysis No. of  No.  Pooled  Pooled  PPV  NPV 
studies analysed sensitivity %  specificity % median % median % 
(95% CrI) (95% CrI) (range) (range)
Patient 18 1,286 99 (97 to 99) 89 (83 to 94) 93 (64 to 100) 100 (86 to 100)
Segment 17 14,199 90 (85 to 94) 97 (95 to 98) 76 (44 to 93) 99 (95 to 100)
Left main arterya 5 393 95 (84 to 99) 100 (99 to 100) 100 (90 to 100) 100b
LAD overall 7 1,685 92 (83 to 97) 96 (91 to 98) 86 (63 to 100) 98 (95 to 100)
LAD proximal 5 358 97 (87 to 99) 97 (90 to 99) 95 (85 to 100) 98 (90 to 100)
LCX overall 7 1,351 85 (69 to 94) 96 (92 to 99) 81 (56 to 100) 98 (93 to 100)
RCA overall 7 1,567 87 (77 to 95) 97 (92 to 98) 82 (74 to 91) 98 (94 to 100)
Stents 6 317 89 (68 to 97) 94 (83 to 98) 77 (33 to 100) 96 (71 to 100)
CABGs 4 543 99 (95 to 100) 96 (86 to 99) 93 (90 to 95) 99 (98 to 100)
a For left main artery analysis the 95% intervals around the pooled sensitivity and specificity estimates are confidence
intervals (CIs) rather than credible intervals (CrIs). 
b All five studies reporting left main artery analysis had an NPV of 100%.A comparison of 11 studies separately reporting
suspected and known CAD found that, in terms of
patient-level analysis (n = 309), 64-slice CT had
higher sensitivity, PPV and NPV, but lower
specificity, for known compared with suspected
CAD. In segment-level analysis (n > 7708), 
64-slice CT reported higher sensitivity for suspected
CAD and lower PPV for known CAD, while
specificity and NPV were similar for both groups.
Three studies65,75,85 involving 274 people (3269
segments) reported the accuracy of 64-slice CT
angiography for detecting 50% or greater stenosis
in segments affected by different degrees of
calcification. In two studies65,75 sensitivity,
specificity, PPV and NPV decreased as the severity
of calcification increased, while in the third study85
sensitivity increased, specificity decreased, and
PPV and NPV remained broadly similar. 
Seven studies49,59,75,79,93,94,102 stated that segments
smaller than 1.5 mm in diameter were excluded
from the analysis, while one study68 excluded
segments 2 mm in diameter or smaller. In the 13
full-text studies included in the pooled estimates
for patient-based detection of CAD, 11 (2%) of
718 patients could not be assessed owing to
unevaluable CT scans (median across studies 0%,
range 0 to 6%). In segment-level analysis, 13
studies reported that 997 (8%) of 12,476 CT
segment scans could not be evaluated (median
across studies 9%, range 0 to 18%). Non-
evaluability was due to poor image quality, for
reasons such as irregular heart rhythm and
coronary calcification. Ten
studies46,55,56,59,65,66,71,79,83,86 reported
interobserver variation in assessing 64-slice CT
scans, with a median kappa score across studies of
0.74 (range 0.53 to 0.95).
Some patients in whom there is diagnostic
uncertainty may be referred for a perfusion scan,
and a possible use for 64-slice CT angiography,
depending on relative diagnostic performance,
may be to replace some perfusion scanning. Two
systematic reviews113,114 and one paper115 that
reanalysed data from one of the reviews provided
information on the sensitivity and specificity of
SPECT. Depending on the type of analysis
undertaken, SPECT sensitivity was reported as
81%, 87% or 88%, while specificity was 64%, 65%
or 69%.
Five studies (one full text55 and four studies
reported as abstracts95,105–107) provided
information on the prognostic usefulness of 64-
slice CT angiography. In three studies the patient
populations were those with suspected ACS.
Hoffmann and colleagues,55 in a study involving
103 patients with acute chest pain with a mean
follow-up of 5.2 months, reported that 81 patients
diagnosed as not having ACS had experienced no
major cardiovascular events at follow-up, and
concluded that 64-slice CT angiography had very
good NPV for the subsequent diagnosis of ACS in
the short term. Gallagher and colleagues,107 in a
study of low-risk patients admitted to the hospital
emergency department with chest pain, reported
that those with negative 64-slice CT and MPI scans
(n = 52) who were discharged experienced no
adverse cardiac events during the 30-day follow-
up. Rubinshtein and colleagues95 examined the
role of 64-slice CT angiography in patients
(n = 40) presenting to the hospital emergency
department with chest pain of uncertain cause.
The authors reported that taking account of 64-
slice CT angiography had led to the diagnosis
being revised in 14 (50%) of 28 patients,
hospitalisation cancelled in 15 (44%) of 34 patients
and early invasive CA postponed in 16 (67%) of
24, but brought forward in one (6%) of 16 patients.
At 30-day follow-up there were no adverse cardiac
events in the 15 patients discharged on the basis
of negative or low-risk 64-slice CT findings.
Of the other two studies, Auseon and colleagues105
reported that, in the year following the
introduction of 64-slice CT compared with the
previous 4 years, the yearly rates of increase in
diagnostic catheterisation volume (7% versus
8.7%) and percutaneous interventions (15% versus
15.2%) had not been significantly affected. Danciu
and colleagues106 reported that in the first
6 months following the introduction of 64-slice
CT, of 486 patients CT results had led to invasive
CA being recommended in 88 (18%) patients and
avoided in 398 (82%), of whom there were
subsequently two hospitalisations for minor CAD-
related issues.
In conclusion, at a cut-off of 50% or greater
stenosis, the high NPVs reported across various
levels of analysis by the diagnostic accuracy studies
appear to be borne out by the few prognostic
studies included in the review that followed up
patients subsequently discharged from hospital on
the basis of negative/low-risk 64-slice CT
angiography scans, who were then found not to
have experienced any adverse cardiac events,
although these results were based on short-term
(mostly 30-day) follow-up.
The implications for invasive CA workload are as
follows.
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investigation of suspected ACS, some low-risk
patients may potentially be reassured and
discharged based on CT findings. However,
troponin-positive patients (i.e. those with MI)
would still need invasive testing with a view to
possible revascularisation. Troponin-negative
patients often have atypical symptoms and would
tend to be clinically assessed and possibly undergo
exercise testing rather than receiving an invasive
CA test. In three diagnostic studies39,55,84 included
in this review the populations were patients
suspected of having ACS (n = 232). In these
studies, for patient-based detection of significant
CAD, 69 (95%) of 73 patients testing negative on
64-slice CT were true negatives by invasive CA,
suggesting that, based on these results, around
30% (69/232) of invasive CA tests may potentially
be avoided for this patient group. Across the
studies the median NPV was 100% (range 94 to
100%). (In the study reporting a 94% NPV,39 three
of four patients whose scans could not be
evaluated were classed as false negatives, which
had the effect of lowering the NPV value.) 
In the elective investigation of suspected CAD, CT
has sufficiently high NPV to rule out significant
CAD in many cases, thereby reducing demands on
invasive CA. In four studies71,85,93,97,102 included in
this review, those with suspected CAD comprised
the entire patient population or a subgroup that
was reported separately (n = 245). One of the four
studies71,102 involving 39 patients did not report
true and false positives and negatives. In the
remaining three studies, for patient-based
detection of significant CAD, 107 (97%) of 110
patients testing negative on 64-slice CT were true
negatives by invasive CA, suggesting that, based
on these results, around 52% (107/206) of invasive
CA tests may potentially be avoided for this
patient group. Across these three studies the
median NPV was 98% (range 93 to 100%).
Sixty-four-slice CT angiography may also replace
some perfusion scanning tests. In two systematic
reviews113,114 of SPECT MPS, sensitivity was
reported as a median of 81% across studies (range
63 to 93%)113 or pooled estimate of 87% (fixed-
effect model, 95% CI 86 to 88%),114 while
specificity was reported as a median of 65% across
studies (range 10 to 90%)113 or pooled estimate of
64% (fixed-effect model, 95% CI 60 to 68%).114
This compares with the pooled estimates for 
64-slice CT angiography patient-based detection
of significant CAD of 99% (95% CrI 97 to 99%)
sensitivity and 89% (95% CrI 83 to 94%)
specificity.
In assessment of prognosis, 64-slice CT can
identify patterns of CAD which carry the greatest
risk of mortality, and in whom revascularisation is
indicated on prognostic grounds. However, 64-
slice CT does not at present seem sufficient to
replace invasive CA in assessment of patients
referred for CABG.
After revascularisation, 64-slice CT angiography is
more accurate for identifying significant stenosis
in bypass grafts (pooled estimates, sensitivity 99%,
95% CrI 95 to 100%; specificity 96%, 95%, 
CrI 86 to 99%; median PPV 93%, range 90 to
95%; NPV 99%, range 98 to 100%) than it is for
identifying significant stenosis in stents (pooled
estimates, sensitivity 89%, 95% CrI 68 to 97%;
specificity 94%, 95% CrI 83 to 98%; median PPV
77%, range 33 to 100%; NPV 96%, range 71 to
100%).
In patients referred for cardiac valve surgery, 
64-slice CT angiography may have a role to play
in obviating the need for invasive investigation in
patients whose CT test results reveal no significant
CAD. 
In conclusion, if in patient-based detection of
significant (50% stenosis) CAD, and taking other
factors into account such as pretest probability of
CAD, a negative 64-slice CT angiography test
allowed an invasive CA test to be avoided, then,
depending on the patient groups involved, this
could potentially result in some reduction in
invasive CA workload.
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Search strategy
Studies that reported both costs and outcomes of
MSCT screening were sought for the systematic
review of the literature. Searches were restricted to
reports published in English and to publications
from 1996 onwards. 
Databases searched were MEDLINE (1996 to
November week 3 2006), EMBASE (1996 to week
49 2006), Medline In-Process (14 December 2006),
NHS EED (December 2006), HTA Database
(December 2006) and HMIC (2000 to May 2006).
In addition, recent conference proceedings and
reference lists of all included studies were scanned
to identify additional potentially relevant studies.
Full details of the search strategies used are
documented in Appendix 1.
Results
Number of studies identified
A total of 144 reports was identified from the
searches, of which 47 papers were selected for full-
text assessment. No studies of the cost-
effectiveness of multidetector computed
tomography (MDCT) for CAD were identified.
One study identifying the necessary cost and
accuracy of MDCT for it to be cost-effective
relative to gadolinium-enhanced MRI was
identified.117 As a consequence, the studies briefly
reviewed below have been used to inform the
modelling of the cost-effectiveness of MDCT in
terms of the structures of both a short-term model
and a more speculative long-term model, and also
to inform the characteristics of the other tests
involved in the diagnosis of CAD within this
modelling: exercise ECG, myocardial perfusion
scanning and CA.
Economic literature review
Several original articles relating to other testing
strategies were identified, the more informative of
which are briefly reviewed below to inform
possible model structure and model inputs for this
review.117–122 Table 12 summarises these studies.
Some systematic reviews and HTAs of MDCT for
CAD were identified, but again these involved no
cost-effectiveness analyses. They did outline a
number of cost-effectiveness issues likely to arise
with using MDCT for CAD, the 2005 review of the
Medical Advisory Secretariat of the Ontario
Ministry of Health22 being the most informative of
these.
Visser and colleagues117 project the required cost
and accuracy of MDCT for it to be cost-effective,
on the basis of a WTP of $100,000 per QALY.
Unfortunately, the comparator test for their study
is gadolinium-enhanced MRI, which is of limited
practical relevance to the UK setting. Given this,
that the accuracy of MDCT has to be defined over
several dimensions, and the US setting in terms of
costs, the projected required accuracy for MDCT is
of little relevance to the current review.
Garber and Solomon118 evaluate the cost-
effectiveness of five non-invasive diagnostic tests
against angiography: exercise testing, planar
thallium imaging, stress echocardiogram, SPECT
and PET. The costs of these are estimated as $110,
$221, $265, $475 and $1500, respectively, these
being taken from Medicare with the exception of
PET which, since Medicare does not reimburse 
for PET myocardial imaging, is based on an
unspecified insurer. A short-term diagnostic model
with patients receiving their continued medication
with ongoing observation, intensified medical
management or revascularisation is coupled with a
longer term model of the effectiveness of these
treatments in terms of avoiding angina, infarctions
and death. Intervention costs are also taken from
Medicare, these being $1180 for CA coupled with
catheterisation, $11,685 for PCI as the Medicare
average of one- and two-vessel procedures, and
$32,824 for CABG. The paper estimates an
infarction resulting in a single admission to cost
$7415.
In terms of the model structure, a negative non-
invasive test at the diagnostic stage leads to
discharge and continued medical management,
with ongoing observation. A positive non-invasive
test result is assumed to result in angiography,
with its associated very low risks of complication,
such as infarction and death. The non-invasive
tests were viewed not as potential replacements for
angiography in assessing CAD, but only as means
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Chapter 3
Assessment of cost-effectivenessof reducing the number of angiographies required
through hopefully being able to rule out
significant CAD. If the angiography results in no
significant CAD, patients are discharged and
managed as for a negative non-invasive test. All
positive CAD states may be managed medically.
One-vessel, two-vessel and three-vessel or left
main disease are treated differently for prognostic
reasons. Three-vessel or left main disease is taken
to require CABG.
Sensitivities were estimated from 68% for exercise
ECG, through 76% and 79% for echocardiography
and thallium imaging, respectively, to 88% for
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TABLE 12 Summary of studies relating to other testing strategies
Study Country Perspective Comparators Main results
Cost-effectiveness modelling of diagnostic tests for CAD
Visser,  USA Societal MDCT enhanced  Given a WTP of $100,000 per QALY MDCT cost-
2003117 MRI effective if test cost $300 and sensitivity 85%
Garber,  USA Societal Stress ECG Thallium imaging similar effectiveness to Echo but more 
1999118 Exercise Echo expensive
Planar thallium 
imaging PET more expensive and inferior to sending all to 
MPS angiography
PET
Kuntz,  USA Societal Exercise ECG Among typical angina patients:
1999119 Exercise Echo • $41,900 per QALY for move from exercise ECG to 
MPS exercise Echo
• $54,800 per QALY for move from exercise ECG to
SPECT
• $36,400 per QALY for move from exercise echo to
routine angiography
For non-specific chest pain:
• $57,700 per QALY for move from no testing to
exercise ECG
Underwood,  UK Healthcare  Exercise ECG Strategies involving MPS as an interim prior to 
1999120 system Exercise Echo angiography are cheaper and equally effective both at 
MPS diagnosis and for outcome over 2 years
Review article of cost-effectiveness consideration of MDCT diagnosis of CAD
Ontario MoH, Canada Healthcare  MDCT MDCT faster turnaround times may reduce waiting lists 
200522 system for CT, provided that complementary inputs (e.g.
portering) are available
However, as applications for MDCT expand, the
number of CT tests requested may similarly expand
Cost-effectiveness modelling of MPS diagnosis of CAD, as nearest likely comparator to MDCT
Patterson,  USA Healthcare  Exercise ECG CAD patients not correctly diagnosed and treated lose 
1995123 system MPS an average of 3 QALYs
PET • If prevalence of CAD is <70% PET has the lowest
cost per QALY
• If prevalence of CAD is >70% angiography has the
lowest cost per QALY
Mowatt,  UK Healthcare  Exercise ECG If prevalence of CAD is 10.5%, for MPS–angiography as 
2004113 system MPS compared to ECG–MPS-angiography, cost-effectiveness
would be £14,123 per QALY
As the prevalence of CAD rises the cost effectiveness of
this move improves
Echo, echocardiography; PET, positron emission tomography; QALY, quality-adjusted life-year; WTP , willingness to pay.SPECT and 91% for PET, with specificities being
77%, 88%, 73%, 77% and 82%, respectively. These
were not differentiated by degree of disease with
the exception of sensitivity to left main or three-
vessel disease, where exercise ECG again
performed least well at 86%, followed by 94% and
93% for echocardiography and thallium imaging,
respectively, and 98% for SPECT.
While the clinical inputs and model structure are
of more interest to the current review, the cost-
effectiveness estimates of Garber and Soloman,118
in a population with a 50% prevalence of CAD,
suggest that thallium imaging has a very similar
but possibly slightly inferior effectiveness
compared to echocardiography, but is around
$120–150 more expensive overall per patient.
Similarly, PET is slightly more expensive than
sending all immediately to angiography, and
performs more poorly. Sensitivity analyses tended
to confirm these results, with echocardiography
having similar effectiveness but reduced costs
compared with thallium imaging, and
angiography typically dominating PET.
Kuntz and colleagues119 mirror the above, but
examine exercise ECG, exercise echocardiography
and exercise SPECT in the US context.
Sensitivities are reported as 68%, 85% and 87%,
respectively, the gap in sensitivities between
exercise echocardiography and exercise SPECT
being somewhat less than in Garber and
Solomon’s118 report between echocardiography
and SPECT. Specificities are reported as 77%, 
77% and 64%, again with exercise
echocardiography being anticipated to perform
relatively better than the corollary in Garber. 
The unit costs of the two papers are similar. Kuntz
also assumed that some tests would be
indeterminate, with an indeterminacy rate for
exercise ECG of 30%, for exercise
echocardiography of 10% and for exercise SPECT
of 2%, although the source of these estimates is
unclear. The prevalence of CAD was estimated as
95%, 71% and 18% in men with typical, atypical
and non-specific chest pain, the prevalences for
women being 68%, 30% and 6%, respectively. For
typical angina, angiography appears cost-effective
relative to all the other tests, with cost-
effectiveness ratios of around $30,000 per QALY.
Within atypical angina, angiography has more
marginal cost-effectiveness relative to the other
tests, its cost-effectiveness ratio rising to around
$70,000 per QALY relative to exercise
echocardiography and exercise SPECT. For
atypical angina, only the move from exercise
echocardiography to exercise SPECT is unlikely to
be cost-effective, involving an anticipated cost per
QALY of around $110,000.
As with other papers reviewed in this section, the
relevance of the results of Kuntz to the current
review is limited, other than to highlight the
importance of the underlying CAD prevalence.
The model structure and clinical inputs are of
greater interest. A lifetime cost–utility analysis is
undertaken within a decision-tree model structure,
the immediate short-term model of diagnosis
having the three possibilities of no diagnostic
testing, non-invasive testing with a positive result
leading to CA, and all patients going straight to
angiography. CA was assumed to have perfect
sensitivity and specificity, but also a small mortality
risk. CA was also able to split patients with one-
and two-vessel disease, who within the modelling
should receive percutaneous transluminal coronary
angioplasty (PTCA), from those with three-vessel
or left main disease who should receive CABG.
Both PTCA and CABG had their own small
procedural mortality risk, but among survivors
conferred a reduction in the mortality risk
associated with CAD and MI. Both true and false
negatives were deemed at low risk and so only
received medication. While the overall model
structure appears reasonable, a major weakness
may be in the treatment of false negatives. They
appear to be assumed only to receive medication,
but in practice it may be that as medication proves
insufficient in managing their symptoms or as
their disease progresses they will present again
and so undergo further testing. If this occurs it
will mitigate a poorer specificity of any particular
testing strategy, with a proportion of the false
negatives who have not had an event in the
intervening period re-presenting for further
testing each year.
Underwood and colleagues120 undertake a similar
analysis to those reported above, examining
diagnostic strategies involving exercise ECG, MPI
and CA from a UK perspective. For the current
review their results are mainly of interest owing to
the unit costs reported, with an exercise ECG
costing £70, a rest echocardiogram £100, MPI
£220, angiography £1100, angioplasty £3700 and
CABG £6900, based on costs from the Royal
Brompton Hospital, London. Four diagnostic
strategies were examined which variously
sequenced exercise ECG, MPI and CA. The text of
the paper is not explicit, but it appears likely that
if an earlier test in the sequence was negative no
further tests were performed, but an
indeterminate result or a positive result would
result in the next test in the strategy. Strategies
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angiography, exercise ECG followed by MPI
followed by angiography, MPI followed by
angiography, and angiography alone. A further
slight complication to the diagnostic pathway
within the paper was that any false negative
experiencing an event during a largely unspecified
follow-up period would have their diagnosis
altered to become a true positive.
The second strategy of perfusion imaging in the
interim between exercise ECG and angiography
was found to have a diagnostic cost of £269 as
against £335 for all ECG-positive patients being
sent straight to angiography. The third strategy of
no exercise ECG before perfusion imaging is of
similar average diagnostic cost to the first strategy
of ECG then angiography, but has higher
downstream patient management costs among
non-CAD patients. However, the results of
Underwood are confused by it being reported 
that the proportion of true positives among final
positive results is less than 100% for all testing
strategies other than coronary angiography. 
Given that each testing strategy has CA as the 
final test, it not clear how these results were
arrived at.
Two papers were available only as abstracts. Raff
and colleagues122 report a study among 200
patients with low-risk acute chest pain randomised
either to immediate 64-slice CT or to a largely
unspecified usual care algorithm that included
enzyme testing and stress nuclear scanning. Those
undergoing 64-slice CT had a median time to
diagnosis of 3.3 hours compared with 12.0 hours
for usual care. This lowered the median cost of
care to $1595 compared with $1784 for usual care,
in spite of 64-slice CT leading to more patients
going on to invasive angiography: 11% as against
3% for usual care. It is not entirely clear whether
the costs of angiography were included within
these estimates, but the abstract concludes that 
64-slice CT can rapidly rule out CAD in chest pain
without increasing risk. How this conclusion was
arrived at is also unclear, given that there does not
appear to have been any gold-standard
investigation or long-term follow-up for those
discharged without angiography. The only
outcomes appear to be cost, time to diagnosis and
time to discharge.
Cole and colleagues121 report the results of a study
of 206 patients with mildly abnormal or equivocal
nuclear perfusion imaging who underwent
immediate 64-slice CT rather than immediate
catheterisation for the diagnosis of CAD at the
discretion of the cardiologist. A cost analysis found
these patients to cost on average $1809 as against
$4075 for the immediate catheterisation, so
realising an average cost saving of $2266 per
patient. The abstract did not report any
measurement of patient outcomes or cost-
effectiveness.
The economic literature search also identified four
review articles,10,17,22,124 although none identified
any economic studies of 64-slice CT for CAD.
They did, however, note a number of economic
considerations that would affect the likely cost-
effectiveness of 64-slice CT in CAD. As already
mentioned, the 2005 review of the Medical
Advisory Secretariat of the Ontario Ministry of
Health22 is the most informative of these from an
economic viewpoint. This notes a major
investment in Ontario in MDCT scanners, and
that proponents of MDCT scanning suggest that
the fast turnaround time will reduce waiting times
for CT scans. 
The review is at pains to point out that any such
reduction in waiting times would depend on a
number of other factors within the system, down
to aspects as simple as having sufficient portering
staff to transfer patients. Another aspect that may
affect waiting times is the increase in demand for
CT scans as more indications are found to take
advantage of the new MDCT’s greater accuracy.
The review also questions the extent to which
cardiologists will be prepared to rely solely on the
MDCT scan result. At least in the interim some
mistrust may arise, given the assumed gold-
standard nature of angiography. It is also possible
that professional differences of opinion may arise,
given that radiologists perform MDCT scans while
cardiologists perform angiographies, which may in
the short to medium term see cardiologists
continue to perform angiographies despite MDCT
results being available.
On a more prosaic level, if after a positive MDCT
an angiography is required, the additional
diagnostic MDCT test may actually increase
waiting times, simply as a result of more tests
being sequenced. This is not to say that costs will
necessarily increase if a negative MDCT could
confidently be used to rule out CAD. The review
also fails to consider the effect this may have on
waiting times for angiography. The review is
wrong to state that the waiting time for
angiography and other cardiac procedures will
increase if both MDCT and angiography are
performed on the same patient. This will only
necessarily occur if both MDCT and angiography
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results. The review estimates a scan time for
MDCT of 15–40 minutes, compared with 60
minutes for traditional angiography. 
In common with all the identified studies, the
review does not consider the possibility of
combining diagnostic angiography with
angioplasty during the same catheterisation
laboratory appointment if angioplasty is found to
be indicated. Depending on timings and the
percentage of patients in whom angioplasty is
indicated, the possibility of combining 
angioplasty with angiography at the same
catheterisation laboratory appointment could 
have a significant impact on the likely cost-
effectiveness of MDCT within the diagnostic
pathway.
Modelling the cost-effectiveness of MPS
Given the lack of studies addressing the cost-
effectiveness of MDCT scanning, an obvious
alternative to inform modelling approaches and
structure is to examine studies of the non-invasive
comparator to MDCT: MPS, as briefly outlined in
the summary of Kuntz and colleagues119 above.
SPECT MPS for the diagnosis of CAD has recently
been the subject of a systematic review by Mowatt
and colleagues.113 The economic literature review
of Mowatt and colleagues highlighted the
importance of the modelling approach adopted by
Patterson and colleagues,123 this being adopted by
a further three studies of the literature review, the
modelling section of Mowatt and colleagues113
also drawing a number of key parameter estimates
from Patterson and colleagues. Both Patterson and
colleagues123 and Mowatt and colleagues113 adopt
a similar modelling strategy of a short-term
decision-tree model for the diagnostic element,
coupled with longer term modelling of the
downstream impact of the resultant distribution of
patient diagnoses.
Patterson and colleagues123 compare a range of
diagnostic strategies involving ECG, MPS, PET
and coronary angiography:
● ECG followed by CA where ECG positive or
indeterminate
● MPS followed by CA where MPS positive or
indeterminate
● PET followed by CA where PET positive or
indeterminate
● CA alone.
Non-invasive tests were taken to have a death rate
of 5 per 100,000 and a complication rate of 5 per
10,000. CA was taken to have a death rate of 150
per 100,000 and a complication rate of 200 per
10,000. Complications were taken to be a non-fatal
MI requiring a week’s stay in hospital. CA was
taken as the gold standard, resulting in all test
strategies resulting in no false positives. Coupling
the above strategies and assumptions with the
sensitivity, specificity, indeterminacy and cost of
the tests enabled estimates of each testing
strategy’s number of true positives, false negatives,
true negatives, deaths and cost within the short-
term diagnostic model. Indeterminacy rates of
18% for ECG and 9% for MPS were somewhat
closer to each other than the 30% for ECG and 2%
for MPS of Kuntz.119
These were then coupled with a longer term
model of the downstream impact of the treatment
of true positives and the lack of treatment of false
negatives. This was based on an assumption that
correct treatment would see 30% receive medical
treatment, 30% PTCA and 40% CABG surgery. For
each of these groups, and for whether they were
treated or not treated, the average QALYs
achieved were estimated, based on
● the proportion likely to be alive at the 10-year
point
● the proportion likely to die before the 10-year
point
● the likely longevity of those dying before the
10-year point
● their associated quality of life.
This was done for both true positives and false
negatives. This resulted in a 10-year estimate of
7.09 undiscounted QALYs for those correctly
treated, and 4.09 undiscounted QALYs for those
incorrectly not treated: a net effect of a missed
diagnosis of 3 QALYs. While this method for the
longer term modelling has the benefits of
simplicity, it may fail to take into account false-
negative patients re-presenting with symptoms at a
later time and subsequently being correctly
diagnosed.
Mowatt and colleagues113 adopted a similar
approach to that of Patterson and colleagues123 for
the short-term modelling of different diagnostic
strategies in their assessment of the cost-
effectiveness of MPS for the diagnosis of CAD:
● ECG followed by CA where ECG positive or
indeterminate
● ECG followed by MPS where ECG positive or
indeterminate, followed by CA where MPS
positive or indeterminate
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indeterminate
● CA alone.
The complications from testing were dropped in
their model. Sensitivities and specificities were
estimated by the review, with the indeterminacy
rates and mortality risks of the tests being drawn
from Patterson and colleagues.123 CA was again
taken to be the gold standard, implying that 
there were no false positives from any of the
diagnostic strategies. There is an additional
qualification of those with CAD being either high
risk or medium risk, the balance between these
being 59:41. It appears that the sensitivity,
specificity and indeterminacy of tests are taken 
to be the same for high risk and medium risk 
and the distinction between patients has no
impact on the short-term diagnostic modelling
base case. 
Within the short-term diagnostic modelling, the
distinction between high risk and medium risk
appears only to impact within a sensitivity analysis
where SPECT is assumed to be able to identify a
proportion of medium-risk patients, these not
requiring CA. Regardless of the background
prevalence, the strategy of ECG followed by MPS
followed by CA was found to always be the
cheapest, then ECG followed by CA, then MPS
followed by CA. The strategy of referring all to CA
was found to be the most expensive, given the
high cost of CA and the avoidance of it among
some patients with the other diagnostic strategies.
The ordering of strategies by the percentage of
those with CAD correctly diagnosed was the same
as the cost ordering, the incremental cost per
correct true diagnosis falling as the background
prevalence rose.
In contrast to Patterson,123 the short-term
modelling of the diagnostic pathways was
augmented by a relatively sophisticated longer
term Markov cost–utility model. Subsequent to the
short-term diagnostic model, patients could be
low-risk true negatives, medium-risk false
negatives, high-risk false negatives, medium-risk
true positives or high-risk true positives. As all
strategies had CA as a final test for those not
deemed negative by previous tests, there were no
false positives. Within each Markov cycle patient-
specific mortality rates were applied, with there
also being a patient-specific possibility of MI, also
with its associated death rate. Survivors of MI
automatically transferred to be high-risk true
positives. Thereafter, true positives could progress
to revascularisation through either PTCA or
CABG, with there also being a small probability of
low-risk true-negative patients also progressing to
revascularisation. Within the longer term
modelling, there was also a probability of false
negatives being rediagnosed before any event such
as an MI, which served to lessen the differences
between the long-term outcomes of the four
diagnostic strategies. 
Coupling the short-term diagnostic model with
the longer term model yielded estimates of cost
and average QALYs. What is immediately striking
within the combined results are the limited
differences that arise from the long-term
modelling over the 25-year time-horizon. The
incremental costs of moving between strategies of
the short-term modelling are affected by less than
10% when long-term costs are added, while the
difference in QALYs between the ECG–MPS–CA
testing strategy and the gold standard of CA alone
is less than a quarter of one per cent. This will in
part have been due to later diagnosis of false
negatives being permitted, which lessens the
distinctions between the testing strategies in
comparison to Patterson and colleagues.123 But
the assumptions as to later diagnosis rates also
raise questions as to the practical impact of what
could be viewed as illustrative long-term
modelling within this area. A key uncertainty
remains the rate at which false negatives remain
undiagnosed and untreated, and at risk of an
event such as a fatal MI.
Clinical effectiveness of 64-slice CT
against MPS and CA for CAD diagnosis:
implications for modelling
The clinical effectiveness section outlines, for
patient-based detection of significant CAD, a
pooled estimate for the sensitivity of 64-slice CT
of 99% (95% CI 97 to 99%) and a specificity of
89% (95% CI 83 to 94%), with an average of 2% of
scans not being read within the studies contained
in the pooled estimates.
The economic model of Mowatt and colleagues113
took a sensitivity for MPS of 83% (95% CI 63 to
93%) and a specificity of 59% (95% CI 44 to 90%)
by pooling the results of the studies identified
within the clinical effectiveness section, although
the clinical effectiveness section did not itself pool
results owing to heterogeneity of studies. These
estimates were coupled with an indeterminacy rate
of 9% taken from Patterson and colleagues.123
Similarly, the sensitivity and specificity of ECG
were estimated from the pooled clinical data of
the review and estimated as being 66% (95% CI 42
to 92%) and 60% (95% CI 43 to 83%), respectively,
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Patterson and colleagues.123
Two other reviews of the accuracy of MPS for the
diagnosis of CAD are also available, by
Fleischmann and colleagues114 and Kymes and
colleagues.115 The Fleischmann review114 reported
pooled data for SPECT from 27 studies, to arrive
at estimates of sensitivity of 87% (95% CI 86 to
88%) and of specificity of 64% (95% CI 60 to
68%), although this has been criticised for pooling
heterogeneous studies. Kymes and colleagues115
reanalysed the same 27 studies using a random-
effects model. This slightly improved the central
estimates for sensitivity and specificity, 86.9% and
69.0% respectively, also increasing the uncertainty
around these estimates to give confidence intervals
of 83.3 to 89.8% for the sensitivity and 60.0 to
77.0% for the specificity of MPS. 
Given these values for sensitivity and specificity,
coupled with failure rates and unreadable scans, it
seems clear that a diagnostic strategy using 64-
slice CT as a non-invasive test is unlikely to be
inferior in clinical effectiveness terms to a similar
strategy using MPS as a non-invasive test. The
costs of 64-slice CT also appear to be less than
those of MPS, and as a consequence short-term
diagnostic modelling will demonstrate that 64-
slice CT is superior to MPS. In these
circumstances there is little need to consider the
downstream impact and longer term modelling as
outlined by Patterson and colleagues123 and by
Mowatt and colleagues.113
The picture remains more complicated for a
comparison of 64-slice CT and CA, given the
gold-standard nature of CA. Despite the extremely
high sensitivity of 64-slice CT and the associated
ability virtually to rule out significant CAD in
those testing negative, this still falls slightly short
of the gold standard of CA. The somewhat poorer
specificity also makes it unlikely in at least the
short term that a positive result will be taken as
confirmation of significant CAD being present.
Confirmation of CAD through CA is likely to
remain necessary for patients with a 64-slice CT
positive result. Given this, a strategy involving 
64-slice CT and CA is unlikely to outperform in
every dimension one where only CA is used. 
While short-term modelling has been undertaken
and will prove to be sufficient to form the main
basis of conclusions, for completeness and to
illustrate where future research needs might 
apply, a long-term model along the lines of
Mowatt and colleagues113 has also been
undertaken. However, given the data uncertainties
associated with this longer term modelling as
outlined below, it should be viewed as illustrative
rather than definitive.
Cost-effectiveness of 64-slice CT against
MPS and CA: short-term diagnostic
model
The test accuracies of the previous section can be
summarised as in Table 13. All of the tests in
Table 13 take CA as the gold standard with 100%
sensitivity and specificity, but also as having a
small risk of death of around 150 per 100,000
tested. There is a considerable range of test
accuracy values for both MPS and ECG, and there
is no obvious reason to prefer one set of estimates
to another. Simple averaging of these suggests the
data shown in Table 14.
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TABLE 13 Test accuracies
Source Test Sensitivity Specificity Indeterminate
Evaluation report 64-Slice CT 99% 89% 2%
Kymes, 2000115 MPS 87% 69% –
Mowatt, 2004113 MPS 83% 59% 9%
Exercise ECG (ETT)  66% 60% 18%
Kuntz 1999119 MPS 87% 64% 2%
Exercise ECG (ETT) 68% 77% 30%
TABLE 14 Scenarios in terms of test accuracies
Test Sensitivity Specificity Indeterminate
Base case 64-Slice CT 99% 89% 2%
CA 100% 100% 0%
MPS 86% 64% 6%
Exercise ECG 67% 69% 24%A relatively simple short-term diagnostic decision-
tree model similar to the literature in the
preceding two sections was adopted for the
assessment of the short-term performance of
different diagnostic strategies, similar to those
outlined above (see the sections ‘Economic
Literature review’, p. 41 and ‘Modelling the 
cost-effectiveness of MPS’, p. 45). 
Tests other than CA may be determinate or
indeterminate. Where, for example, an image
cannot be read or interpreted clearly these patients
are referred to the next test in the sequence. If the
test is determinate, a positive test result leads to
referral to the next test in the sequence. If the test
is determinate, a negative test result can be either a
true negative or a false negative. CA, being an
invasive procedure, is also associated with a small
death rate.
A patient might undergo up to three tests within
the diagnostic strategies: exercise ECG, followed
by MDCT, MPS or CA, with MDCT or MPS in
turn being followed by CA. For example, the test
strategy of exercise ECG followed by MDCT
followed by CA would be as shown in Figure 18.
Note that within this diagnostic strategy, given the
assumed gold standard of CA there would be no
false positives. 
Current expert opinion suggests that all diagnostic
test strategies would require CA as a final
confirmation of diagnosis. However, this may in
part be reflective of tests other than MDCT having
a somewhat poorer sensitivity than CA. It may be
envisaged, given the high sensitivity of MDCT,
that this alone could be used as final confirmation
of a diagnosis (although not enough for
assessment for revascularisation) of CAD. As a
consequence, in addition to the strategies where
positive results are always finally confirmed by CA,
two strategies where MDCT is the final test in the
diagnostic pathway will be considered.
Strategies 4, 5 and 6 in Table 15 mirror the first
three strategies, only with there being no prior
ECG, with strategy 8 similarly mirroring strategy
7. It should be noted that in some patients
exercise ECG is not possible, for example those
with arthritis or LBBB (Table 15). These are
included not as accurate representations of current
or possible service structure, but rather to present
more clearly the cost-effectiveness of the main
tests of interest in the absence of uncertainty as to
the prevalence of CAD among those coming
through from ECG. However, major uncertainties
within the modelling remain as to the CAD
prevalence in the population presenting for
diagnosis and in the CAD prevalence among 
those being referred on from ECG for further
diagnostic tests. One might expect that the
proportion with CAD would increase after each
positive test.
Strategies 7 and 8 represent a departure from the
modelling of the literature, in that there will be
some false positives within the diagnostic pathway.
Note that within these it has been assumed that
any indeterminate test results still go on to CA.
The more speculative modelling suggests that
among those deemed to be medium risk there is
an annual 50% likelihood of undergoing
revascularisation. However, these figures relate to
previous diagnostic pathways within which there
were no false positives. If the CAD prevalence in
Assessment of cost-effectiveness
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Test 1
ECG
Indeterminate
TP
FP
FN TN FN TN FN TN
Test 2
MDCT
Indeterminate
TP
FP
Test 3
CA
TP
FP
TP
FP
CA death
TN
FN
FIGURE 18 Test strategy of exercise ECG followed by MDCT followed by CA
TABLE 15 Strategies involving comparators to 64-slice CT
Test order 1st 2nd 3rd
Strategy 1 ECG MPS CA
Strategy 2 ECG CT CA
Strategy 3 ECG CA Nil
Strategy 4 MPS CA Nil
Strategy 5 CT CA Nil
Strategy 6 CA Nil Nil
Strategy 7 ECG CT Nil
Strategy 8 CT Nil Nilthe presenting group were relatively low, these
false positives could make up a relatively large
proportion of those given a positive diagnosis.
As noted above, a key clinical uncertainty relates
to the prevalence of CAD in the relevant patient
population. Shaw and colleagues,125 in a study of
11,372 stable angina patients referred to MPS or
CA for diagnosis, found in the CA group a
prevalence of 57%, with those having CAD being
split 41% medium risk and 59% high risk.
However, this population seems likely to have
already been tested with exercise ECG. If so, given
the accuracy and indeterminacy rates for ECG as
reported above, this would suggest a prevalence of
around 50% in the population being referred to
ECG. It is unclear what previous testing these
patients may have had before being eligible for
inclusion in the study,125 which is also US based.
The papers in the literature review have used a
range of values, with Mowatt and colleagues113
reflecting this and taking a base case of 10.5%
CAD prevalence from the British Heart
Foundation statistics for 50-year-old men, but
varying this all the way up to 90% to reflect the
underlying uncertainty as to the likely prevalence
of CAD in those referred for diagnosis. 
Within the short-term diagnostic model it is
desirable that those with CAD are assessed as
positive, and within the modelling strategies
considered this would always lead to eventual CA.
This is despite the very small death rate associated
with CA. What is clearly undesirable from both a
cost and clinical viewpoint is sending those
without CAD for angiography. As a consequence,
the death rates from these undesirable CAs are
also reported in the results below. All results relate
to a hypothetical cohort of 100 patients.
Costs of MPS, MDCT and CA were provided by
Aberdeen Royal Infirmary, based on a bottom–up
costing approach. Although capital costs for MPS
and MDCT were similar between the two, with the
£800,000 capital cost for 64-slice CT being in line
with the range of £600,000 to £1.2 million
reported by the Horizon Scanning Technology
Briefing,126 fewer MPS investigations could be
performed per session. As a consequence, despite
similar staff costs per session, the cost per MPS
investigation was estimated at around £293 while
the cost per 64-slice CT investigation was
estimated at around £206. 
CA was estimated as costing on average £320.
Expert opinion indicated that around five CAs
would be performed during each clinical session,
the same as had been indicated for CT scans. The
greater cost of CA largely arose from the increased
staffing levels required. However, it may be
possible that more CT scans could be performed
within a session compared with CA.
The £293 per MPS investigation corresponds
closely to the detailed bottom–up costing
undertaken by Underwood and colleagues,120
which when uprated to current prices using the
Hospital and Community Health Services (HCHS)
pay and prices index would correspond to £311.
Underwood and colleagues derived 1996 costs
from the average from a number of hospitals
through a very detailed bottom–up costing where
all resource use was itemised and costed
(G. Mowatt, University of Aberdeen, 2007).
Underwood and colleagues120 also undertook a
similar exercise for CA, which in current prices
equates to £1556. Note that this is considerably
higher than the current NHS reference costs for
angiography within healthcare resource group
(HRG) E02op, which are around £370, although it
is not immediately clear whether these reference
costs might also encompass coronary investigation
techniques other than just invasive CA. Given this
uncertainty, sensitivity analyses will be presented
for the cost of CA. 
NHS reference costs give a cost of £66 per exercise
test which will be adopted for the modelling. This
cost has little impact on the modelling, being
common to strategies 1, 2, 3 and 7. Similarly,
while strategies 4, 5, 6 and 8 do not involve this
cost, the intention of modelling these strategies is
not to permit a read across between them and
strategies 1, 2, 3 and 7, but rather to illustrate
more clearly the cost-effectiveness of 64-slice CT if
the prevalence of CAD in those being referred on
from ECG was known with greater certainty than it
is at present. 
The base case will assume the costs per test shown
in Table 16, although given the uncertainty around
the relative cost of CT and CA, a sensitivity
analysis using higher costs of CA also will be
performed.
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TABLE 16 Base-case costs per test
Test Cost Source
Exercise ECG £66 NHS reference costs
64-Slice CT £206 Aberdeen Royal Infirmary
MPS £293 Aberdeen Royal Infirmary
CA £320 Aberdeen Royal InfirmaryShort-term diagnostic modelling: base-case results
The cost-effectiveness of the different diagnostic
strategies is presented in Table 17. For the base
case, as was anticipated given costs and clinical
effectiveness results, the strategies involving 
64-slice CT in place of MPS are superior in all
dimensions. While 64-slice CT is cost-saving
relative to MPS, this cost saving is gradually
eroded as the prevalence of CAD increases in the
presenting population. The considerably better
specificity of 64-slice CT than MPS is of gradually
less importance as the prevalence of CAD in the
presenting population rises, since this increase
implies that the number of false positives being
wrongly sent for costly CA falls. However, as would
be anticipated given costs and clinical
effectiveness, a strategy with 64-slice CT is better
in all dimensions than a strategy with MPS at the
same point within the strategy.
Sending patients directly to CA without a 64-slice
CT is more expensive for lower prevalences of
CAD. When the prevalence of CAD is low, the CT
scan with its high specificity manages to rule out
CAD in a high percentage of patients, with the
additional benefit of avoiding the admittedly small
mortality risk associated with CA among these
patients. However, as the prevalence of CAD rises,
a greater proportion of patients are referred on to
CA, with 64-slice CT ruling out CAD and the need
for CA in fewer and fewer cases. Since 64-slice CT
is not that much less expensive than CA in the
base case, the prevalence of CAD does not have to
be particularly high for 64-slice CT followed by
CA to become more expensive than having all
patients go straight to CA.
With regard to diagnostic accuracy, strategies with
immediate CA also perform considerably better
than their counterpart involving an interim MPS
investigation, in large part because of the poor
specificity of MPS. The same is not true with
regard to the comparison with strategies involving
64-slice CT investigations. Sixty-four-slice CT
results in extremely few false negatives, and as a
consequence the number of true positives detected
by strategies involving 64-slice CT is only
marginally worse than those where patients are
sent immediately to CA without an interim 64-slice
CT investigation. Indeed, given the assumed
death rate of 150 per 100,000 from invasive CA, it
appears likely that the avoidance of deaths from
CA among those without CAD given the
reasonable specificity of 64-slice CT may be
sufficient to outweigh the very marginally fewer
number of true positives detected by strategies
involving 64-slice CT. 
The strategies where CT scanning is taken to be
sufficient to form a diagnosis without the need for
Assessment of cost-effectiveness
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TABLE 17 Cost-effectiveness of the different diagnostic strategies
Base case Strategy
S1 S2 S3 S4 S5 S6 S7 S8
10% CAD prevalence
TPs 6.50 7.41 7.48 8.67 9.89 9.99 7.42 9.90
FPs 0.00 0.00 0.00 0.00 0.00 0.00 4.61 9.70
CAD-negative deaths 0.03 0.01 0.06 0.05 0.02 0.14 0.00 0.00
Cost £28,876 £21,085 £22,695 £43,553 £27,449 £32,000 £17,283 £21,240
30% CAD prevalence
TPs 19.49 22.22 22.44 26.01 29.66 29.96 22.26 29.71
FPs 0.00 0.00 0.00 0.00 0.00 0.00 3.59 7.55
CAD-negative deaths 0.02 0.01 0.05 0.04 0.01 0.11 0.00 0.00
Cost £33,430 £26,572 £24,446 £46,561 £32,969 £32,000 £18,445 £21,240
50% CAD prevalence
TPs 32.48 37.04 37.40 43.35 49.44 49.93 37.09 49.51
FPs 0.00 0.00 0.00 0.00 0.00 0.00 2.56 5.39
CAD-negative deaths 0.01 0.00 0.04 0.03 0.01 0.08 0.00 0.00
Cost £37,985 £32,058 £26,197 £49,569 £38,488 £32,000 £19,607 £21,240
70% CAD prevalence
TPs 45.47 51.85 52.37 60.70 69.21 69.90 51.93 69.31
FPs 0.00 0.00 0.00 0.00 0.00 0.00 1.54 3.23
CAD-negative deaths 0.01 0.00 0.02 0.02 0.01 0.05 0.00 0.00
Cost £42,539 £37,544 £27,948 £52,577 £44,007 £32,000 £20,770 £21,240CA are around one-quarter to one-third less
expensive than if those scanned as CT positive
require CA. However, this is at the expense of
considerable numbers of false positives at low CAD
prevalences, and even at higher CAD prevalences
the proportion of false positives is not
insignificant. For the strategies where 64-slice CT
replaces CA at the lower CAD prevalences of 10%
and 30%, the additional treatment cost associated
with a false positive would be £1100 and £1600,
respectively, for the diagnostic cost advantage of
64-slice CT to be overturned by greater
downstream costs from the treatment of false
positives. For the higher CAD prevalence of 50%,
this additional treatment cost associated with a
false positive would have to rise to between £2000
and £2500 for the diagnostic cost advantage of 
64-slice CT to be overturned by greater
downstream costs from the treatment of false
positives, while for a CAD prevalence of 70% the
additional downstream cost of false positives
would have to rise to over £4500.
In terms of the clinical impact, replacing CA with
64-slice CT has only a minor impact on the
number of true positives detected. If the deaths
associated with CA are factored in, 64-slice CT
looks increasingly attractive. However, this applies
only with regard to the diagnostic pathway, not the
assessment one. 
Sensitivity analysis: cost of CA
The cost of CA is one of the key inputs.
Underwood and colleagues120 suggest a
considerably greater cost of £1556 as compared
with the £320 of the base case. Taking a rough
midpoint of these gives a cost per CA of £900,
which results in the revised diagnostic strategy
costs shown in Table 18. Although the
performances of strategies with 64-slice CT before
CA relative to those without are not particularly
affected by this, there is an obvious major impact
on the relative performance of 64-slice CT
replacing CA. To render 64-slice CT strategies
more expensive than CA, for a CAD prevalence of
10%, the additional cost of a false positive would
have to be around £7000. For a CAD prevalence of
50% the corresponding range is £9000–10,000,
while for CAD prevalences of 50% and 70% the
ranges increase to £12,000–16,000 and
£20,000–30,000.
Sensitivity analysis: poorer 64-slice CT test
performance
Applying the lower confidence limit values for 
64-slice CT for both its sensitivity (97%) and its
specificity (83%) results in the costs as shown in
Table 19. While this does not affect the superiority
of 64-slice CT over MPS, it naturally causes 
64-slice CT to perform slightly worse when set
against those strategies in which no interim non-
invasive test, MPS or 64-slice CT, is performed
with patients going straight to CA. However, the
differences remain relatively slight in terms of the
number of true positives being diagnosed,
particularly for lower CAD prevalences. The main
impact is on the greater number of false positives
that result from strategies in which 64-slice CT
replaces CA.
Illustrative longer term modelling
The above short term diagnostic modelling
suggests that given the high sensitivity of 64-slice
CT, diagnostic strategies involving 64-slice CT are
likely to be cost-effective for low CAD-prevalent
populations as a negative test result means that
unnecessary invasive CAs can be reliably avoided.
Sixty-four-slice CT is anticipated to dominate
strategies where it replaces MPS.
Illustrative longer term modelling can be
undertaken to explore the possible effects of
diagnosis and misdiagnosis for CAD for the
diagnostic strategies with the greatest uncertainty
around their relative cost-effectiveness: strategies
2, 3 and 7. This modelling follows the format of
that presented in Mowatt and colleagues,113 the
model structure being presented in Appendix 9.
Long-term model inputs are likewise mainly 
drawn from Mowatt and colleagues113 as
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TABLE 18 Sensitivity analysis
£900 per CA Strategy
S1 S2 S3 S4 S5 S6 S7 S8
10% CAD prevalence £42,540 £28,561 £51,866 £69,386 £39,864 £90,000 £17,866 £22,400
30% CAD prevalence £52,444 £41,948 £56,791 £77,846 £55,387 £90,000 £19,092 £22,400
50% CAD prevalence £62,347 £55,334 £61,716 £86,306 £70,910 £90,000 £20,318 £22,400
70% CAD prevalence £72,251 £68,721 £66,641 £94,766 £86,433 £90,000 £21,543 £22,400summarised in Appendix 10, although the costs of
MI, PTCA and CABG are taken from NHS
reference costs.
The short-term diagnostic model results in
patients being true negatives who are deemed to
be at low risk, true positives, false negatives or
false positives. Note that in strategies with CA,
there are no false positives since all positive test
results will, if they remain positive from interim
tests, eventually face CA, which will identify false
positives and correctly classify them as true
negatives. Those with CAD, whether true positives
or false negatives, are roughly equally split
between being high risk and being medium risk,
based on the results of Shaw and colleagues,125
that around 41% of those with CAD had single-
vessel disease and 59% had multiple-vessel disease
or left main disease. Note that a key underlying
assumption of the longer term modelling is that
the sensitivities and specificities of tests do not
vary across disease severity. While a simplifying
assumption, this may to some extent
underestimate the cost-effectiveness of strategy 2
to the extent that 64-slice CT is more likely to
detect high-risk disease and result in the
immediate treatment of those at most risk. 
In common with the short-term modelling, the
effect of a higher CA cost and of the lower CI
effectiveness bound of 64-slice CT can be explored.
Note also that the base case assumes that correct
diagnosis of false negatives only occurs after an
event. This is partly unrealistic because some
patients will present again with symptoms, given
that they will not be receiving the ideal treatment.
As a consequence, the effects of this can be
explored by an arbitrary assumption of an annual
10% rediagnosis rate among false negatives.
Table 20 shows the longer term modelling results
over a 25-year time-horizon. From the base case,
in clinical effectiveness terms strategies 2 and 3
are effectively identical, strategy 3 being only
marginally inferior owing to the slightly higher
death rate from the initial CA diagnoses. 
Higher costs for CA affect the analyses as would be
anticipated, increasing the anticipated savings
from strategy 7 to around £300 per patient at the
low CAD prevalence, this increasing in line with
the base case to around £400 per patient at the
higher CAD prevalence. As with the short-term
modelling, while the lower CI bound for the
effectiveness of 64-slice CT leads to a lower
aggregate QALY, given the tightness of the CIs the
impact of this is limited. Similarly, if patients
wrongly diagnosed as being of low risk return with
symptoms, and are reclassified correctly as being
of higher risk and treated accordingly, this tends
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TABLE 19 Sensitivity analysis: poorer 64-slice CT test performance
Lower effectiveness Strategy
S1 S2 S3 S4 S5 S6 S7 S8
10% CAD prevalence
TPs 6.50 7.26 7.48 8.67 9.69 9.99 7.27 9.71
FPs 0.00 0.00 0.00 0.00 0.00 0.00 7.13 14.99
CAD-negative deaths 0.03 0.01 0.06 0.05 0.03 0.14 0.00 0.00
Cost £28,876 £21,844 £22,695 £43,553 £29,080 £32,000 £17,283 £21,240
30% CAD prevalence
TPs 19.49 21.78 22.44 26.01 29.07 29.96 21.82 29.12
FPs 0.00 0.00 0.00 0.00 0.00 0.00 5.55 11.66
CAD-negative deaths 0.02 0.01 0.05 0.04 0.02 0.11 0.00 0.00
Cost £33,430 £27,057 £24,446 £46,561 £34,098 £32,000 £18,445 £21,240
50% CAD prevalence
TPs 32.48 36.30 37.40 43.35 48.46 49.93 36.36 48.53
FPs 0.00 0.00 0.00 0.00 0.00 0.00 3.96 8.33
CAD-negative deaths 0.01 0.01 0.04 0.03 0.01 0.08 0.00 0.00
Cost £37,985 £32,270 £26,197 £49,569 £39,115 £32,000 £19,607 £21,240
70% CAD prevalence
TPs 45.47 50.83 52.37 60.70 67.84 69.90 50.90 67.94
FPs 0.00 0.00 0.00 0.00 0.00 0.00 2.38 5.00
CAD-negative deaths 0.01 0.00 0.02 0.02 0.01 0.05 0.00 0.00
Cost £42,539 £37,483 £27,948 £52,577 £44,133 £32,000 £20,770 £21,240to reduce any differences between the diagnostic
strategies in terms of patient impact.
Economic considerations for chest pain
admissions and diagnosis of ACS
Patients presenting with chest pain but with
negative initial cardiac biomarkers and negative
ECG results may be admitted for observation and
repeat tests. The immediate availability of 64-slice
CT within a 24-hour emergency department
setting may reduce the likelihood of admission.
Variable availability of CT through the day would
reduce the scope for reducing admissions.
Among those admitted for observation for 24
hours, with twice negative troponin tests, 64-slice
CT could be used to rule out the need for CA,
possibly in place of or subsequent to an exercise
test. The European Society of Cardiology
recommends that among low-risk patients with
twice negative troponin tests, only those showing
significant ischaemia during an exercise test
should be considered for CA. While formal
estimates of the sensitivity and specificity of 
64-slice CT are not available for such
circumstances, it appears likely that the
performance of 64-slice CT may be superior to
that of exercise testing. Paralleling the conclusions
as to the diagnosis of CAD, if exercise ECG has a
poor specificity in this setting and if the
prevalence of ACS is also low among those with
twice negative troponin tests, as seems reasonable
to conclude, the introduction of 64-slice CT before
CA may reduce costs through the avoidance of
unnecessary CA. Provided that its sensitivity is no
worse than that of the exercise test in these
circumstances, patients could also benefit from its
introduction. However, MPS could perform a
similar role, and it is not clear which if either
would necessarily be superior in this setting. 
Discussion
Sixty-four-slice CT appears to be superior to MPS
for the diagnosis of CAD in all clinical dimensions
and also in terms of cost. As a consequence,
diagnostic strategies involving 64-slice CT in place
of MPS appear to be cost-effective in the short
term. 
The high sensitivity and NPV of 64-slice CT
suggest scope for avoiding unnecessary CAs in
those referred for investigation but who do not
have CAD. Given the invasive nature of CA and a
possible, although small, associated death rate,
avoiding these unnecessary CAs through the use of
64-slice CT may also confer a small immediate
survival advantage. This in itself may be sufficient
to outweigh the marginally inferior rates of
detection of true positives by strategies involving
64-slice CT.
The avoidance of unnecessary CAs through the
use of 64-slice CT may result in cost savings even
if positive results still require confirmation by CA.
However, as the prevalence of CAD in the
presenting population increases, so the cost of CA
relative to that of 64-slice CT has to rise for this to
remain the case.
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TABLE 20 Longer term modelling: base case
Base case Higher CA cost Lower CT effect Re-presentations
Cost QALYs Cost QALYs Cost QALYs Cost QALYs
10% CAD prevalence
S2 £616,732 1060.5 £624,208 1060.5 £617,104 1060.4 £619,099 1061.3
S3 £618,196 1060.0 £647,367 1060.0 £618,196 1060.0 £620,496 1060.7
S7 £618,629 1056.9 £618,629 1056.9 £620,972 1055.0 £620,996 1057.6
30% CAD prevalence
S2 £642,800 1005.2 £658,176 1005.2 £642,174 1004.8 £649,901 1007.4
S3 £640,966 1005.0 £673,311 1005.0 £640,966 1005.0 £647,865 1007.1
S7 £639,186 1002.6 £639,186 1002.6 £640,195 1000.8 £646,288 1004.8
50% CAD prevalence
S2 £668,868 949.9 £692,144 949.9 £667,245 949.2 £680,704 953.6
S3 £663,736 949.9 £699,255 949.9 £663,736 949.9 £675,235 953.5
S7 £659,743 948.3 £659,743 948.3 £659,418 946.6 £671,579 952.0
70% CAD prevalence
S2 £694,935 894.6 £726,112 894.6 £692,316 893.6 £711,506 899.7
S3 £686,506 894.9 £725,199 894.9 £686,506 894.9 £702,605 899.9
S7 £680,300 894.0 £680,300 894.0 £678,640 892.4 £696,871 899.1If 64-slice CT can displace CA in the diagnostic
pathway, it is likely that the average diagnostic cost
per patient can be reduced by around one-quarter
to one-third. Given the sensitivity of 64-slice CT,
there is only a very minor clinical difference in
terms of the number of patients with CAD who are
wrongly diagnosed as being of low risk. The
principal difference in strategies where 64-slice CT
scanning replaces CA is in the number of false
positives. These would only matter if they were
treated medically, since those referred for
assessment for revascularisation would be 
correctly diagnosed at angiography. However,
some apparently treated successfully by 
medical treatment alone would be receiving
unnecessary treatment and incur unnecessary
anxiety.
In conclusion, the main value of 64-slice CT may
be to rule out significant CAD both in the elective
investigation of suspected CAD and in those
presenting with acute chest pain.
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The included diagnostic accuracy studies reported
the sensitivity and specificity of multislice CT
angiography using 64-slice or higher machines for
detecting CAD compared with invasive CA as the
reference standard. Studies that reported true and
false positive and negative results or provided
information that allowed these data to be
calculated were included in the pooled estimates
(meta-analyses). Almost all studies used a cut-off
for significant CAD of greater than 50% or at least
50% stenosis, allowing a common cut-off to be
used for studies included in the pooled estimates.
Meta-analyses were performed on a number of
different levels:
● patient
● segment
● left main artery
● LAD artery
● proximal LAD artery
● LCX artery
● RCA
● stents or stented segments
● CABGs.
Although segmental analysis is useful to validate
the accuracy of the test, patient-level data are
more useful in determining management. In the
pooled estimates, 64-slice CT angiography was
highly sensitive (99%, 95% CrI 97 to 99%) for
patient-based detection of significant CAD, while
across studies the median NPV was very high
(100%, range 86 to 100%). These results suggest
that one of the potential benefits of 64-slice CT
angiography may be to avoid the use of invasive
CA in people with a low pretest probability of CAD
who have negative/low-risk CT scans. In the 13
full-text studies included in the pooled estimates
for patient-based detection of CAD, 11 (2%) of
718 patients could not be assessed owing to
unevaluable CT scans (median 0%, range 0 to 6%).
Two studies65,85 reported that all vessels were
analysed including those less than 1.5 mm in
diameter, while three studies79,93,94 reported that
all vessels of less than 1.5 mm were excluded from
analysis.
The studies included in the pooled estimates were
heterogeneous with respect to the participants and
prevalence of significant (50% stenosis) CAD. In
some studies the whole patient population had
suspected CAD, in others known CAD or a
mixture of suspected and known CAD, in others
acute chest pain, had previously undergone PCI or
CABG, had LBBB or had all been referred for
cardiac valve surgery. The median prevalence of
significant CAD across these studies was 58%
(range 23 to 96%). Nevertheless, there was no
substantial statistical heterogeneity across the
studies as assessed by the I2 statistic (I2 for
sensitivity = 0.1%; I2 for specificity = 31.7%),
where a value above 50% is considered to
represent substantial statistical heterogeneity. 
The overall quality of the full-text diagnostic
accuracy studies was reasonably good. This was
partly due to the review’s strict inclusion criteria.
Only studies in which results were reported for
participants who received both 64-slice or higher
CT angiography (index test) and a reference
standard of either invasive CA or long-term follow-
up were included. In some studies only some of
the participants received both the index test and
reference standard and it was these participants
whose results were included, rather than the whole
patient population. In all studies the reference
standard was considered likely to classify CAD
correctly. In 85% of studies those interpreting 
64-slice CT data were blinded to the results of the
reference standard test and in 71% of studies vice
versa. In 48% of studies the participants belonged
to specific groups, for example those with LBBB,
or who had undergone previous PCI or CABG, or
who had been referred for cardiac valve surgery.
While this would cause a problem with spectrum
bias if the results of these studies were applied to
all who may receive CT angiography, their data
are nevertheless useful when considering the
specific groups studied, for example in excluding
the presence of significant CAD in patients before
scheduled aortic valve replacement.
In segment-level analysis compared with patient-
based detection, sensitivity was lower (90%, 95%
CrI 85 to 94%, versus 99%, 95% CrI 97 to 99%)
and specificity higher (97%, 95% CrI 95 to 98%,
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Chapter 4
Discussionversus 89%, 95% CrI 83 to 94%), while across
studies the median NPV was similar (99%, range
95 to 100%, versus 100%, range 86 to 100%). At
individual coronary artery level diagnostic accuracy
was highest for the left main artery and lowest for
the LCX artery. Sensitivity ranged from 85% (95%
CrI 69 to 94%) for LCX to 95% (95% CI 84 to
99%) for the left main artery, specificity ranged
from 96% for both LAD (95% CrI 91 to 98%) and
LCX (95% CrI 92 to 99%) to 100% (95% CI 99 to
100%) for the left main artery, while across studies
the PPV ranged from 81% (range 56 to 100%) for
the LCX to 100% (range 90 to 100%) for the left
main artery and NPV was very high, ranging from
98% for the LAD (range 95 to 100%), LCX (range
93 to 100%) and RCA (range 94 to 100%) to 100%
(all five studies) for the left main artery. For the
proximal LAD artery analysis sensitivity was 97%
(95% CrI 87 to 99%) and specificity was 97% (95%
CrI 90 to 99%), while across studies the median
PPV and NPV were 95% (range 85 to 100%) and
98% (range 90 to 100%), respectively. Diagnostic
accuracy was higher for analysis of CABGs, with
99% (95% CrI 95 to 100%) sensitivity and 96%
(95% CrI 86 to 99%) specificity, while across
studies the median PPV and NPV were 93% (range
90 to 95%) and 99% (range 98 to 100%),
respectively. Given that data are reported and
analysed at levels in addition to the patient level
and that a number of studies contributed data to
more than one level of analysis, some degree of
correlation may exist between the results for the
different levels of analysis.
Although there are suggestions that imaging of
stents is improving with greater experience and
better machines, in the included studies
assessment of stents caused some problems for 64-
slice CT. In the pooled estimates sensitivity was
89% (95% CrI 68 to 97%) and specificity 94%
(95% CrI 83 to 98%), while across studies the
median values for PPV and NPV were 77% (range
33 to 100%) and 96% (range 71 to 100%),
respectively. In the study by Leber and
colleagues58 four of nine stents without any
restenosis on invasive CA were diagnosed as
having greater than 50% restenosis on 64-slice CT,
owing to artefacts caused by the dense stent
material. In the study by Rixe and colleagues,89 30
of 31 stents with a diameter of at least 3.0 mm
that were classified as unevaluable were of a type
with a strut thickness of 0.14 mm, while only one
with a strut thickness of 0.13 mm was classified as
unevaluable. Rist and colleagues86 noted that the
cases in which image quality was considered poor
or moderate typically involved patients fitted with
small-diameter stents in distal segments of the
coronary arteries, and that 3.5 mm was a
threshold below which the rate of evaluable stents
was very low. Therefore, although the performance
of 64-slice CT for identifying in-stent restenosis
was reasonably good, it may vary according to the
type, diameter and location of the stent.
Coronary artery calcification caused some 64-slice
CT scans to be either unevaluable or misclassified.
Ong and colleagues75 reported that 48 (6%) of 748
segments with AS below 142 were not evaluable,
compared with 95 (13%) of 726 segments with AS
of 142 or above. Although in the study by
Ghostine and colleagues52 no segment was
excluded from analysis owing to calcification, the
authors reported that heavily calcified segments
accounted for 21 (81%) of 26 false-negative
results. Raff and colleagues85 reported 14 (2%)
false positives in 709 segments with a calcium
rating of none, five (6%) false positives in 89
segments rated as mild, six (13%) false positives in
48 segments rated as moderate and 16 (18%) false
positives in 88 segments rated as severe. Other
studies cited coronary calcification as a cause of
unevaluable CT scans.45,46,93,94,99,100,102 Therefore,
some patients with severe coronary artery
calcification may be considered less suitable for
64-slice CT angiography.
Five studies (one full text55 and four reported as
abstracts95,105–107) provided information on the
prognostic usefulness of 64-slice CT angiography,
with three reporting patients with suspected ACS,
although with only short-term (mostly 30-day)
follow-up. Hoffmann and colleagues55 concluded
that 64-slice CT angiography had very good
negative predictive value for the subsequent
diagnosis of ACS in the short term. Gallagher and
colleagues107 reported that patients with chest
pain, with negative 64-slice CT and MPI scans
(n = 52) who were discharged, experienced no
adverse cardiac events during a 30-day follow-up.
Rubinshtein and colleagues95 reported that taking
account of 64-slice CT angiography had led to a
revised diagnosis in 14 (50%) of 28 chest pain
patients, hospitalisation cancelled in 15 (44%) of
34 and early invasive CA postponed in 16 (67%) of
24, but brought forward in one (6%) of 16
patients. At 30-day follow-up there were no
adverse cardiac events in the 15 patients
discharged on the basis of negative or low-risk 
64-slice CT findings. Of the other two studies,
Auseon and colleagues105 reported that, in the
year following the introduction of 64-slice CT
compared with the previous 4 years, the yearly
Discussion
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volume and percutaneous interventions had not
been significantly affected. Danciu and
colleagues106 reported that in the first 6 months
following the introduction of 64-slice CT, invasive
CA had been avoided in 398 (82%) of 486
patients.
Some invasive CA may also potentially be avoided
in the prognostic assessment of patients with
known CAD. Once CAD has been confirmed,
medical management may or may not relieve
symptoms. If it does not, patients are usually
referred for potential revascularisation as in
Figure 4 (p. 9). If symptoms are relieved by
medical management, revascularisation may still
be of value on prognostic grounds, in those with
proximal disease, such as left main, LAD or triple-
vessel disease. At present prognosis is assessed by
an ETT (those who can exercise using the Bruce
protocol for over 6 minutes without symptoms or
ECG changes being unlikely to have prognostically
poor patterns of disease) or by invasive CA. Given
the very good performance of 64-slice CT in
detecting proximal disease, CT provides another
option in this group of patients. In the absence of
significant proximal CAD, patients with well-
controlled symptoms could receive medical
management rather than revascularisation.
Sixty-four-slice CT angiography may have the
potential to replace some perfusion scanning tests.
In two systematic reviews113,114 of SPECT MPS,
sensitivity was reported as a median of 81% across
studies (range 63 to 93%)113 or pooled estimate of
87% (fixed-effect model, 95% CI 86 to 88%),114
while specificity was reported as a median of 65%
across studies (range 10 to 90%)113 or pooled
estimate of 64% (fixed-effect model, 95% CI 60 to
68%).114
In conclusion, for patient-based detection of
significant (50% stenosis) CAD, the high
sensitivity in the pooled estimates and the high
NPV across studies suggest that one of the major
potential benefits of 64-slice CT could be that of
avoiding invasive CA in people with negative/low-
risk CT scans. The high NPV values in the
diagnostic studies appear to be supported by the
few prognostic studies that followed up patients
discharged from hospital on the basis of
negative/low-risk 64-slice CT scans, although these
results need to be interpreted with caution as they
were based on short-term (mostly 30-day) follow-
up and from only five studies, four of which were
reported as abstracts.
Cost-effectiveness
Sixty-four-slice CT angiography appears to be
superior to MPS for the diagnosis of CAD in all
clinical dimensions and also in terms of cost. As a
consequence, diagnostic strategies involving 64-
slice CT in place of MPS appear to be cost-effective
in the short term. This short-term diagnostic cost-
effectiveness will carry through to improved
patient outcomes, and with the proviso that
treatments for CAD are cost-effective diagnostic
strategies involving 64-slice CT in place of MPS
will also be more cost-effective in the longer term.
Given the high sensitivity of 64-slice CT,
diagnostic strategies involving it have an almost
identical PPV to those where there is no interim
non-invasive test and patients are sent directly for
invasive CA. The reasonably high specificity of 64-
slice CT also avoids the costs of unnecessary
invasive CAs in those referred for investigation but
who do not have CAD. Given the invasive nature
of CA and a possible, although small, associated
death rate, avoiding these unnecessary CAs
through the use of 64-slice CT may also confer a
small immediate survival advantage on the
presenting population. This in itself may be
sufficient to outweigh the marginally inferior rates
of detection of true positives by strategies
involving 64-slice CT.
The avoidance of unnecessary invasive CAs
through the use of 64-slice CT also appears likely
to result in overall cost savings in the diagnostic
pathway. Only if both the cost of invasive CA is
relatively low and the prevalence of CAD in the
presenting population is relatively high is it likely
that the use of 64-slice CT in the diagnostic
pathway will result in a higher overall diagnostic
cost per patient.
Longer term illustrative modelling indicates that
strategies involving 64-slice CT are likely to be
cost-effective options, but considerable
uncertainties surround this modelling, as outlined
in the previous section. 
Provided that within the population presenting to
64-slice CT the prevalence of CAD is not too high,
owing to either a high general population
prevalence or extremely accurate exercise testing,
and that 64-slice CT is a reasonable amount
cheaper than invasive CA, the short-term
diagnostic model enables the conclusion that 64-
slice CT is likely to be a cost-effective option in the
diagnosis of CAD.
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review
In terms of strengths, the reference standard –
invasive CA – was the same for all of the included
diagnostic studies, and only the results for people
who received both tests were included in the meta-
analyses, thereby avoiding partial and differential
verification bias. Meta-analyses were undertaken
on a number of different levels, including patient,
segment and individual artery level, as well as for
stents/stented segments and CABGs. In terms of
limitations, non-English-language studies were
excluded. Only five studies (four of which were
abstracts) reported the prognostic usefulness of
64-slice CT angiography, with only short-term
(mostly 30-day) follow-up.
The lack of outcome data makes modelling
inevitably speculative. Ideally, we would have data
on outcomes from all the arms of the diagrams in
Chapter 1 (Figures 1–5). For example, the
outcomes in patients who would be false negatives
are not known. If their CAD progresses, they may
present again and be correctly diagnosed, in which
case little harm has been done. However, they may
suffer a fatal heart attack and die, leading to 
life-years lost.
Uncertainties
When considering whether 64-slice CT may
replace some invasive CA, one issue to bear in
mind is that the technical factors that enhance
image quality in 64-slice CT also result in a higher
radiation dose compared with invasive CA. This
has resulted in concerns being raised about
repetitive use of 64-slice CT or use in younger
individuals or women of childbearing age.127
For MSCT, radiation dose depends on X-ray tube
voltage, current, scan time, speed of table
movement and the number of overlapping
adjacent scans.128 Retrospective ECG gating is
used to obtain images during the diastolic phase
of the cardiac cycle, when motion is least. Using
ECG-controlled dose modulation reduces the tube
current during the less important systolic phase,
when motion is greatest, resulting in a 30–50%
reduction in the effective radiation dose.7
However, dose modulation may not be
appropriate for certain categories of patients, such
as those with arrhythmias or fast heart rates, for
whom it may be necessary to obtain images
throughout the cardiac cycle without loss of image
quality.77 Effective dose is an estimate of the
whole-body dose that would be required to
produce the same risk as partial-body dose
delivered by a localised radiological procedure.128
A systematic review by Stein and colleagues9
quoted an effective radiation dose of 11–22 mSv
for 64-slice CT angiography, which could be
reduced to 7–11 mSv by using ECG-controlled
dose modulation. A study by Hausleiter and
colleagues8 on multislice CT radiation dose
estimates reported an effective radiation dose of
11.0 (SD 4.1) mSv for 64-slice CT. In a subgroup
analysis, effective radiation dose was reduced 
from 14.8 (SD 1.8) mSv to 9.4 (SD 1.0) mSv by
using ECG-controlled dose modulation.8
Effective dose values quoted for invasive CA
include less than 5 mSv by a British
Cardiovascular Society Working Group,12 4–8 mSv
by the TEC10 and 5–10 mSv by the International
Commission on Radiological Protection (ICRP).129
The ICRP129 also quotes typical effective doses of
13–16 mSv for sestamibi MPI and 35–40 mSv for
thallium MPI. By comparison, the average yearly
effective dose of background radiation is around
2.5 mSv.9 The ICRP states that the maximal yearly
effective dose of radiation should not exceed 50
mSv in radiation workers or 100 mSv over
5 years.129
In this review 12 full-text studies reported 64-slice
CT radiation dose, with six studies52,55,56,58,71,86
providing information for the patient group as a
whole and six65,66,83,85,93,94 reporting men and
women separately. Across the studies reporting
this information for the patient group as a whole,
the CT radiation dose ranged from 6–11 mSv55 to
10–14 mSv,58 with all studies using ECG-
controlled dose modulation. In studies reporting
CT radiation dose separately for men and women,
women tended to receive a higher dose. Across
these studies the radiation dose ranged from
7.5 mSv93 to 15.2 mSv65,66 for men and from
10.2 mSv94 to 21.4 mSv65,66 for women. Only two
of these studies93,94 used ECG-controlled dose
modulation, reporting an estimated radiation dose
of 7.5 mSv93 and 8.6 mSv94 for men and
10.2 mSv93 and 12.2 mSv94 for women. Across the
four studies not using dose modulation, the
radiation dose ranged from 13 mSv85 to
15.2 mSv65,66 for men and from 18 mSv85 to
21.4 mSv65,66 for women. In total, 11 full-text
studies52,55,56,58,71,75,77,86,89,93,94 used ECG-
dependent dose modulation, five59,65,66,83,85 did
not, and the remainder, and all studies reported as
abstracts, did not report this information. 
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rates above 70 bpm, although -blockers can be
used to reduce the heart rate in an attempt to
minimise this. Across 16 included studies
reporting the average heart rate during the CT
scan, this ranged from 58 to 72 bpm. In studies
reporting whether or not -blockers were given,
140 (32%) patients were already on -blocker
treatment, 184 (42%) were given -blockers to
reduce heart rate and 113 (26%) did not receive 
-blockers. 
Increased image noise associated with the thinner
slices from 64-slice CT may adversely affect test
accuracy in obese patients. However, only one of
the included studies reported test performance
according to patient weight. Raff and colleagues85
reported patient-based detection of significant
(> 50% stenosis) CAD for patients with a BMI of
30 or greater (obese) compared with those with
BMI below 25 (normal). For the BMI 30 or greater
group compared with the BMI below 25 group,
sensitivity was 90 versus 100%, specificity was 86
versus 100%, PPV was 90 versus 100% and NPV
was 86 versus 100%.85 None of the included
studies mentioned weight as an exclusion criterion
and none, other than Raff and colleagues, raised
the issue of weight in the discussion sections of
their reports.
Calcification in the coronary arteries would often
be a problem, and as one of this review’s
anonymous referees pointed out, those with high
levels of calcification such as elderly people with
diabetes are often not included in trials.
One issue to be considered is the cut-off used to
describe significant CAD, usually 50% and
occasionally 70% stenosis. These figures are based
on the degrees of stenosis at which lesions are
thought to be of potential functional significance
and where revascularisation may be indicated.
However, these figures are based on two outcomes:
relief of anginal symptoms, and reduction in
mortality in those with patterns of CAD associated
with the poorest prognosis, such as left main stem
disease. 
Sixty-four-slice CT would also show lesser degrees
of stenosis, and could therefore influence
management other than revascularisation. For
example, a patient with 30% stenosis may receive
lifestyle advice, a statin, and perhaps intensified
control of blood pressure or blood glucose. Several
studies have reported regression of CAD after
statin treatment, although usually modest.126,127
64-Slice CT angiography in the
detection of non-calcified plaques
It is thought that MI usually follows the rupture of
an atheromatous plaque, and that the plaques
most likely to rupture are soft, lipid-rich non-
calcified ones. Most patients with such plaques will
have other evidence of arterial disease, but
Hausleiter and colleagues53 reported that in a
small proportion, non-calcified plaques were the
only sign of CAD. They carried out 64-slice CT
angiography in 161 patients who were considered
to be at moderate risk of significant CAD, based
on having chest pain with negative stress tests, or
positive stress tests without chest pain, or neither
but with intermittent arrhythmias. Of these
patients, 98 had coronary calcifications and 63 did
not. Ten of the 63 (6.2% of the whole group) had
non-calcified plaques. Such plaques were also seen
in 38 of the 98 patients with calcifications. Only 23
of the group had invasive CA, but it was
noteworthy that most of the non-calcified plaques
caused less than 50% stenosis. There were 40 non-
calcified plaques in these 23 patients and about
half caused only minor wall irregularities, with less
than 25% stenosis. Nine had stenosis between 25%
and 50% and 11 had greater than 50% stenosis
and were treated by PCI. 
Chin and colleagues130 also studied vulnerable
plaques in a mixed group of patients who had
stable angina, unstable angina or non-ST elevated
MI, and ST-elevated MI. They hypothesised that
the ‘culprit’ lesions might have lower density,
because of lower calcification and overlying
thrombus, and developed a measure of vessel
density. They confirmed that culprit lesions had
lower density. Chin and colleagues also noted that
25% of culprit lesions were associated with less
than 50% stenosis. They suggested that further
research was needed into how best to use CT to
examine plaque morphology.
There are two implications from these studies. The
first is that invasive CA is not quite a gold
standard, and will miss some vulnerable plaques
on which coronary thrombosis can occur. Secondly,
advances in CT technology now allow the
identification of vulnerable plaques. Neither paper
gave details of time and other costs.
256-Slice machines
CT technology is advancing rapidly and the first
256-slice machines are now arriving. It is perhaps
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carry a significant marginal benefit over 64-slice
machines. Only one study68 included in this review
used a 256-slice machine (Toshiba prototype),
involving ten patients. In segment-based detection
of significant (>50% stenosis) CAD, when
segments with severe calcification were excluded
from analysis, sensitivity, specificity, PPV and NPV
were 100%, 96%, 73% and 100%, respectively.68 By
comparison, in the pooled estimates for 64-slice
CT segment-based detection of significant CAD,
sensitivity and specificity were 90% (95% CrI 85 to
94%) and 97% (95% CrI 95 to 98%), respectively,
while across studies the median PPV and NPV
were 76% (range 44 to 93%) and 99% (range 95 to
100%), respectively. 
Implementation issues
If 64-slice CT were to be used in people with acute
chest pain, it would need to be readily available,
ideally 24 hours a day. This would have
implications for radiographer staffing and the
expertise of on-call radiologists. It is unlikely that
all on-call radiologists would have experience in
cardiac CT, except in some very large hospitals
with subspecialty interests. An on-call registrar
would be unlikely to have the expertise. Overnight
admissions with early-morning CT followed by
discharge after a cardiologist ward round may be a
more realistic scenario. That would reduce the
savings, as would any increased on-call service.
It is likely that more centres will provide
immediate angioplasty for MI in future,131 which
may mean that immediate angiography is more
readily available than immediate CT.
The effect of replacing an invasive with a non-
invasive test needs to be considered, since demand
may increase. A recent example has been the
introduction of CT pulmonary angiography; far
larger numbers of CT pulmonary angiography
studies are done than of the invasive conventional
pulmonary angiography which preceded it
(G. Walsh, Royal Berkshire Hospital: personal
communication, 2007). Increased use may negate
any cost savings from reducing angiography.
Acceptability to patients may be an issue for two
reasons. One is the radiation dose. The other is
claustrophobia; not all patients would be willing to
enter the scanner.
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The proportion of invasive CA that could be
replaced by 64-slice CT is currently uncertain.
Further information is needed on current CA
workload. Reduction in CA would be mainly at the
diagnostic end of the pathway, both in elective
assessment of chest pain of possibly anginal
origin, and in emergency assessment of suspected
acute coronary syndromes in patients with normal
or equivocal ECGs and negative troponin tests. In
the emergency situation, some hospital admissions
may be avoided; however, 64-slice CT would need
to be readily available, ideally on a 24-hour basis,
which is unlikely to be the case in most hospitals.
Some perfusion studies could be replaced by 
64-slice CT angiography.
Assuming that the NHS does invest in more
modern CT machines, one issue is whether to
acquire 64-slice machines or wait until 256-slice
machines become available. Evidence on 256-slice
CT is currently sparse, but the review of
publications in Chapter 1 showed that the pace of
research is brisk, and it is likely that evidence on
the next generation will be available within
18 months or so. It is very unlikely that
performance would be less good, and if the cost
difference between 64-slice and 256-slice machines
was small, it could be argued that the NHS should
bypass 64-slice machines in favour of 
256-slice ones. However, the pace of change will
create difficulties in decision-making on replacing
old CT systems; no matter what a radiology
department buys, there will be something better
coming along in a year or two, although the
marginal costs and benefits will be unknown.
There must come a time when the extra data do
not provide additional clinical benefit, but it is
unclear when that point will be reached.
Recommendations for research
As previously noted, CT technology is advancing
rapidly and the first 256-slice machines are
arriving. Studies are required of their marginal
advantages and costs over 64-slice CT. Because of
its newness most information available on 256-
slice CT is commercial in origin. One of the main
potential advantages of 256-slice machines is that
of obtaining all the necessary information on one
cardiac cycle, resulting in faster scans, avoiding
problems with ECG gating, and delivering a lower
radiation dose (which may be particularly
important if CT was to be used as a screening test
in relatively low-risk populations).
More research is needed on the usefulness of 64-
slice CT in people with suspected ACS, in terms of
both diagnostic accuracy and prognostic value,
with a follow-up of at least 1 year for prognostic
studies. It would also be important to show the
additional value, if any, of 64-slice CT in this
setting over and above standard methods of risk
stratification. This review identified only a few
studies, mostly reported as abstracts, containing
very small numbers of patients, most of whom
were low risk and would be expected to have low
event rates. In addition, the results of prognostic
studies involving patients with suspected ACS 
were based on only short-term (mostly 30-day)
follow-up. 
There have been a few reports on the potential of
64-slice CT to examine plaque morphology, and
more research is needed here, although whether
that should be done using 64-slice machines or
the emerging 256-slice ones is for debate.
The role of CT in identifying patients for CABG
needs further research. CT can identify stenoses,
but research is needed into its ability to identify
distal insertion sites and adequacy of run-off. Such
research may be done by carrying out CT in a
large group of patients before CABG (with
preceding invasive CA), with assessment of
suitability for CABG by observers unaware of the
invasive CA results and arterial findings at CABG.
In deciding patient selection criteria, research
studies involving 64-slice or higher CT
angiography should take account of concerns
raised about repetitive use, or use in younger
individuals or women of childbearing age.
Few of the studies so far have looked at effects on
outcomes. Most have been at stage 2 in the
Fryback and Thornbury classification.
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Technol Assess 2003;7(15).
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Search strategies used to identify reports of
clinical effectiveness of MSCT for CAD.
MEDLINE (2002 to November 
week 3 2006), EMBASE (2002 to 
week 49 2006), Medline In-Process 
(14 December 2006) 
Ovid Multifile Search URL:
http://gateway.ovid.com/athens
1 exp myocardial ischemia/ use medf 
2 exp ischemic heart disease/ use emef 
3 exp coronary artery disease/ 
4 exp myocardial infarction/ 
5 exp chest pain/ 
6 coronary artery blood flow/ use emef 
7 (isch?emi$ adj3 (heart or coronary or
myocardial)).tw. 
8 ((myocardial or coronary or heart) adj3
(infarct$ or thrombosis or stenosis or restenosis
or arteriosclerosis or arter$)).tw. 
9 angina.tw. 
10 (chest adj3 pain).tw. 
11 or/1-10 
12 tomography, x-ray computed/ use medf 
13 tomography, spiral computed/ use medf 
14 computer assisted tomography/ use emef 
15 computed tomographic angiography/ use emef 
16 electron beam tomography/ use emef 
17 high resolution computer tomography/ use
emef 
18 spiral computer assisted tomography/ use emef 
19 or/12-18 
20 (detector? or slice? or slide? or row?).tw. 
21 19 and 20 
22 multidetector computed tomography/ use emef 
23 (msct or mdct).tw. 
24 (multi slice? or multislice?).tw. 
25 (multi row? or multirow?).tw. 
26 (multi slide? or multislide?).tw. 
27 (multi detect$ or multidetect$).tw.
28 (tomograph$ adj5 (multi$ or slice? or row? or
slide? or detector?)).tw. 
29 or/21-28 
30 11 and 29 
31 exp coronary angiography/ 
32 ((coronary or myocardi$) adj3 (angiograph$ or
angiogram$ or arteriograph$)).tw. 
33 or/31-32 
34 30 and 33 
35 animal/ not human/ use medf 
36 (animal/ or nonhuman/) not human/ use 
emef 
37 34 not (35 or 36) 
38 remove duplicates from 37 
39 limit 38 to yr="2002 - 2006" 
40 eng.la. 
41 39 and 40 
SCI (2002 to 9 December 2006), 
ISI Proceedings (7 December 2006),
BIOSIS (2002 to 8 December 2006) 
Web of Knowledge URL: http://wok.mimas.ac.uk/ 
#1 TS=(ischemi* SAME (heart OR coronary OR
myocardial))
#2 TS=(ischaemi* SAME (heart OR coronary
OR myocardial))
#3 TS=((myocardial OR coronary OR heart)
SAME (infarct* OR thrombosis OR stenosis))
#4 TS=((myocardial OR coronary OR heart)
SAME (restenosis OR arteriosclerosis OR
arter*))
#5 TS=angina
#6 TS=(chest SAME pain)
#7 #6 OR #5 OR #4 OR #3 OR #2 OR #1
#8 TS=(msct OR mdct)
#9 TS=(multislice* OR multi slice*)
#10 TS=(multi row* OR multirow*)
#11 TS=(multislide* OR multi slide*)
#12 TS=(multidetector* OR multi detector*)
#13 TS=(tomograph* SAME (multi* OR slice*
OR row* OR slide* OR detector*))
#14 #13 OR #12 OR #11 OR #10 OR #9 OR
#8
#15 #14 AND #7
#16 TS=(angiograph* OR angiogram* OR
arteriograph*)
#17 #16 AND #15
Cochrane Library (Issue 4, 2006)
URL: http://www3.interscience.wiley.com/cgi-bin/
mrwhome/106568753/HOME
#1 MeSH descriptor Myocardial Ischemia
explode all trees 
#2 MeSH descriptor Coronary Disease explode
all trees 
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Search strategies#3 MeSH descriptor Myocardial Infarction
explode all trees 
#4 MeSH descriptor Chest Pain explode all
trees 
#5 (ischemi* or ischaemi*) NEAR/3 (heart OR
coronary OR myocardial):ti,ab,kw 
#6 (chest NEAR/3 pain):ti,ab,kw 
#7 (myocardial OR coronary OR heart) NEAR/3
(infarct* or thrombosis OR stenosis):ti,ab,kw 
#8 (myocardial or heart or coronary) NEAR/3
(restenosis or arteriosclerosis or arter*) 
#9 (angina):ti,ab,kw 
#10 (#1 OR #2 OR #3 OR #4 OR #5 OR #6
OR #7 OR #8 OR #9) 
#11 MeSH descriptor Tomography, X-Ray
Computed, this term only 
#12 MeSH descriptor Tomography, Spiral
Computed, this term only 
#13 (detector* or slice* or slide* or row*):ti,ab,kw 
#14 (( #11 OR #12 ) AND #13) 
#15 (msct or mdct):ti,ab,kw or (multislice* or
multi slice*):ti,ab,kw or (multirow* or multi
row*):ti,ab,kw or (multislide* or multi
slide*):ti,ab,kw or (multidetector* or multi
detector*):ti,ab,kw 
#16 (tomograph* near/5 (multi* or slice* or
slide* or row* or detector*)):ti,ab,kw 
#17 (#14 OR #15 OR #16) 
#18 (#10 AND #17) 
#19 (#18), from 2002 to 2006 
DARE (December 2006)
URL: http://www.crd.york.ac.uk/crdweb/
tomograph/All fields AND multi or detector or
slide or slice or row/All fields AND coronary or
heart or myocardial or angina or isch?emia or
isch?emic/All fields
NRR (Issue 3, 2006)
URL: http://www.update-software.com/National/
#1. MYOCARDIAL ISCHEMIA explode all trees
(MeSH) 
#2. CORONARY DISEASE explode all trees
(MeSH) 
#3. MYOCARDIAL INFARCTION explode all
trees (MeSH) 
#4. CHEST PAIN explode all trees (MeSH) 
#5. (heart or coronary or myocardial) 
#6. angina 
#7. (#1 or #2 or #3 or #4 or #5 or #6) 
#8. TOMOGRAPHY X-RAY COMPUTED single
term (MeSH) 
#9. TOMOGRAPHY SPIRAL COMPUTED
single term (MeSH) 
#10. (#8 or #9) 
#11. (detector* or slice* or slide* or multi* or
row*) 
#12. (#10 and #11) 
#13. (msct or mdct) 1 
#14. (multislice* or (multi next slice*)) 
#15. (multirow* or (multi next row*)) 
#16. (multislide* or (multi next slide*)) 
#17. (multidetector* or (multi next detector*)) 
#18. tomograph* 1 
#19. (#11 and #18) 
#20. (#12 or #13 or #14 or #15 or #16 or #17
or #19) 
#21. (#7 and #20) 
Clinical Trials (July 2006)
URL: http://clinicaltrials.gov/ct/gui/c/r
(heart or coronary or myocardial) and tomograph*
Current Controlled Trials (December
2006) 
URL: http://www.controlled-trials.com/
tomograph% and (multi% or detector% or slide*
or slice% or row%) and (heart or coronary or
myocardial )
Conference Papers Index (2002 to 
31 August 2006)
CSA URL: http://www.csa1.co.uk/
((MDCT or MSCT) or (((multi* or detector* or
slice*) or row*) and (ct or tomography))) and
((coronary or cardiac or heart) or (myocardial or
ischemi* or ischaemi*) or (stenosis or restenosis or
Arteriosclerosis)
Cost-effectiveness and economic
evaluations
Search strategies used to identify reports of cost-
effectiveness and economic evaluations of MSCT
for CAD.
MEDLINE (1996 to November 
week 3 2006), EMBASE (1996 to 
week 49 2006), Medline In-Process 
(14 December 2006) 
Ovid Multifile Search URL:
http://gateway.ovid.com/
1 exp "costs and cost analysis"/ 
2 economics/
3 exp economics,hospital/ 
4 exp economics,medical/ 
5 economics,pharmaceutical/ 
Appendix 1
746 exp budgets/ 
7 exp models, economic/ 
8 exp decision theory/ 
9 ec.fs. use medf
10 monte carlo method/ 
11 markov chains/ 
12 exp quality of life/ 
13 "Value of Life"/ 
14 cost of illness/ 
15 exp health status indicators/ 
16 cost$.ti. 
17 (cost$ adj2 (effective$ or utilit$ or benefit$ or
minimis$)).ab. 
18 economics model$.tw. 
19 (economics$ or pharmacoeconomic$ or
pharmo-economic$).ti. 
20 (price$ or pricing$).tw. 
21 (financial or finance or finances or
financed).tw. 
22 (value adj2 (money or monetary)).tw. 
23 quality adjusted life.tw. 
24 disability adjusted life.tw. 
25 (qaly? or qald? or qale? or qtime? or daly?).tw. 
26 (euroqol or euro qol or eq5d or eq 5d).tw. 
27 (hql or hqol or h qol or hrqol or hr qol).tw. 
28 (hye or hyes).tw. 
29 (health adj3 (indicator? or status or utilit?)).tw. 
30 markov$.tw. 
31 monte carlo.tw. 
32 (decision$ adj2 (tree? or analy$ or model$)).tw. 
33 or/1-32 
34 exp myocardial ischemia/ use medf 
35 exp ischemic heart disease/ use emef 
36 exp coronary artery disease/ 
37 exp myocardial infarction/ 
38 exp chest pain/ 
39 coronary artery blood flow/ use emef 
40 (isch?emi$ adj3 (heart or coronary or
myocardial)).tw
41 ((myocardial or coronary or heart) adj3
(infarct$ or thrombosis or stenosis or restenosis
or arteriosclerosis or arter$)).tw. 
42 angina.tw. 
43 (chest adj3 pain).tw. 
44 or/34-43 
45 tomography, x-ray computed/ use medf 
46 tomography, spiral computed/ use medf 
47 computer assisted tomography/ use emef 
48 computed tomographic angiography/ use emef 
49 electron beam tomography/ use emef 
50 high resolution computer tomography/ use
emef 
51 spiral computer assisted tomography/ use emef 
52 or/45-51 
53 (detector? or slice? or slide? or row?).tw. 
54 52 and 53 
55 multidetector computed tomography/ use emef 
56 (msct or mdct).tw. 
57 (multi slice? or multislice?).tw. 
58 (multi row? or multirow?).tw. 
59 (multi slide? or multislide?).tw
60 (multi detect$ or multidetect$).tw. 
61 (tomograph$ adj5 (multi$ or slice? or row? or
slide? or detector?)).tw. 
62 or/54-61 
63 33 and 44 and 62 
64 remove duplicates from 63 
NHS EED (December 2006)
URL: http://nhscrd.york.ac.uk/welcome.htm
tomograph/All fields AND multi or detector or
slide or slice or row/All fields AND coronary or
heart or myocardial or angina or isch?emia or
isch?emic/All fields
General searches
Search strategies used to identify reports of
clinical effectiveness or cost-effectiveness of
MSCT for CAD.
HMIC (2000 to May 2006)
URL: http://gateway.ovid.com/
1 computed tomography scanners/ 
2 (detector? or slice? or slide? or row?).tw. 
3 1 and 2 
4 (multi slice? or multislice?).tw. 
5 (msct or mdct).tw. 
6 (multi row? or multirow?).tw. 
7 (multi slide? or multislide?).tw. 
8 (multi detect$ or multidetect$).tw. 
9 (tomograph$ adj5 (multi$ or slice? or row? or
slide? or detector?)).tw
10 3 or 9
HTA Database (December 2006)
URL: http://nhscrd.york.ac.uk/welcome.htm
tomograph/All fields AND multi or detector or
slide or slice or row/All fields AND coronary or
heart or myocardial or angina or isch?emia or
isch?emic/All fields
Conference proceedings
American College of Cardiology
53rd Annual Scientific Sessions, New Orleans,
March 2004
54th Annual Scientific Sessions, Orlando, March
2005
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2006 
American Heart Association
Annual Scientific Sessions, Orlando, November
2003
Annual Scientific Sessions, New Orleans,
November 2004
Annual Scientific Sessions, Dallas, November 2005
European Society of Radiology
European Congress on Radiology, Vienna, March
2003
European Congress on Radiology, Vienna, March
2004
European Congress on Radiology, Vienna, March
2005
European Congress on Radiology, Vienna, March
2006
European Society of Cardiology
Annual Congress, Munich, August 2004
Annual Congress, Stockholm, September 2005
North American Society of Cardiology
Imaging
32nd Annual Meeting, Ameila Island, Florida,
2004
33rd Annual Meeting, Ameila Island, Florida,
2005
Radiological Society of North American
Annual Scientific Meeting, Chicago, December
2003
Annual Scientific Meeting, Chicago, December
2004
Annual Scientific Meeting, Chicago, December
2005
Society of Cardiovascular Tomography
1st Scientific Meeting, Washington DC, July 2006
World Congress of Cardiology 2006
Barcelona, September 2006
WEBSITES
Searched for other evidence-based reports and
background information.
American College of Cardiology
URL: http://www.acc.org/ (accessed May 2006)
American College of Radiology 
URL: http://www.acr.org/s_acr/index.asp (accessed
May 2006)
American Heart Association
URL: http://my.americanheart.org/portal/
professional (accessed May 2006)
British Society of Cardiac Radiology
URL: http://www.bscr.co.uk/ (accessed May 2006)
Cardiac Radiographers Advisory Group
URL: http://www.craguk.org/ (accessed May 2006)
European Society of Cardiac Radiology
URL: http://www.escr.org/society_ear.shtml
(accessed May 2006)
European Society of Cardiology
URL: http://www.escardio.org/ (accessed May 2006)
Health Protection Agency
URL: http://www.hpa.org.uk/ (accessed May 2006)
ImPACT (Imaging Performance Assessment of CT
scanners) Group
URL: http://www.impactscan.org/ (accessed May
2006)
Radiological Society of North America
URL: http://www.rsna.org/ (accessed May 2006)
TRIP database 
URL: http://www.tripdatabase.com/ (accessed May
2006)
Systematic reviews comparing
MSCT with SPECT for CAD
DARE (December 2006)
HTA Database (December 2006)
URL: http://www.crd.york.ac.uk/crdweb/
Medion Database (December 2006)
URL: http://www.mediondatabase.nl/
Exp Myocardial Ischemia/di
Appendix 1
76Quality assessment checklist (derived from QUADAS tool)29
Study ID:  Paper no.:
Assessor initials:  Date assessed: 
Item Yes No Unclear
Mandatory quality items
1. Was the spectrum of patients representative of the patients who will 
receive the test in practice?
2. Is the reference standard likely to correctly classify the target 
condition?
3. Is the time period between the reference standard and index test 
short enough to be reasonably sure that the target condition did not 
change between the two tests?a
4. Did the whole sample or a random selection of the sample receive 
verification using a reference standard of diagnosis?
5. Did patients receive the same reference standard regardless of the 
index test result?
6. Was the reference standard independent of the index test (i.e. the 
index test did not form part of the reference standard)? 
7. Were the index test results interpreted without knowledge of the 
results of the reference standard? 
8. Were the reference standard results interpreted without knowledge 
of the results of the index test?
9. Were the same clinical data available when test results were 
interpreted as would be available when the test is used in practice?b
10. Were uninterpretable/intermediate test results reported? 
11. Were withdrawals from the study explained? 
Additional items
12. Has an established cut-off point been used?c
13. Were data on observer variation reported and within an acceptable 
range?
14. Were data presented for appropriate subgroups of patients?d
a For Q3 to be checked Yes, the period should be less than 6 months.
b For Q9 to be checked Yes, the data should be for CT results only.
c For Q12, one example of an established cut-off point is >50% stenosis.
d For Q14, appropriate subgroups include people with suspected CAD, known CAD, diabetes, previous
PCI or CABG, and women.
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Modified QUADAS quality assessment checklistDiagnostic studies (full text)
Ehara (2006a)46
Primary reference
Ehara M, Surmely J-F, Kawai M, Katoh O, Matsubara T,
Terashima M, et al. Diagnostic accuracy of 64-slice
computed tomography for detecting angiographically
significant coronary artery stenosis in an unselected
consecutive patient population: comparison with
conventional invasive angiography. Circ J 2006;
70:564–71.
Secondary references
Ehara M, Kato O, Matsubara T, Terashima M,
Tsuchikane E, Suzuki T, et al. Accuracy of non-invasive
angiography with 64-slice computed tomography for
detection of significant coronary stenosis in a
prospective registry: comparison with invasive coronary
angiography. Circulation 2005;112:U621.
Ehara M, Kawai M, Kato O, Matsubara T, Terashima M,
Tsuchikane E, et al. Diagnostic accuracy of coronary
angiography using 64-slice computed tomography for
detection of coronary artery disease in an unselected
population: reliability in the ‘real world’. Am J Cardiol
2005;96:21H.
Ehara M, Kato O, Matsubara T, Trashima M,
Tsuchikane E, Ito T, et al. Diagnostic accuracy of 64-slice
computed tomography compared with invasive
angiography: feasibility of this non-invasive modality on
the clinical practice. Eur Heart J 2005;26:533.
Fine (2006a)49
Primary reference
Fine JJ, Hopkins CB, Ruff N, Newton FC. Comparison
of accuracy of 64-slice cardiovascular computed
tomography with coronary angiography in patients with
suspected coronary artery disease. Am J Cardiol 2006;
97:173–4.
Secondary reference
Fine JJ, Hall PA, Hopkins CB, Newton FC. Noninvasive
coronary angiography: agreement of 64-slice
cardiovascular computed tomography and selective
catheter angiography. J Am Coll Cardiol 2006;47:127A.
Ghostine (2006)52
Primary reference
Ghostine S, Caussin C, Daoud B, Habis M, Perrier E,
Pesenti-Rossi D, et al. Non-invasive detection of coronary
artery disease in patients with left bundle branch block
using 64-slice computed tomography. J Am Coll Cardiol
2006;48:1929–34.
Secondary reference
Ghostine S, Caussin C, Daoud B, Habis M, Perrier E,
Rossi R, et al. Noninvasive detection of coronary artery
disease in patients with left bundle branch block using
64-slice computed tomography. J Am Coll Cardiol 2006;
47:136A.
Hoffmann (2006)55
Primary reference
Hoffmann U, Nagurney JT, Moselewski F, Pena A,
Ferencik M, Chae CU, et al. Coronary multidetector
computed tomography in the assessment of patients
with acute chest pain. Circulation 2006;114:2251–60.
Johnson (2007)56
Primary reference
Johnson TR, Nikolaou K, Wintersperger BJ, Knez A,
Boekstegers P, Reiser MF, et al. ECG-gated 64-MDCT
angiography in the differential diagnosis of acute chest
pain. AJR Am J Roentgenol 2007;188:76–82.
Leber (2005)58
Primary reference
Leber AW, Knez A, Von Ziegler F, Becker A, Nikolaou K,
Paul S, et al. Quantification of obstructive and
nonobstructive coronary lesions by 64-slice computed
tomography: a comparative study with quantitative
coronary angiography and intravascular ultrasound. 
J Am Coll Cardiol 2005;46:147–54.
Secondary reference
Knez A, Leber A, Becker A, Von Ziegler F, Becker C.
Non invasive coronary angiography with 64 multislice
spiral CT: ready to replace diagnostic angiography in
patients with suspected CAD. Circulation 2005;112:U743.
Leschka (2005)59
Primary reference
Leschka S, Alkadhi H, Plass A, Desbiolles L,
Grunenfelder J, Marincek B, et al. Accuracy of MSCT
coronary angiography with 64-slice technology: first
experience. Eur Heart J 2005;26:1482–7.
Meijboom (2006)65
Primary reference
Meijboom WB, Mollet NR, Van Mieghem CAG, 
Kluin J, Weustink AC, Pugliese F, et al. Pre-operative
computed tomography coronary angiography to detect
significant coronary artery disease in patients referred
for cardiac valve surgery. J Am Coll Cardiol
2006;48:1658–65.
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List of included studiesSecondary reference
Meijboom WB, Van Mieghem C, Kluin J, Pugliese F,
Mollet N, Cademartiri F, et al. Comparison of computed
tomography coronary angiography with conventional
coronary angiography for the detection of significant
coronary lesions in the pre-operative valve surgery
patient. J Am Coll Cardiol 2006;47:126A.
Mollet (2005)66
Primary reference
Mollet NR, Cademartiri F, Van Mieghem CA, Runza G,
McFadden EP, Baks T, et al. High-resolution spiral
computed tomography coronary angiography in
patients referred for diagnostic conventional coronary
angiography. Circulation 2005;112:2318–23.
Secondary references
Cademartiri F, Mollet N, Van Mieghem C, Runza G,
Belgrano M, Baks T, et al. Diagnostic accuracy of non-
invasive 64-slice CT coronary angiography. European
Congress on Radiology, Vienna, March 2005. Abstract
B-342.
Mollet NR, Cademartiri F, Van Mieghem C, Runza G,
Baks T, McFadden EP, et al. Non-invasive 64-slice multi-
detector CT coronary angiography of the entire
coronary tree in patients with stable angina pectoris or
an acute coronary syndrome. J Am Coll Cardiol 2005;
45:267A.
Nikolaou (2006)71
Primary reference
Nikolaou K, Knez A, Rist C, Wintersperger BJ, Leber A,
Johnson T, et al. Accuracy of 64-MDCT in the diagnosis
of ischemic heart disease. AJR Am J Roentgenol 2006;
187:111–17.
Secondary references
Nikolaou K, Rist C, Wintersperger B, Flohr T, 
Johnson T, Von Ziegler F, et al. 64-detector row
computed tomography of the coronary arteries: initial
experience. European Congress on Radiology, Vienna,
March 2005. Abstract B-346.
Nikolaou K, Wintersperger B, Rist C, Johnson T, 
Reiser M, Becker C. Sixty-four-slice computed
tomography in the diagnosis of ischemic heart disease:
impact on clinical decision making. Radiological Society
of North America, Annual Scientific Meeting, Chicago,
December 2005. Abstract SSC05-05.
Ong (2006)75
Primary reference
Ong TK, Chin SP, Liew CK, Chan WL, Seyfarth MT,
Liew HB, et al. Accuracy of 64-row multidetector
computed tomography in detecting coronary artery
disease in 134 symptomatic patients: influence of
calcification. Am Heart J 2006;151:1323e1–6.
Secondary reference
Ong K, Chin SP, Chan WL, Liew CK, Seyfarth MT, 
Liew HB, et al. Feasibility and accuracy of 64-row MDCT
coronary imaging from a centre with early experience: a
review and comparison with established centres. Med J
Malaysia 2005;60:629–36.
Pache (2006)77
Primary reference
Pache G, Saueressig U, Frydrychowicz A, Foell D,
Ghanem N, Kotter E, et al. Initial experience with 64-
slice cardiac CT: non-invasive visualization of coronary
artery bypass grafts. Eur Heart J 2006;27:976–80.
Plass (2006)79
Primary reference
Plass A, Grunenfelder J, Leschka S, Alkadhi H, 
Eberli FR, Wildermuth S, et al. Coronary artery imaging
with 64-slice computed tomography from cardiac
surgical perspective. Eur J Cardiothorac Surg 2006;
30:109–16.
Secondary reference
Plass AR, Haeussler AK, Grunenfelder J, Leschka S,
Widermuth S, Zund G, et al. First experiences in
evaluating coronary artery disease with the 64-MDCT.
Br J Surg 2005;92:915.
Pugliese (2006a)83
Primary reference
Pugliese F, Mollet NR, Runza G, Van Mieghem C,
Meijboom WB, Malagutti P, et al. Diagnostic accuracy of
non-invasive 64-slice CT coronary angiography in
patients with stable angina pectoris. Eur Radiol 2006;
16:575–82.
Raff (2005)85
Primary reference
Raff GL, Gallagher MJ, O’Neill WW, Goldstein JA.
Diagnostic accuracy of noninvasive coronary
angiography using 64-slice spiral computed
tomography. J Am Coll Cardiol 2005;46:552–7.
Rist (2006)86
Primary reference
Rist C, Von Ziegler F, Nikolaou K, Kirchin MA,
Wintersperger BJ, Johnson TR, et al. Assessment of
coronary artery stent patency and restenosis using 
64-slice computed tomography. Acad Radiol 2006;
13:1465–73.
Rixe (2006)89
Primary reference
Rixe J, Achenbach S, Ropers D, Baum U, Kuettner A,
Ropers U, et al. Assessment of coronary artery stent
restenosis by 64-slice multi-detector computed
tomography. Eur Heart J 2006;27:2567–72.
Secondary references
Rixe J, Anders K, Ropers D, Kuettner A, Baum U,
Ludwig J, et al. Assessment of coronary artery stent
patency by 64-slice multi-detector computed
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Rixe J, Anders K, Ropers D, Baum U, Kuettner A,
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Ropers (2006a)93
Primary reference
Ropers D, Rixe J, Anders K, Kuttner A, Baum U, 
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Schuijf (2006)100
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Secondary reference
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Ehara, 2006a
42–44,46
Aim: T
o evaluate the diagnostic accuracy of
64-slice CT in various types of patients,
including those with severely calcified
arteries or post-PCI, as well as detecting
CAD in patients with imperfect breath-
holding, or arrhythmias occurring during
the scan
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). Coronary arteries
were classified into 14 segments. Significant
stenosis was defined as >50% reduction
of minimal lumen diameter 
Method of recruitment
: Consecutive
P
eriod: October 2004 to January 2005
Country: Japan
Enrolled: 69 
Analysed: 67
Age (years): Mean 67, SD 11
Gender: M 52; F 17
P
revious PCI: 46
P
revious CABG: 2
Indications for testing
: Suspected CAD
19; proven CAD 50 
Inclusion criteria: NS
Ex
clusion criteria: P
atients with
contraindications to iodinated contrast
media (such as renal insufficiency with a
serum creatinine >1.5 mg/dl, known
allergy or thyroid disorder), chronic
arrhythmias or unable to hold their breath
64-Slice CT
: Sensation 64, Siemens
R
etrospective ECG gating: Y
es
R
otation time: 330 ms
Slice thickness: 0.6 mm
T
otal scan time
: Mean 13.6 s (range
10.5–24.1)
T
otal e
xamination time: NS
R
adiation dose: NS
Dose modulation used: NS 
Use of drugs to limit heart rate: At the
time of the MSCT scan 15 patients were
on 
-blockers. No additional 
-blocker
medication was given to the remaining
54
patients before the scan
Heart rate during CT scan: Mean 71.8,
SD 13 (range 51–115) bpm
Invasive CA: Quantitative CA was
performed using CMS (MEDIS, The
Netherlands). At least two different views
were obtained for each vessel
P
revalence of significant CAD
: 88%
(61/69)
Cut-
off
: >50% stenosis
Segments (n
= 884); patients (n
= 67): 
Sensitivity: 90%, 98% 
Specificity: 94%, 86% 
PPV
: 89%, 98% 
NPV
: 95%, 86% 
Image quality (all segments):
Fine: 767 (80%)
Adequate: 117 (12%)
P
oor: 82 (8%) 
CT interobserver agreement: 
= 0.95 
CT intraobserver agreement: 

= 0.93 
F
ryback and Thornbury grading:
a
Level 2
Fine, 2006a
47,49
Aim: T
o evaluate the accuracy of 64-slice
CT and the frequency distribution of
indications for MSCT to determine
whether improved performance offers a
low
-risk and patient-friendly mode of CA,
which in selected clinical situations may
replace the need for catheter angiography
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). V
essel-by
-vessel
analysis. Significant stenosis was defined as
>50% reduction of minimal lumen
diameter
. V
essels with a diameter 
Enrolled: 66 
Analysed: 66
Age (years): Mean 62, SD 7
Gender: M 32; F 34
P
revious PCI: NS
P
revious CABG: 9 vein grafts
Indications for testing
: Chest pain 33;
previous revascularisation 9; abnormal
ECG 5; dyspnoea 7; abnormal calcium
score 2; known coronary disease 3;
abnormal cardiovascular study 7
Inclusion criteria: NS
Ex
clusion criteria: NS
64-Slice CT
: Sensation 64, Siemens
R
etrospective ECG gating: Y
es
R
otation time: 33 ms
Slice thickness: 0.6 mm
T
otal scan time
: NS
T
otal e
xamination time: NS
R
adiation dose: NS
Dose modulation used: NS
Use of drugs to limit heart rate
:
P
atients with high heart rates were given
oral and/or i.v
. metoprolol as needed to
decrease their heart rate to 50–60 bpm 
Heart rate during CT scan: NS
P
revalence of significant CAD
: NS
Cut-
off
: >50% stenosis
Arteries (n
= 245?): 
Sensitivity: 95% 
Specificity: 96%
PPV
: 97% 
NPV
: 92% 
Image quality: CT provided images of
technical quality that allowed for diagnosis
among 94% (62/66) of study subjects
CT interobserver agreement: NS
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2Health Technology Assessment 2008; Vol. 12: No. 17
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<1.5
mm were excluded from correlation
and technical quality analysis 
Method of recruitment
: Sequential
P
eriod: NS
Country: USA
Invasive CA: Details NS, vessels with a
diameter <1.5
mm were excluded from
correlation and image quality analysis
Ghostine, 2006
51,52
Aim: T
o evaluate the diagnostic accuracy of
64-slice CT to identify CAD in patients
with complete LBBB 
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). AHA 15-segment
model. The diagnostic accuracy of 64-slice
CT was performed for lesions with mean
lumen diameter reduction >50% 
Method of recruitment
: Consecutive
P
eriod: September to November 2005
Country: F
rance
Enrolled: 66 
Analysed: 66
Age (years): Mean 69, SD 13
Gender: M 40; F 26
P
revious PCI: NS 
P
revious CABG: NS
Indications for testing
: P
atients with
complete LBBB, sinus rhythm, without a
history of CAD
Inclusion criteria: NS
Ex
clusion criteria: Suspicion of A
CS,
known history of CAD, arrhythmia, renal
insufficiency (serum creatinine
>150
mol/l), iodine allergy
, pregnancy
64-Slice CT
: Sensation 64, Siemens,
Germany
R
etrospective ECG gating: Y
es
R
otation time: 330 ms
Slice thickness: 0.6 mm
T
otal scan time
: 12 (SD 2) s
T
otal e
xamination time: NS
R
adiation dose: 7 (SD 2) mSv
Dose modulation used: Y
es
Use of drugs to limit heart rate
: All
patients received oral 
-blocker
medication if not contraindicated
(metoprolol 100
mg, 1 hour before
acquisition) to lower heart rate below
70
bpm 
Heart rate during CT scan: Mean 67,
SD 13 (range 46–119) bpm 
Invasive CA: Invasive coronary
angiograms were evaluated by quantitative
CA, with the mean diameter reduction
determined in two orthogonal views
P
revalence of CAD at >50% luminal
narrowing: 44% (29/66)
Cut-
off
: >50% stenosis
Segments (n
= 94); patients (n
= 29): 
Sensitivity: 97%, 72% 
Specificity: 95%, 99% 
PPV
: 93%, 91%
NPV
: 97%, 97% 
Image quality: Image quality score was
good on average (3.8, SD 1.4). Score 5
(n
=
32), 4 (n
=
10), 3 (n
=
6), 2 (n
=1
4
)
and 1 (n
=
4) were for a heart rate of
60
(SD 8), 67 (SD 8), 71 (SD 3), 72 (SD 10)
and 101 (SD 13) bpm, respectively
. All the
patients with a heart rate >90 bpm
presented blurred image quality (score 1) 
CT interobserver agreement: NS
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2Appendix 5
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Hoffmann, 2006
55
Aim: T
o assess CT angiographic patterns of
CAD – any coronary atherosclerotic
plaque and significant stenosis – in patients
who were being admitted for chest pain
and who had negative initial cardiac
biomarkers and a non-diagnostic ECG on
presentation 
Study design: Non-randomised
comparative study in which some patients
received both MSCT and invasive CA
(reference standard). Modified AHA 
17-segment model. The diagnostic
accuracy of 64-slice CT was performed for
luminal obstruction 
50% diameter
reduction in cross-sectional images
(corresponding to >~70% stenosis in
planimetric invasive CA)
Method of recruitment
: Consecutive
P
eriod: May to July 2005
Country: USA
Enrolled: 106 
Analysed: 103 (8 received both MSCT and
invasive CA)
Age (years): Mean 54, SD 12 (whole
group)
Gender: M 62; F 41 (whole group)
P
revious PCI: NS 
P
revious CABG: NS
Indications for testing
: Adults with acute
chest pain in whom initial ED evaluation
was inconclusive 
Inclusion criteria: Age >18 years,
>5
minutes of chest pain within the
previous 24 hours, no or non-diagnostic
ECG changes, normal initial cardiac
biomarkers, sinus rhythm, ability to
perform a breath-hold of 10–15 seconds 
Ex
clusion criteria: Elevated troponin-l or
creatine kinase-MB levels in the initial
blood sample obtained in the ED, new
diagnostic ECG changes (ST
-segment
elevation or depression >1
mm or T
-wave
inversion >4
mm in more than two
anatomically contiguous leads),
haemodynamic or clinical instability
, known
allergy to iodinated contrast agent, serum
creatinine >1.3
mg/dl, metformin
treatment, hyperthyroidism, inability to
provide informed consent, perceived
interference with standard clinical care of
patients
64-Slice CT
: Sensation 64, Siemens,
Germany
R
etrospective ECG gating: Y
es
R
otation time: 330 ms
Slice thickness: 0.6 mm
T
otal scan time
: 13.6 (SD 2.2) s 
T
otal e
xamination time: Including patient
preparation 12 (SD 1) minutes
R
adiation dose: 6–11 mSv
Dose modulation used: Y
es
Use of drugs to limit heart rate: All
patients with a heart rate >60
bpm
received a -blocker (i.v
. metoprolol
5–20
mg) unless their systolic blood
pressure was <100
mmHg or other
contraindications were present 
Heart rate during CT scan: NS
Invasive CA: NS
P
revalence of CAD at >50% luminal
narrowing: 63% (5/8)
Cut-
off
: >50% stenosis
P
atients (n
= 8): 
Sensitivity: 100%
Specificity: 100%
PPV
: 100% 
NPV
: 100%
Image quality: NS 
CT interobserver agreement: 
Detection of any plaque per patient:

=
0.92
Detection of any plaque per segment:

=
0.81
Detection of stenosis per patient: 
=
0.82
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2Health Technology Assessment 2008; Vol. 12: No. 17
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56
Aim: T
o evaluate the diagnostic value of an
ECG
-gated 64 MSCT angiography protocol
for simultaneous assessment of the
pulmonary arteries, coronary arteries and
aorta within a single breath-hold 
Study design: Non-randomised
comparative study in which some patients
received both MSCT and invasive CA
(reference standard). AHA 15-segment
model. The diagnostic accuracy of 64-slice
CT was performed for lesions with luminal
narrowing >50% or occlusion
Method of recruitment
: Consecutive
P
eriod: July 2004 to March 2005
Country: Germany
Enrolled: 55
Analysed: 55 (20 received both MSCT and
invasive CA)
Age (years): NS
Gender: NS
P
revious PCI: NS 
P
revious CABG: NS
Indications for testing
: P
atients with
acute chest pain
Inclusion criteria: P
atients with acute
chest pain and the origin of the pain was
unclear
, i.e. if ECG findings were absent or
inconclusive and if the clinical appearance
did not suggest a specific cause 
Ex
clusion criteria: P
atients who could not
hold their breath for at least 15 seconds. In
the acute setting, relative contraindications
were arrhythmia, history of severe allergic
reaction to iodinated contrast media, renal
insufficiency and young age (<55
years)
64-Slice CT
: Sensation 64, Siemens
R
etrospective ECG gating: Y
es
R
otation time: 330 ms
Slice thickness: 0.6 mm
T
otal scan time
: 21.4 (SD 3.2) s
T
otal e
xamination time
: NS
R
adiation dose: ~6.9 mSv
Dose modulation used: Y
es
Use of drugs to limit heart rate
: 
-Blockers were not administered in
preparation for the scan 
Heart rate during CT scan: Mean 71,
SD 15 (range 51–123) bpm
Invasive CA: In 20 patients, X
-ray
coronary angiograms were available for
correlation. T
en patients had undergone
CA within 1
year before CT
, the other ten
underwent CA within 4 days after CT for
confirmation of or intervention in lesions
detected with CT 
P
revalence of CAD at >50% luminal
narrowing: 85% (17/20)
Cut-
off: >50% stenosis or occlusions
P
atients (n
= 20):
Sensitivity: 94%
Specificity: 0%
PPV
: 84%
NPV
: 0% 
Image quality: One right coronary artery
resulted in image quality insufficient for
diagnosis. The overall image quality rating
was 1.2 (SD 0.4)
CT interobserver agreement: R
egarding
presence or absence of clinically significant
stenosis in each patient 
= 0.81, regarding
number of significant stenoses per patient

=
0.62, regarding wall irregularities with
stenosis <50%, 
= 0.43 
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2
Leber
, 2005
57,58
Aim: T
o determine the diagnostic accuracy
of 64-slice CT to identify and quantify
atherosclerotic coronary lesions in
comparison with catheter
-based
angiography and intravascular ultrasound 
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). AHA 15-segment
model. The diagnostic accuracy of 64-slice
CT was performed for lesions with various
degrees of luminal narrowing: >75%,
>50% and <50% 
Enrolled: 59 
Analysed: 59
Age (years): Mean 64, SD 10
Gender: NS
P
revious PCI: NS (stenting >1 vessel
excluded)
P
revious CABG: Excluded
Indications for testing
: NS
Inclusion criteria: NS
Ex
clusion criteria: P
atients with atrial
fibrillation, previous bypass surgery
,
previous stenting of more than one vessel,
an unstable clinical condition, or a 
64-Slice CT
: Sensation 64, Siemens
R
etrospective ECG gating: Y
es
R
otation time: 330 ms
Slice thickness: 0.6 mm
T
otal scan time
: 8–11 s 
T
otal e
xamination time: NS
R
adiation dose: Mean 10–14 mSv
Dose modulation used: Y
es
Use of drugs to limit heart rate
:
P
atients with heart rates >70 bpm were
given 50
mg of metoprolol 60 minutes
before the scheduled CT scan. In the
presence of contraindications for a 
-blocker
, or an unsatisfactory lowering of 
P
revalence of CAD at >50% luminal
narrowing: 42% (25/59)
Cut-
off
: >50% stenosis
Segments (n
= 697), patients (n
= 55):
Sensitivity: 73%, 88% 
Specificity: 97%, NS 
PPV
: 60%, NS 
NPV
: 98%, NS 
Image quality: Four of 59 patients had CT
angiograms that were severely affected by
motion artefacts or poor contrast-to
-noise
ratio, making an evaluation of all coronary
segments impossible. In the remaining Appendix 5
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Method of recruitment
: Consecutive
P
eriod: July to November 2004
Country: Germany
contraindication to the administration of
contrast agent
the heart rate, the scan was performed
even at higher heart rates 
Heart rate during CT scan: Mean 62,
SD? 13 bpm
Invasive CA: Invasive coronary
angiograms were evaluated by quantitative
CA, with the mean diameter reduction
determined in two projections
55
patients all coronary segments were
graded to provide good or intermediate
image quality that was sufficient for
evaluation
CT interobserver agreement: NS
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2
Leschka, 2005
59
Aim: T
o investigate the accuracy of 64-slice
CT for assessing haemodynamically
significant stenosis of the coronary arteries
in comparison with invasive CA
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). AHA 15-segment
model. Significant stenosis was defined as
vessel reduction >50%. Coronary artery
analysis was performed in all vessels with a
diameter down to 1.5
mm, including those
vessels distal to complete occlusions
Method of recruitment
: Consecutive
P
eriod: October 2004 to January 2005
Country: Switzerland
Enrolled: 67 
Analysed: 67
Age (years): Mean 60.1, SD 10.5 (range
34–82)
Gender: M 50; F 17
P
revious PCI: NS (stenting excluded)
P
revious CABG: Excluded
Indications for testing
: Signs of unstable
angina 24; prior to CABG 43
Inclusion criteria: Suspected CAD; prior
to CABG
Ex
clusion criteria: P
revious allergic
reactions to iodine contrast media, severe
renal insufficiency (creatinine level
>120
mol/l), haemodynamic instability
,
atrial fibrillation, inability to follow breath-
hold commands, previous percutaneous
transluminal coronary stent placement,
previous bypass surgery
64-Slice CT
: Sensation 64, Siemens
R
etrospective ECG gating: Y
es
R
otation time: 0.37 s 
Slice thickness: 0.6 mm
T
otal scan time
: <12 s (median 11.2,
range 10.7–11.9)
T
otal e
xamination time
: <15 minutes
(median 12, range 8–14)
R
adiation dose: NS
Dose modulation used: No
Use of drugs to limit heart rate
: 
40 patients had taken -blockers as part of
their baseline medication at the time of the
CT scan. No additional -blockers were
administered before the CT scan
Heart rate during CT scan: Mean 66.3,
SD 14.7 (range 48–90) bpm
Invasive CA: Invasive CA was performed
according to standard techniques
P
revalence of significant CAD
: 70%
(47/67)
Cut-
off: >50% stenosis
Segments (n
= 1005):
Sensitivity: 94% 
Specificity: 97% 
PPV
: 87% 
NPV
: 99% 
Image quality (segments):
Excellent: 61% (612/1005)
Good: 31% (310/1005)
Adequate: 8% (83/1005)
CT interobserver agreement: 

=
0.88
(image quality), 0.87 (calcifications), 0.95
(stenoses detection) 
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2Health Technology Assessment 2008; Vol. 12: No. 17
95
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
T
ABLE 21
Diagnostic studies: full text (cont’d)
Study
, design and methods
P
articipants
T
ests
Outcomes summary
continued
Meijboom, 2006
64,65
Aim: T
o study the diagnostic performance
of 64-slice CT to rule out or detect
significant coronary stenosis in patients
referred for valve surgery
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). 17-Segment modified
AHA model. Significant stenosis was
defined as lumen diameter reduction
50% 
Method of recruitment
: Consecutive
P
eriod: 6 months
Country: The Netherlands 
Enrolled: 70 
Analysed: 70
Age (years): Mean 63, SD 11
Gender: M 49; F 21
P
revious PCI: 0
P
revious CABG: 0
Indications for testing
: Scheduled for
valve surgery
Inclusion criteria: P
atients scheduled for
valve surgery
Ex
clusion criteria: Irregular heart rhythm
26, impaired renal function 5, known
contrast allergy 4, hospitalisation in
community hospital 4, no need for CA 4,
previous coronary artery bypass surgery 1
or percutaneous coronary intervention 4,
no consent 27 
64-Slice CT
: Sensation 64, Siemens
R
etrospective ECG gating: Y
es
R
otation time: 330 ms
Slice thickness: 0.6 mm
T
otal scan time
: Mean 12.8, SD 1.3 s
T
otal e
xamination time
: NS
R
adiation dose: 15.2–21.4 mSv for men
and women, respectively
Dose modulation used: No
Use of drugs to limit heart rate
: 
-Blocker administered in 71% and 64%
received lorazepam
Heart rate during CT scan: Mean 60,
SD 8 bpm
Invasive CA: Stenoses were evaluated in
two orthogonal views. Segments distal to a
chronic total occlusion were excluded
because of poor distal filling by collaterals
P
revalence of significant CAD
: 26%
(18/70)
Cut-
off
: 
50% stenosis
Segments (n
= 1003), patients
(n
=
70): 
Sensitivity: 94%, 100% 
Specificity: 98%, 92% 
PPV
: 65%, 82% 
NPV
: 100%, 100% 
Image quality: NS
CT interobserver agreement: 

= 0.71 
CT intraobserver agreement: 

= 0.74 
F
ryback and Thornbury grading: Level 2
Mollet, 2005
40,66,67
Aim: T
o assess the diagnostic performance
of 64-slice CT in detecting the extent and
severity of coronary stenosis in the
clinically relevant coronary tree of patients
with atypical chest pain, stable or unstable
angina, or non-ST
-segment elevation MI
referred for diagnostic invasive CA 
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). 17-Segment modified
AHA model. Significant stenosis was
defined as mean lumen diameter reduction
50% 
Method of recruitment
: Consecutive
P
eriod: 6 weeks
Enrolled: 70 
Analysed: 52
Age (years): Mean 59.6, SD 12.1
Gender: M 34; F 18
P
revious PCI: NS
P
revious CABG: NS
Indications for testing
: Atypical chest
pain 6; stable angina pectoris 32; unstable
angina pectoris 3; non-ST
-segment
elevation MI 11
Inclusion criteria: P
atients scheduled for
diagnostic conventional CA with sinus heart
rhythm, able to hold breath for
15
seconds, and no previous PCI or CABG
surgery 
64-Slice CT
: Sensation 64, Siemens
R
etrospective ECG gating: Y
es
R
otation time: 330 ms
Slice thickness: 0.6 mm
T
otal scan time
: Mean 13.3, SD 0.6 s
T
otal e
xamination time: NS
R
adiation dose: 15.2–21.4 mSv for men
and women, respectively
Dose modulation used: No
Use of drugs to limit heart rate
:
P
atients with heart rates >70 bpm
received, unless they had known overt
heart failure or ECG A
V conduction
abnormalities, a single oral dose of 100
mg
metoprolol 45 minutes before the scan.
P
atients with heart rates >80 bpm
received an additional single oral dose of
1
mg lorazepam
P
revalence of significant CAD
: 75%
(39/52)
Cut-
off
: 
50% stenosis
Segments (n
= 725), patients (n
= 51): 
Sensitivity: 99%, 100% 
Specificity: 95%, 92% 
PPV
: 76%, 97% 
NPV
: 100%, 100% 
Image quality (all segments):
Good: 90%
Moderate: 7%
P
oor: 3% 
CT interobserver agreement: 

= 0.73 
CT intraobserver agreement: 

= 0.79 
F
ryback and Thornbury grading: Level 2Appendix 5
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Country: The Netherlands
Ex
clusion criteria: Logistical inability to
perform a CT scan before the conventional
angiogram (n
=
9), presence of arrhythmia
(n
=
4), impaired renal function (serum
creatinine >120 mmol/l) (n
=
4) and
known contrast allergy (n
=1
)
Heart rate during CT scan: Mean 57.8,
SD 6.8 bpm
Invasive CA: Stenoses were evaluated in
two orthogonal views using a validated
quantitative CA algorithm
Nikolaou, 2006
69–71
Aim: T
o evaluate the diagnostic accuracy of
64-slice CT for detecting significant CAD in
both patients with known CAD and
patients without a history of CAD
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). AHA 15-segment
model. Significant stenosis was defined as,
on a per
-patient basis, one or more
stenoses >50%, independent of the
segmental location
Method of recruitment
: NS
P
eriod: 6 months
Country: Germany
Enrolled: 72 
Analysed: 72
Age (years): Mean 64, SD 10 (range
38–89)
Gender: M 59; F 13
P
revious PCI: 15 (24 stents)
P
revious CABG: Excluded
Indications for testing
: NS 
Inclusion criteria: NS
Ex
clusion criteria: P
atients with CABG.
Known allergic reactions to iodine-
containing contrast media, severe renal
failure, pregnancy or an unstable clinical
condition
64-Slice CT
: Sensation 64, Siemens
R
etrospective ECG gating: Y
es
R
otation time: 330 ms
Slice thickness: 0.6 mm
T
otal scan time
: NS
T
otal e
xamination time: NS
R
adiation dose: ~8–10 mSv
Dose modulation used: Y
es
Use of drugs to limit heart rate
: i.v
.
administration of 5–10 mg metoprolol
shortly before the CT scan in patients with
heart rates >70
bpm. If contraindicated for
-blockers or with an unsatisfactory
lowering of the heart rate, the scan was
still performed, even at higher heart rates 
Heart rate during CT scan: Mean 61,
SD 9 (range 42–87) bpm
Invasive CA: Quantitative CA was
performed for all coronary artery lesions,
determining the mean diameter reduction
of these lesions in two projections
P
revalence of significant CAD
: 57%
(39/68)
Cut-
off
: > 50% stenosis
Segments (n
= 923), patients (n
= 68):
Sensitivity: 82%, 97% 
Specificity: 95%, 79% 
PPV
: 69%, 86% 
NPV
: 97%, 96% 
Image quality (all segments):
High: 64%
Moderate: 30%
P
oor: 6% 
CT interobserver agreement: 

= 0.75
(segments), 0.81 (patients) 
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2Health Technology Assessment 2008; Vol. 12: No. 17
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Ong, 2006
74,75
Aim: T
o investigate the accuracy of 64-slice
CT in detecting CAD in symptomatic
patients with mild and moderate-to
-severe
degrees of coronary calcification
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). P
atients were divided
into those with calcium score <142 A
S
(group A, n
= 68) and those with calcium
score 
142 A
S (group B, n
= 66). 
11-Segment modified AHA model.
Moderate to severe stenosis was defined
as 
50% luminal narrowing 
Method of recruitment
: Consecutive
P
eriod: 4 months
Country: Malaysia 
Enrolled: 134 
Analysed: 134
Age (years): Mean 54.5, SD 8.8
Gender: M 98; F 36
P
revious PCI: NS (segments with stents
excluded)
P
revious CABG: Excluded
Indications for testing
: NS 
Inclusion criteria: P
atients with ischaemic
heart disease (defined as new or chronic
stable exertional angina with typical ECG
changes or positive ETT) scheduled for
conventional CA. Eligibility criteria included
regular heart rate, ability to hold breath for
>12 seconds, and no renal impairment
Ex
clusion criteria: P
revious bypass graft
surgery
, presence of tachyarrhythmias,
atrial fibrillation and other irregular heart
rhythms, known allergies or
contraindications to iodine contrast media
and 
-adrenergic antagonists and
preprocedural serum creatinine
>140
mol/l 
64-Slice CT
: Sensation 64, Siemens
R
etrospective ECG gating: Y
es
R
otation time: 330 ms
Slice thickness: 0.75 mm
T
otal scan time
: NS
T
otal e
xamination time
: NS
R
adiation dose: NS
Dose modulation used: Y
es
Use of drugs to limit heart rate
: In the
absence of contraindications, all patients
with a resting heart rate >60 bpm each
received a 100
mg tablet of atenolol the
night before the scan and another tablet
2
hours before the scan. P
atients who
could not tolerate 
-blockade received
80
mg of oral verapamil. If the prescan rate
remained >80 bpm, an additional 5-mg
dose of i.v
. metoprolol was given before
the scan to reduce the heart rate further
.
P
atients with resting heart rates >80 bpm
after treatment were asked to continue
with atenolol 100
mg daily and given a
second appointment a week later for
MDCT angiography 
Heart rate during CT scan: Mean 62,
SD 9 bpm
Invasive CA: P
erformed with a biplane
digital fluoroscopy
. A minimum of six
orthogonal views were obtained.
Assessment of diameter stenosis was by
visual estimation 
P
revalence of significant CAD
: 73%
(98/134)
Cut-
off: 
50% stenosis
Segments: 
Group A (
n
= 68), group B (n
= 66): 
Sensitivity: 85%, 80% 
Specificity: 98%, 93% 
PPV
: 83%, 77% 
NPV
: 98%, 94% 
Image quality (all segments):
Evaluable segments
Group A
: 93.6%
Group B: 86.9%
CT interobserver agreement: 
V
ariability <5%
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2 Appendix 5
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P
ache, 2006
77
Aim: T
o evaluate the diagnostic accuracy of
64-slice CT in the assessment of CABG
compared with invasive CA
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). Significant stenosis
defined as a luminal diameter >50% 
Method of recruitment
: NS 
P
eriod: NS 
Country: Germany 
Enrolled: 31 
Analysed: 31
Age (years): Mean 68.4, SD 8.4 (range
45–83)
Gender: M 26; F 5
P
revious PCI: NS 
P
revious CABG: 31
Indications for testing
: Suspected
recurrent anginal symptoms after CABG
surgery
Inclusion criteria: P
atients who had
received a CT examination and who had
had previous CABG surgery and had been
referred to the authors’ clinic for invasive
CA evaluation because of suspected
recurrent anginal symptoms after CABG
surgery 
Ex
clusion criteria: P
atients in whom a
conventional catheter angiography had not
been performed within 4 weeks (of the 
CT scan?) 
64-Slice CT
: Sensation 64, Siemens
R
etrospective ECG gating: Y
es
R
otation time: 330 ms
Slice thickness: NS
T
otal scan time
: NS
T
otal e
xamination time: NS
R
adiation dose: NS
Dose modulation used: Y
es
Use of drugs to limit heart rate: The 
-blocker metoprolol tartrate (50–100
mg)
was administered before the scan if a
patient’s heart rate was >65 bpm and no
contraindications for -blockade were
present 
Heart rate during CT scan: Mean 63.3,
SD 7.3 (range 29–164) bpm
Invasive CA: Coronary bypass angiograms
were evaluated by quantitative CA with
automated vessel contour detection 
P
revalence of significant CAD
: 77%
(24/31)
Cut-
off
: >50% stenosis
Grafts (n
= 93), patients (n
= 31): 
Sensitivity: 98%, 100% 
Specificity: 89%, 71% 
PPV
: 90%, 92% 
NPV
: 98%, 100% 
Image quality: NS
CT interobserver agreement: NS
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2
Plass, 2006
79,80
Aim: T
o investigate the diagnostic accuracy
of 64-slice CT with regard to coronary
artery stenoses for preoperative planning
of CABG when image analysis is performed
by cardiovascular surgeons 
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). 11-Segment modified
AHA model. Significant stenosis defined as
vessel lumen constriction >50% 
Method of recruitment
: NS
P
eriod: NS
Enrolled: 50 
Analysed: 50
Age (years): Mean 66, SD 8
Gender: M 39; F 11
P
revious PCI: NS
P
revious CABG: NS
Indications for testing
: NS 
Inclusion criteria: NS
Ex
clusion criteria: P
atients with
arrhythmia, allergy to iodinated contrast
media and renal insufficiency (serum
creatinine >120 mmol/l)
64-Slice CT
: Sensation 64, Siemens
R
etrospective ECG gating: Y
es
R
otation time: 0.37 s 
Slice thickness: 0.6 mm
T
otal scan time
: ~12 s (range 10–13)
T
otal e
xamination time: Mean
<13
minutes (range 8–14)
R
adiation dose: NS
Dose modulation used: NS
Use of drugs to limit heart rate
: No
additional 
-blockers were administered
before the CT scan
P
revalence of significant CAD
: 80%
(40/50)
Cut-
off
: >50% stenosis
Segments (n
= 550), patients (n
= 50): 
Sensitivity: 87%, 100% 
Specificity: 96%, 90% 
PPV
: 86%, 98% 
NPV
: 96%, 100% 
Image quality (all segments):
Excellent: 506/550 (92%)
Limited but still diagnostic: 27/550 (5%)
Not assessable: 17/550 (3%) Health Technology Assessment 2008; Vol. 12: No. 17
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Country: Switzerland 
Heart rate during CT scan: Mean 65,
SD 11 (range 38–89) bpm
Invasive CA: P
erformed according to
standard techniques. Coronary arteries
with diameter as large as 1.5
mm were
analysed including those vessels distal to an
occlusion
CT interobserver agreement: 

= 0.93 
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2 
Pugliese, 2006a
83
Aim: T
o evaluate the diagnostic
performance of 64-slice CT to detect
significant stenoses in the entire coronary
tree in a patient cohort with stable angina
pectoris
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). 17-Segment modified
AHA model. Significant stenosis was
defined as mean lumen diameter reduction
of 
50% 
Method of recruitment
: Consecutive
P
eriod: NS
Country: Italy
Enrolled: 35 
Analysed: 35
Age (years): Mean 61, SD 10, range 46 to
80
Gender: M 21; F 14
P
revious PCI: NS (previous stenting
excluded)
P
revious CABG: Excluded
Indications for testing
: NS
Inclusion criteria: P
atients with stable
angina pectoris. P
atients exhibiting sinus
heart rhythm incapable of holding their
breath for 15 seconds and/or without
contraindications to the administration of
iodinated contrast agents were
prospectively included 
Ex
clusion criteria: P
resence of
arrhythmias, previous CABG or PCI with
stent implantation
64-Slice CT
: Sensation 64, Siemens
R
etrospective ECG gating: Y
es
R
otation time: 330 ms
Slice thickness: 0.6 mm
T
otal scan time
: A
verage 13 s (SD 1,
range 11–15)
T
otal e
xamination time: NS
R
adiation dose: 15 and 20 mSv (male and
female, respectively)
Dose modulation used: No
Use of drugs to limit heart rate
:
P
atients with prescan heart rates >70 bpm
received a single oral dose of 100
mg
metoprolol 1 hour before the CT scan 
Heart rate during CT scan: Mean 58,
SD 6 bpm
Invasive CA: The coronary lumen of all
coronary segments was quantitatively
evaluated on two projections using
dedicated software
P
revalence of significant CAD
: 71%
(25/35)
Cut-
off
: 
50% stenosis
Segments (n
= 494), patients (n
= 35): 
Sensitivity: 99%, 100% 
Specificity: 96%, 90% 
PPV
: 78%, 96% 
NPV
: 100%, 100% 
Image quality (all segments):
Good: 455/494 (92%)
Moderate: 25/494 (5%)
P
oor: 14/494 (3%) 
CT interobserver agreement: 

= 0.73 
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2Appendix 5
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, 2005
85
Aim: T
o assess the accuracy of 64-slice CT
in patients previously scheduled to undergo
invasive selective CA for suspected CAD 
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). 15-Segment AHA
model. Significant stenosis defined as mean
lumen diameter reduction of 
50% 
Method of recruitment
: Consecutive
P
eriod: September 2004 to February 2006
Country: USA
Enrolled: 70 
Analysed: 70
Age (years): Mean 59, SD 11 (range
22–81)
Gender: M 53; F 17
P
revious PCI: NS
P
revious CABG: NS
Indications for testing
: NS
Inclusion criteria: P
atients scheduled to
have elective invasive CA for suspected
CAD
Ex
clusion criteria: Irregular heart rate,
patients at risk for iodinated contrast
agents (congestive heart failure, dye allergy
or elevated serum creatinine >1.5
mg/dl)
or contraindications to -blocking drugs 
64-Slice CT
: Sensation 64, Siemens
R
etrospective ECG gating: Y
es
R
otation time: 330 ms
Slice thickness: 0.6 mm
T
otal scan time
: NS
T
otal e
xamination time: NS
R
adiation dose: 13 and 18 mSv (men and
women, respectively)
Dose modulation used: No
Use of drugs to limit heart rate
:
P
atients not already on -blocking drugs
received 100
mg of atenolol for heart rates
>65
bpm, or 50
mg of atenolol for heart
rates <65
bpm but >50
bpm, 1 hour
before MSCT imaging. Additional i.v
.
metoprolol (5–30
mg) was administered as
required to achieve a target heart rate
<65
bpm. However
, no patient was
excluded because of a heart rate above this
target. Sublingual nitroglycerin 0.4 mg was
given 1 minute before image acquisition 
Heart rate during CT scan: <70 bpm
54/70 (77%); 70–80 bpm 10/70 (14%);
>80 bpm 6/70 (9%)
Invasive CA: Stenosis severity in each
segment was classified according to the
maximal luminal diameter stenosis present
in each segment. Lesions were examined in
orthogonal views, and stenosis severity was
determined using an automated edge-
detection system 
P
revalence of significant CAD
: 57%
(40/70)
Cut-
off
: 
50% stenosis
Segments (n
= 935), patients (n
= 70): 
Sensitivity: 86%, 95% 
Specificity: 95%, 90% 
PPV
: 66%, 93% 
NPV
: 98%, 93% 
Image quality: NS 
CT interobserver agreement: NS
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2Health Technology Assessment 2008; Vol. 12: No. 17
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Rist, 2006
86
Aim: T
o evaluate the diagnostic accuracy of
high-resolution 64-slice CT in a pilot study
for the assessment of the lumen of
coronary artery stents
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). AHA 15-segment
model. Significant stenosis was defined as
stent restenosis with a luminal decrease
50% or occlusion 
Method of recruitment
: NS
P
eriod: 4 months
Country: Germany
Enrolled: 25 
Analysed: 25
Age (years): Mean 59.4, SD 12 (range
40–83)
Gender: M 23; F 2
P
revious PCI: 25
P
revious CABG: NS
Indications for testing
: For the majority
of studied population (n
= 17), the
indication for conventional angiography
after stent placement was the suspicion of
in-stent stenosis because of new or
changing clinical symptoms 
Inclusion criteria: P
atients had coronary
artery stent placement
Ex
clusion criteria: Atrial fibrillation and
over
-severe arrhythmias, severe renal
failure, hyperthyroidism, hypersensitivity to
iodine-containing contrast agent,
pregnancy
, unstable clinical conditions 
64-Slice CT
: Sensation 64, Siemens
R
etrospective ECG gating: Y
es
R
otation time: 330 ms
Slice thickness: 0.6 mm
T
otal scan time
: ~10 s 
T
otal e
xamination time
: NS
R
adiation dose: 8–10 mSv
Dose modulation used: Y
es
Use of drugs to limit heart rate
: 
-Blocker treatment (metoprolol 5–10
mg)
was administered i.v
. to patients (
n
= 14)
with heart rates >70
bpm shortly before
the MSCT examination 
Heart rate during CT scan: Mean 62.2,
SD 8 (range 49–79) bpm
Invasive CA: Standard projections were
obtained and evaluated quantitatively
.
Lesions in two projections were
determined 
P
revalence of significant in-stent
stenosis or occlusion
: 18% (8/45 stents)
Cut-
off: 
50% stenosis or occlusion
Stent (n
= 45): 
Sensitivity: 75%
Specificity: 92% 
PPV
: 67% 
NPV
: 94% 
Image quality: 
High quality: 30/46 stents (65%)
Moderate quality: 15/46 stents (33%)
P
oor quality: 1/46 stents (2%)
CT interobserver agreement: 
In-stent stenosis: 
= 0.53
P
roximal stenoses: 
= 0.65
Distal stenoses: 
= 0.66
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2
Rix
e, 2006
87–89
Aim: T
o investigate the feasibility of
assessing coronary artery stent restenosis
using a new generation 64-slice
multidetector CT scanner in comparison to
conventional quantitative angiography 
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). Significant stenosis
was defined as stent diameter decrease
>50% 
Method of recruitment
: Consecutive
P
eriod: NS
Country: Germany
Enrolled: 64 
Analysed: 64
Age (years): Mean 58, SD 10
Gender: M 41; F 23
P
revious PCI: 64
P
revious CABG: NS
Indications for testing
: NS 
Inclusion criteria: P
atients with previously
implanted coronary artery stents scheduled
for invasive CA
Ex
clusion criteria: Stent-in-stent
implantation and renal failure, known
allergy to contrast agent, possible
pregnancy
, non-sinus rhythm
64-Slice CT
: Sensation 64, Siemens
R
etrospective ECG gating: NS
R
otation time: 330 ms
Slice thickness: 0.6 mm
T
otal scan time
: NS
T
otal e
xamination time
: NS
R
adiation dose: NS
Dose modulation used: Y
es
Use of drugs to limit heart rate
:
P
atients with a heart rate >60 bpm
received 100
mg of atenolol orally
45
minutes before scanning; if heart rate
remained >60 bpm at the time of MDCT
investigation, up to four doses of 5
mg of
metoprolol were administered i.v
.
P
revalence of significant stent stenosis
:
12% (7/59 evaluable stents)
Cut-
off: >50% stenosis
Stent (n
= 59): 
Sensitivity: 86% 
Specificity: 98%
PPV
: 86% 
NPV
: 98%
Image quality:
Evaluable: 59/102 (58%)
The mean diameter of unevaluable stents
was 3.03 (SD 0.31) mm, whereas the mean
diameter of evaluable stents was 3.28
(SD
0.4) mm (
p
=
0.0002); of all 13 stents Appendix 5
102
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Heart rate during CT scan: Mean 60,
SD 5 (range 49–64) bpm
Invasive CA: Standardised projections
were obtained and evaluated using
quantitative coronary angiographic
software
with a diameter <3.0
mm, only one stent
was evaluable 
CT interobserver agreement: NS
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2
R
opers, 2006a
90,92,93
Aim: T
o analyse the accuracy of 64-slice
CT for the detection of significant coronary
stenoses compared with quantitative CA
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). 17-Segment modified
AHA model. Significant stenosis was
defined as lesions with a luminal decrease
50% 
Method of recruitment
: NS
P
eriod: NS
Country: Germany
Enrolled: 84 
Analysed: 81
Age (years): Mean 58, SD 10 (range
35–77) 
Gender: NS
P
revious PCI: NS
P
revious CABG: NS
Indications for testing
: NS 
Inclusion criteria: P
atients referred for a
first invasive CA due to suspected CAD
Ex
clusion criteria: A
CS, contraindications
to administration of contrast agent, cardiac
arrhythmias, possible pregnancy or an
unstable clinical situation
64-Slice CT
: Sensation 64, Siemens
R
etrospective ECG gating: Y
es
R
otation time: 330 ms
Slice thickness: 0.6 mm
T
otal scan time
: NS
T
otal e
xamination time: NS
R
adiation dose: A
verage 7.45 and
10.24
mSv (men and women, respectively)
Dose modulation used: Y
es
Use of drugs to limit heart rate
:
P
atients with a heart rate >60 bpm
received 100
mg of atenolol orally 1 hour
before scanning; if heart rate remained
>60 bpm at the time of MDCT
investigation, up to four doses of 5
mg of
metoprolol were administered i.v
. to lower
heart rate to 
60 bpm. In addition, all
patients received 0.8
mg of isosorbide
dinitrate sublingually immediately before
MDCT scanning 
Heart rate during CT scan: Mean 59,
SD 9 bpm
Invasive CA: Standard projections were
obtained and evaluated using quantitative
coronary angiographic software. P
roximal
luminal diameters of all coronary segments
were measured. Segments with a diameter
<1.5
mm were excluded 
P
revalence of significant CAD
: 32%
(26/81)
Cut-
off
: 
50% stenosis
Segments (n
=
1083), patients
(n
=
81):
Sensitivity: 93%, 96% 
Specificity: 97%, 91% 
PPV
: 56%, 83% 
NPV
: 100%, 98% 
Image quality:
Evaluable: 1083/1128 (96%)
Unevaluable: 45/1128 (4%) 
CT interobserver agreement: NS
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2Health Technology Assessment 2008; Vol. 12: No. 17
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R
opers, 2006b
91,94
Aim: T
o assess the accuracy of 64-slice
MSCT CA for the evaluation of patients
after coronary artery bypass surgery 
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). AHA 16-segment
model. Significant stenosis was defined as
lesions with a luminal decrease 50–99% 
Method of recruitment
: Consecutive
P
eriod: NS
Country: Germany
Enrolled: 50 
Analysed: 50
Age (years): Mean 67 (range 44–82)
Gender: M 38; F 12
P
revious PCI: NS
P
revious CABG: 50
Indications for testing
: P
atients with
previous coronary artery bypass surgery
who had been referred for invasive CA for
clinical reasons 
Inclusion criteria: P
atients in stable
clinical condition, in sinus rhythm, without
implanted pacemakers or valve prostheses,
and without contraindications to the
administration of iodinated contrast agent 
Ex
clusion criteria: P
ossible pregnancy
,
A
CS, or stent in native coronary arteries or
bypass grafts 
64-Slice CT
: Sensation 64, Siemens
R
etrospective ECG gating: Y
es
R
otation time: 330 ms
Slice thickness: 0.6 mm
T
otal scan time
: NS
T
otal e
xamination time
: NS
R
adiation dose: A
verage 8.55 and
12.24
mSv (men and women, respectively)
Dose modulation used: Y
es
Use of drugs to limit heart rate
:
42
patients (84%) were on long-term
medication with -blockers. P
atients with 
a heart rate of >60
bpm received 100
mg
atenolol orally 1 hour before the scan. 
If the heart rate was still >60 bpm at the
time of MSCT investigation, up to four
doses of 5 mg metoprolol were
administrated i.v
. to lower the heart rate to
60 bpm 
Heart rate during CT scan: Mean 59,
SD 9 bpm
Invasive CA: Standard projections were
obtained and evaluated using quantitative
coronary angiographic software. P
roximal
luminal diameters of all coronary segments
and bypass grafts were measured.
Segments with a diameter <1.5
mm were
excluded 
P
revalence of significant CAD
: Evaluable
native segments: 18% (101/566); evaluable
grafts: 0% (0/138)
Cut-
off: 
50% stenosis
Native segments (n
=
566), grafts
(n
=
138): 
Sensitivity: 86%, 100% 
Specificity: 76%, 94% 
PPV
: 44%, 92%
NPV
: 96%, 100% 
Image quality:
Evaluable native segments: 566/621 (91%)
Evaluable grafts: 100% (138/138)
CT interobserver agreement: NS
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2Appendix 5
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Schuijf
, 2006,
100
Aim: T
o determine the diagnostic accuracy
of current 64-slice MSCT in the detection
of significant CAD, using conventional CA
as the gold standard 
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). AHA
-based segment
model was used. Significant stenosis was
defined as lesions with a luminal decrease
50% 
Method of recruitment
: NS
P
eriod: NS
Country: The Netherlands 
Enrolled: 61 
Analysed: 60
Age (years): Mean 60, SD 11
Gender: M 46; F 14
P
revious PCI: 33 (55%)
P
revious CABG: 0
Indications for testing
: P
atients
scheduled for conventional CA 
Inclusion criteria: NS
Ex
clusion criteria: P
atients with
contraindications to MSCT 
64-Slice CT
: T
oshiba Multi-Slice Aquilion
64 system (T
oshiba Medical Systems,
T
okyo, Japan)
R
etrospective ECG gating: Y
es
R
otation time: 0.4 s 
Slice thickness: 0.5 mm
T
otal scan time
: 8–10 s 
T
otal e
xamination time: NS
R
adiation dose: NS
Dose modulation used: NS
Use of drugs to limit heart rate: NS,
mentioned in a table, 43 (72%) patients
were on -blocker medication 
Heart rate during CT scan: NS, in one
patient, the heart rate was >90 bpm
during MSCT
, resulting in the complete
data set being uninterpretable 
Invasive CA: Standard projections were
obtained and evaluated for the presence of
50% diameter stenosis, on the basis of
the evaluation of two orthogonal views 
P
revalence of significant CAD
: 52%
(31/60)
Cut-
off
: 
50% stenosis
Segments (n
= 842), patients (n
= 60):
Sensitivity: 85%, 94% 
Specificity: 98%, 97% 
PPV
: 82%, 97%
NPV
: 99%, 93% 
Image quality:
Evaluable segments: 842/854 (99%)
CT interobserver agreement: NS
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2Health Technology Assessment 2008; Vol. 12: No. 17
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NS, not stated; ED, emergency department.
a
F
ryback and Thornbury grading: level 1, technical quality of the images; level 2, diagnostic accuracy
, sensitivity and specific
ity of the images; level 3, degree to which results influence
physicians’ diagnostic thinking; level 4, degree to which imaging results affect patient management; level 5, efficacy studies 
measuring the degree of effect on patient management;
level 6, analyses of societal costs and benefits of a diagnostic imaging technology
.
Sheth, 2006
101
Aim: T
o evaluate the accuracy of CT for
the detection of complex lesion
morphology
, including the presence of
severe calcium, total occlusion, and ostial
or bifurcation location, and compare the
results with those of invasive angiography 
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). P
ositive tests in
MSCT were defined as: severe calcium,
any dense vessel-calcific deposit that
obscured the underlying lumen because of
blooming artefact was considered severe
calcium on CT
; total occlusion, complete
absence of contrast within the lumen at the
site of significant stenosis. Significant
stenosis in invasive CA was defined as
lesions with a luminal decrease >70%,
severe calcium was identified as
radiopacities seen without cardiac motion
and before contrast injection. On both CT
and CA, a bifurcation lesion was defined as
a lesion in which a branch vessel with a
diameter >1.5
mm originated within the
stenosis; an ostial lesion was a stenosis that
began within 3
mm of a major coronary
ostium 
Method of recruitment
: NS,
retrospective
P
eriod: December 2004 to September
2005
Country: USA
Enrolled: 29 
Analysed: 29
Age (years): Mean 60.3
Gender: M 24; F 5
P
revious PCI: 2
P
revious CABG: 0
Indications for testing
: P
atients with
stable or unstable angina, who had at least
one significant coronary artery stenosis as
detected by invasive angiography 
Inclusion criteria: P
atients with significant
coronary artery stenosis who underwent
coronary CT before invasive selective CA
among the patients referred for coronary
CT because of stable or unstable angina 
Ex
clusion criteria: NS
64-Slice CT
: Sensation 64, Siemens
R
etrospective ECG gating: NS
R
otation time: 330 ms
Slice thickness: 0.6 mm
T
otal scan time
: NS
T
otal e
xamination time
: NS
R
adiation dose: NS
Dose modulation used: NS
Use of drugs to limit heart rate
: All
patients with a heart rate >65 bpm
received 5–30
mg i.v
. metoprolol before
the CT scan
Heart rate during CT scan: NS
Invasive CA: Angiograms were
quantitatively assessed 
P
revalence of 1 feature of comple
xity
(i.e. severe calcium, total occlusion,
ostial or bifurcation)
: 47%
(26/55
segments)
1 feature of comple
xity:
Segments (n
= 55):
Sensitivity: 89% 
Specificity: 83% 
PPV
: 82%
NPV
: 89% 
Image quality:
Evaluable segments: 55/65 (85%)
CT interobserver agreement: NS
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2Appendix 5
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Beck, 2006
37,38
Aim: NS
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). 13-Segment model.
Significant stenosis was defined as >50%
diameter stenoses 
Method of recruitment
: Consecutive 
P
eriod: NS 
Country: Germany 
Enrolled: NS
Analysed: 102
Age (years): Mean 62, SD 10
Gender: M 82; F 20 
P
revious PCI: NS
P
revious CABG: NS
Indications for testing
: NS 
Inclusion criteria: P
atients with suspected
obstructive coronary stenoses
Ex
clusion criteria: NS 
64-Slice CT
: Sensation 64, Siemens,
Germany
R
etrospective ECG gating: NS 
R
otation time: 330 ms
Slice thickness: 0.6 mm
T
otal scan time
: NS
T
otal e
xamination time: NS
R
adiation dose: NS
Dose modulation used: NS
Use of drugs to limit heart rate
: NS
Heart rate during CT scan: NS
Invasive CA: Details NS 
P
revalence of significant CAD
: NS
Cut-
off
: >50% stenosis
Segments (n
= 1326): 
Sensitivity: 90%
Specificity: 99%
PPV
: 95%
NPV
: 98%
Image quality: NS
CT interobserver agreement: NS
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2
Becker
, 2006
39
Aim: T
o examine the possibility to improve
the diagnostic accuracy by combining
coronary calcium screening with non-
invasive CA using 64 MSCT 
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). No definition stated
for significant stenosis 
Method of recruitment
: NS
P
eriod: NS 
Country: Germany 
Enrolled: NS 
Analysed: 199
Age (years): Mean 61.3, SD 12.6
Gender: M 82; F 117 
P
revious PCI: NS
P
revious CABG: NS
Indications for testing
: Attended the ED
with acute chest pain 
Inclusion criteria: NS
Ex
clusion criteria: NS 
64-Slice CT
: Sensation 64, Siemens,
Germany
R
etrospective ECG gating: NS 
R
otation time: NS
Slice thickness: NS
T
otal scan time
: NS
T
otal e
xamination time: NS
R
adiation dose: NS
Dose modulation used: NS
Use of drugs to limit heart rate
: NS
Heart rate during CT scan: NS
Invasive CA: Details NS 
P
revalence of significant CAD
: 59%
(117/199)
Sensitivity: 97%
Specificity: 79%
PPV
: 87%
NPV
: 94%
Image quality: In three patients evaluation
was not possible
CT interobserver agreement: NS 
CT intraobserver agreement: NS 
F
ryback and Thornbury grading: Level 2Health Technology Assessment 2008; Vol. 12: No. 17
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Ehara, 2006b
45
Aim: T
o assess the diagnostic value of 64
MSCT to detect coronary in-stent stenosis
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). Significant stenosis
was defined as >50% stent diameter
stenosis 
Method of recruitment
: NS
P
eriod: NS 
Country: Japan 
Enrolled: NS 
Analysed: 80
Age (years): 68
Gender: M 62; F 18 
P
revious PCI: 80
P
revious CABG: NS
Indications for testing
: Had previously
undergone coronary stent implantation
Inclusion criteria: NS
Ex
clusion criteria: NS 
64-Slice CT
: Sensation 64, Siemens
R
etrospective ECG gating: NS 
R
otation time: NS
Slice thickness: NS
T
otal scan time
: Mean 13.2 s 
T
otal e
xamination time
: NS
R
adiation dose: NS
Dose modulation used: NS
Use of drugs to limit heart rate
: NS
Heart rate during CT scan: Mean
69.9
bpm
Invasive CA: quantitative CA was used 
P
revalence of significant in-stent
stenosis: 20% (22/113 stents)
Sensitivity: 95%
Specificity: 90%
PPV
: 70%
NPV
: 99%
Image quality: 15 lesions (12%) were not
assessable by MSCT mainly because of
motion artefact and calcification 
CT interobserver agreement: NS
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2
Fine, 2006b
48
Aim: T
o determine the ability of 64-slice
CT to measure the prevalence,
morphology and severity of coronary
plaque in high-risk patients and assess its
accuracy compared with invasive CA
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). Disease severity was
categorised as: no disease, subclinical
disease (lesions <70%), clinically significant
disease (lesions >70%). Plaque
morphology was stratified as either
vulnerable (AHA type IV/V
a lipid core) or
stable [AHA type Vb (calcific) or Vc
(fibrotic)] 
Method of recruitment
: NS 
P
eriod: NS 
Country: USA 
Enrolled: NS 
Analysed: 101
Age (years): NS
Gender: NS 
P
revious PCI: NS
P
revious CABG: NS
Indications for testing
: NS 
Inclusion criteria: NS
Ex
clusion criteria: NS 
64-Slice CT
: Sensation 64, Siemens
R
etrospective ECG gating: NS 
R
otation time: NS
Slice thickness: NS
T
otal scan time
: NS
T
otal e
xamination time: NS
R
adiation dose: NS
Dose modulation used: NS
Use of drugs to limit heart rate
: NS
Heart rate during CT scan: NS
Invasive CA: Details NS
P
revalence of significant (lesions
>70%) CAD: 41% diabetes group, 
33% metabolic syndrome group, 
15% comparator group 
Cut-
off: >70% stenosis
Segments? (n
= NS)
Diabetes group, metabolic syndrome
group, comparator group:
Sensitivity: 87%, 91%, 91%
Specificity: 94%, 94%, 98%
PPV
: 87%, 87%, 93%
NPV
: 94%, 94%, 98%
Stable coronary plaque: 
52% diabetes
group, 25% metabolic syndrome group,
20% comparator group
Image quality: NS
CT interobserver agreement: NS
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2Appendix 5
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Hausleiter
, 2005
53
Aim: T
o compare the accuracy of 64-slice
CT angiography with invasive CA for
patency and relevant stenoses of CABG
including the anastomoses and run-
off
vessels 
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). 13-Segment model.
Significant stenosis was defined as diameter
reduction 
50% 
Method of recruitment
: NS 
P
eriod: NS 
Country: Germany 
Enrolled: NS 
Analysed: 43
Age (years): NS
Gender: NS 
P
revious PCI: NS
P
revious CABG: 43
Indications for testing
: NS 
Inclusion criteria: P
atients with CABG
Ex
clusion criteria: NS 
64-Slice CT
: NS
R
etrospective ECG gating: NS 
R
otation time: NS
Slice thickness: NS
T
otal scan time
: NS
T
otal e
xamination time: NS
R
adiation dose: NS
Dose modulation used: NS
Use of drugs to limit heart rate
: NS
Heart rate during CT scan: NS
Invasive CA: NS 
P
revalence of significant CAD
: NS
Cut-
off
: 
50% stenosis
CABGs (n
= 130):
Sensitivity: 97%
Specificity: 98%
PPV
: 94%?
NPV
: 99%
Image quality: NS
CT interobserver agreement: NS
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2
Makaryus, 2006a
61a
Aim: T
o investigate the accuracy of 64-slice
CT for assessing significant coronary
stenoses in comparison with conventional
CA 
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). Significant stenosis
was defined as >50% 
Method of recruitment
: Consecutive 
P
eriod: May to July 2005 
Country: USA 
Enrolled: 374 
Analysed: NS
Age (years): NS
Gender: NS 
P
revious PCI: NS
P
revious CABG: NS
Indications for testing
: NS 
Inclusion criteria: P
atients suspected of
having CAD or who had experienced
recurrent symptoms after prior coronary
interventions and whose 64-slice CT
results prompted conventional CA
investigation 
Ex
clusion criteria: NS
64-Slice CT
: GE Light-Speed VCT
, GE
Healthcare
R
etrospective ECG gating: NS 
R
otation time: NS
Slice thickness: NS
T
otal scan time
: NS
T
otal e
xamination time: NS
R
adiation dose: NS
Dose modulation used: NS
Use of drugs to limit heart rate
: NS
Heart rate during CT scan: NS
Invasive CA: Details NS 
P
revalence of significant CAD
: NS
Cut-
off: >50% stenosis
Unit of analysis unclear: 
Sensitivity: 88%
Specificity: 97%
PPV
: NS
NPV
: NS
Image quality: NS
CT interobserver agreement: NS
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2Health Technology Assessment 2008; Vol. 12: No. 17
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Makaryus, 2006b
60
a
Aim: NS
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). Significant stenosis
was not defined
Method of recruitment
: NS 
P
eriod: May to July 2005 
Country: USA 
Enrolled: 18
Analysed: 18
Age (years): NS
Gender: NS 
P
revious PCI: NS
P
revious CABG: 18
Indications for testing
: NS 
Inclusion criteria: P
atients with a history
of CABG
Ex
clusion criteria: NS 
64-Slice CT
: GE Light-Speed VCT
, GE
Healthcare
R
etrospective ECG gating: NS 
R
otation time: NS
Slice thickness: NS
T
otal scan time
: NS
T
otal e
xamination time
: NS
R
adiation dose: NS
Dose modulation used: NS
Use of drugs to limit heart rate
: NS
Heart rate during CT scan: NS
Invasive CA: Details NS
P
revalence of significant CAD
: NS
Cut-
off
: Graft occlusion
Bypass grafts (n
= 43): 
Sensitivity: 90%
Specificity: 97%
PPV
: NS
NPV
: NS
Image quality: NS
CT interobserver agreement: NS
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2
Malagutti, 2006
62,63
Aim: T
o evaluate the performance of 64-
slice MSCT angiography in patients who
had previously undergone CABG, for
detection of graft obstruction and native
coronary artery stenosis
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). Significant stenosis
was defined as >50% luminal narrowing 
Method of recruitment
: NS
P
eriod: NS
Country: The Netherlands
Enrolled: NS 
Analysed: 52
Age (years): NS
Gender: NS
P
revious PCI: NS
P
revious CABG: 52
Indications for testing
: Symptomatic
post-
CABG
Inclusion criteria: NS
Ex
clusion criteria: NS
64-Slice CT
: Siemens Sensation 64,
Germany
R
etrospective ECG gating: NS
R
otation time: 330 ms
Slice thickness: 0.6 mm
T
otal scan time
: NS
T
otal e
xamination time: NS
R
adiation dose: NS
Dose modulation used: NS
Use of drugs to limit heart rate
: NS
Heart rate during CT scan: NS
Invasive CA: Conventional quantitative
CA was used
P
revalence of significant CAD
: 96%
(50/52)
Cut-
off: >50% luminal narrowing
Coronary artery grafted segments
(n
=
182), patients (n
= 52):
Sensitivity: 99%, 100%
Specificity: 96%, 50%
PPV
: 95%, 98%
NPV
: 99%, 100%
Image quality: NS
CT interobserver agreement: NS
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2Appendix 5
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Motoyama, 2006
68
Aim: T
o compare the diagnostic accuracy
of 256-slice CT angiography with
conventional, invasive CA 
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). Segments >2
mm
were examined. Significant stenosis was
defined as >50%
Method of recruitment
: Consecutive 
P
eriod: NS 
Country: Japan 
Enrolled: 10 
Analysed: 10
Age (years): NS
Gender: NS 
P
revious PCI: NS
P
revious CABG: NS
Indications for testing
: NS 
Inclusion criteria: NS
Ex
clusion criteria: NS
256-Slice CT
: P
rototype, T
oshiba, Japan
R
etrospective ECG gating: NS 
R
otation time: 500 ms
Slice thickness: 0.5 mm
T
otal scan time
: 3 s 
T
otal e
xamination time: NS
R
adiation dose: NS
Dose modulation used: NS
Use of drugs to limit heart rate
: NS
Heart rate during CT scan: NS
Invasive CA: NS, segments 
2m
m
diameter were not examined 
P
revalence of significant CAD
: NS
Cut-
off
: >50% stenosis
Segments (n
= NS) with severe
calcification e
x
cluded, severe
calcification assumed as stenosis: 
Sensitivity: 100%, 100%
Specificity: 96%, 90%
PPV
: 73%, 61%
NPV
: 100%, 100%
Image quality: No segments were
excluded due to motion artefact
CT interobserver agreement: NS
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2
Oncel, 2006
72,73
Aim: T
o assess the role of MSCT in the
evaluation of coronary stent patency and
in-stent restenosis
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). Significant in-stent
stenosis was defined as >50% 
Method of recruitment
: NS
P
eriod: NS
Country: T
urkey 
Enrolled: NS
Analysed: 43
Age (years): NS
Gender: NS
P
revious PCI: 43
P
revious CABG: NS
Indications for testing
: P
atients
suspected for in-stent restenosis and
scheduled for conventional angiography
Inclusion criteria: NS
Ex
clusion criteria: NS 
64-Slice CT
: Sensation 64, Siemens,
Germany
R
etrospective ECG gating: Y
es
R
otation time: 0.33 s 
Slice thickness: 0.6 mm
T
otal scan time
: NS
T
otal e
xamination time: NS
R
adiation dose: NS
Dose modulation used: NS
Use of drugs to limit heart rate
: NS
Heart rate during CT scan: NS
Invasive CA: NS 
P
revalence of significant in-stent
stenosis: 58% (25/43 stents)
Cut-
off
: >50% stenosis
Sensitivity: 92%
Specificity: 94%
PPV
: 96%
NPV
: 89%
Image quality: In all patients, the image
quality was eligible for the evaluation of
stent patency
CT interobserver agreement: NS
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2Health Technology Assessment 2008; Vol. 12: No. 17
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Onuma, 2006
76
Aim: T
o assess the accuracy of 64-slice CT
to detect CAD 
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). 17-Segment modified
AHA model with segment 17 being the
intermediate branch of the left coronary
artery
. Significant stenosis was defined as
>50% 
Method of recruitment
: Consecutive 
P
eriod: November 2004 to June 2005 
Country: Japan 
Enrolled: NS 
Analysed: 29
Age (years): NS
Gender: NS 
P
revious PCI: NS
P
revious CABG: NS
Indications for testing
: NS
Inclusion criteria: NS
Ex
clusion criteria: NS 
64-Slice CT
: Sensation 64, Siemens
R
etrospective ECG gating: NS 
R
otation time: 330 ms
Slice thickness: 0.6 mm
T
otal scan time
: NS
T
otal e
xamination time
: NS
R
adiation dose: NS
Dose modulation used: NS
Use of drugs to limit heart rate
: NS
Heart rate during CT scan: NS
Invasive CA: T
raditional CA
P
revalence of significant CAD
: NS
Cut-
off
: >50% stenosis
Segments (n
= 430): 
Sensitivity: 94%
Specificity: 99%
PPV
: 93%
NPV
: 99%
Image quality: 430/442 (97.2%) segments
were judged visible
CT interobserver agreement: NS
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2
Pinto, 2006
78
Aim: T
o evaluate the accuracy of 64-slice
MSCT to evaluate the presence of in-stent
restenosis and the minimal lumen diameter 
Study design: Non-randomised
comparative study in which patients
received exercise treadmill testing, 64-slice
CT and invasive CA (reference standard).
Definition of significant stenosis NS
Method of recruitment
: NS 
P
eriod: NS 
Country: Brazil 
Enrolled: NS 
Analysed: 30
Age (years): NS
Gender: NS 
P
revious PCI: 30
P
revious CABG: NS
Indications for testing
: NS 
Inclusion criteria: P
atients completed 
9-month follow
-up after the implantation
of bare metal stents
Ex
clusion criteria: NS 
64-Slice CT
: NS
R
etrospective ECG gating: NS 
R
otation time: NS
Slice thickness: NS 
T
otal scan time
: NS
T
otal e
xamination time: NS
R
adiation dose: NS
Dose modulation used: NS
Use of drugs to limit heart rate
: 
-Blockers were used in all patients with
heart rate >70 bpm
Heart rate during CT scan: NS
Invasive CA: Details NS
P
revalence of significant in-stent
restenosis: 10% (3/30)
P
atients (n
= 30): 
Sensitivity: 100%
Image quality: NS
CT interobserver agreement: NS
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2Appendix 5
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Pugliese, 2006b
81,82
Aim: T
o compare the diagnostic accuracy
of 64-slice MSCT in the assessment of
CAD with conventional CA as the
reference standard 
Study design: Non-randomised
comparative study in which patients
received exercise treadmill testing, 64-slice
CT and invasive CA (reference standard).
Definition of significant stenosis NS
Method of recruitment
: Consecutive
P
eriod: NS 
Country: The Netherlands 
Enrolled: 51 
Analysed: 51
Age (years): NS
Gender: NS 
P
revious PCI: 0
P
revious CABG: 0
Indications for testing
: P
atients referred
for conventional angiography for suspected
CAD
Inclusion criteria: NS
Ex
clusion criteria: NS 
64-Slice CT
: NS
R
etrospective ECG gating: NS 
R
otation time: 330 ms
Slice thickness: NS 
T
otal scan time
: NS
T
otal e
xamination time: NS
R
adiation dose: NS
Dose modulation used: NS
Use of drugs to limit heart rate
: NS
Heart rate during CT scan: NS
Invasive CA: Details NS
P
revalence of significant CAD
: NS
P
resence of CAD: >2
mm segments; all
segments:
Sensitivity: 99%, 99%
Specificity: 96%, 95%
PPV
: 80%, 76%
NPV
: 99%, 99%
Image quality: All segments >2
mm
diameter were evaluable
CT inter-
observer agreement: NS
CT intra-
observer agreement: NS
F
ryback and Thornbury grading: Level 2
Pugliese, 2006c
84
Aim: T
o test the feasibility and accuracy of
64-slice MSCT in patients with A
CS
Study design: Non-randomised
comparative study in which patients
received exercise treadmill testing, 64-slice
CT and invasive CA (reference standard).
Definition of significant stenosis NS
Method of recruitment
: NS
P
eriod: NS 
Country: The Netherlands
Enrolled: NS 
Analysed: 25
Age (years): NS
Gender: NS 
P
revious PCI: NS
P
revious CABG: NS
Indications for testing
: P
atients with
unstable angina or suspected acute MI 
Inclusion criteria: P
atients with unstable
angina or suspected acute MI underwent
CT within 24 hours before cardiac
catheterisation
Ex
clusion criteria: P
atients with
heart/renal failure or allergy to contrast
agent 
64-Slice CT
: NS
R
etrospective ECG gating: NS 
R
otation time: 330 ms
Slice thickness: NS 
T
otal scan time
: NS
T
otal e
xamination time
: NS
R
adiation dose: NS
Dose modulation used: NS
Use of drugs to limit heart rate
: 
-Blockers were administered to 15
patients with heart rates >65 bpm
Heart rate during CT scan: Mean
58
bpm
Invasive CA: Details NS 
P
revalence of significant CAD
: 96%
(24/25)
P
resence of CAD: patients (
n
= 25): 
Sensitivity: 100%
Specificity: 100%
PPV
: 100%
NPV
: 100%
Image quality: NS
CT interobserver agreement: NS
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2Health Technology Assessment 2008; Vol. 12: No. 17
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R
ubinshtein, 2006a
50,95
Aim: T
o assess the additional benefit of 
64-slice multidetector CT scanning for
detection of obstructive coronary disease 
Study design: Non-randomised
comparative study in which patients
received exercise treadmill testing, 64-slice
CT and invasive CA (reference standard).
Significant stenosis was defined as 
50%
stenosis (arterial segments proximal to
functional bypass grafts excluded) 
Method of recruitment
: Consecutive 
P
eriod: NS 
Country: Israel 
Enrolled: NS
Analysed: 133
Age (years): Mean 58.2, SD 11.8
Gender: M 88; F 45 
P
revious PCI: NS
P
revious CABG: NS (49 patients had
prior myocardial revascularisation)
Indications for testing
: Suspected A
CS (n
= 54) or chronic stable angina (
n
= 79) 
Inclusion criteria: P
atients with chest pain
and negative/equivocal ETT (<1
mm
horizontal, or upsloping, ST segment
depression)
Ex
clusion criteria: NS 
64-Slice CT
: Brilliance 64, Philips
R
etrospective ECG gating: NS 
R
otation time: NS
Slice thickness: NS 
T
otal scan time
: NS
T
otal e
xamination time
: NS
R
adiation dose: NS
Dose modulation used: NS
Use of drugs to limit heart rate
: NS
Heart rate during CT scan: NS
Invasive CA: Details NS 
P
revalence of significant CAD
: 30%
(40/133)
P
atients (n
= 133): 
Sensitivity: 100% (CT), 55% (ETT)
Specificity: 96% (CT), 62% (ETT) 
PPV
: 91% (CT), 39% (ETT) 
NPV
: 100% (CT), 76% (ETT)
Image quality: NS
CT interobserver agreement: NS
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2
R
ubinshtein, 2006b
96
Aim: T
o use 64-slice MSCT to examine the
prevalence of significant stenosis in
coronary arteries supplying myocardial
territories with low
-grade myocardial
perfusion defects on SPECT 
Study design: Non-randomised
comparative study in which patients
received exercise treadmill testing, 64-slice
CT and invasive CA (reference standard).
Significant stenosis was defined as >50%
stenosis 
Method of recruitment
: NS 
P
eriod: NS 
Country: Israel 
Enrolled: NS 
Analysed: 40 
Age (years): Mean 59, SD 11
Gender: M 24; F 16 
P
revious PCI: 9
P
revious CABG: NS
Indications for testing
: Significant
stenosis in coronary arteries supplying
myocardial territories with low
-grade
myocardial perfusion defects on SPECT 
Inclusion criteria: NS
Ex
clusion criteria: NS 
64-Slice CT
: Brilliance 64, Philips
R
etrospective ECG gating: NS 
R
otation time: NS
Slice thickness: NS 
T
otal scan time
: NS
T
otal e
xamination time: NS
R
adiation dose: NS
Dose modulation used: NS
Use of drugs to limit heart rate
: NS
Heart rate during CT scan: NS
Invasive CA: Details NS 
P
revalence of significant CAD
: 23%
(9/40)
Cut-
off
: >50% stenosis
Stents (n
= 51), patients (n
= 40): 
Sensitivity: 100%, 100%
Specificity: 88%, 84% 
PPV
: 67%, 64%
NPV
: 100%, 100%
Image quality: NS
CT interobserver agreement: NS
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2Appendix 5
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Savino, 2006
41,54,97,104
Aim: T
o investigate the diagnostic accuracy
of 64-slice MSCT in the assessment of
CAD 
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). Significant stenosis
was defined as >50% of the lumen
diameter 
Method of recruitment
: NS 
P
eriod: NS 
Country: USA 
Enrolled: NS 
Analysed: 55
Age (years): NS
Gender: NS 
P
revious PCI: NS
P
revious CABG: NS
Indications for testing
: P
atients with
suspected CAD
Inclusion criteria: NS
Ex
clusion criteria: NS 
64-Slice CT
: NS
R
etrospective ECG gating: Y
es 
R
otation time: NS
Slice thickness: NS
T
otal scan time
: NS
T
otal e
xamination time: NS
R
adiation dose: NS
Dose modulation used: NS
Use of drugs to limit heart rate
: NS
Heart rate during CT scan: NS
Invasive CA: Details NS 
P
revalence of significant CAD
: 35%
(19/55)
Cut-
off
: >50% stenosis
Segments (n
= 826), patients (n
= 55): 
Sensitivity: 82%, 100%
Specificity: 97%, 83% 
PPV
: 69%, 76%
NPV
: 99%, 100%
Image quality: All CT angiograms were
considered of diagnostic quality
CT interobserver agreement: NS
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2
Schlosser
, 2006
98,99
Aim: T
o evaluate the value of 64-detector
CT for ruling out high-grade coronary
stenoses in patients with a low to
moderate pretest probability of significant
CAD 
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). Significant stenosis
was defined as 50% of the lumen
diameter by visual assessment. Only those
patients in whom significant stenoses could
not be ruled out underwent invasive CA 
(n
= 61) 
Method of recruitment
: NS 
P
eriod: NS 
Country: Germany 
Enrolled: 179 
Analysed: 61
Age (years): NS
Gender: NS 
P
revious PCI: NS
P
revious CABG: NS
Indications for testing
: Atypical angina,
ambiguous findings in non-invasive stress
testing and a class II indication for invasive
CA
Inclusion criteria: P
atients with a low to
moderate pretest probability of CAD 
Ex
clusion criteria: NS 
64-Slice CT
: NS
R
etrospective ECG gating: NS 
R
otation time: 330 ms
Slice thickness: 0.6 mm
T
otal scan time
: NS
T
otal e
xamination time: NS
R
adiation dose: NS
Dose modulation used: NS
Use of drugs to limit heart rate
:
P
atients with heart rates >60 bpm
received 
-blockers, and all patients
received nitrates
Heart rate during CT scan: Mean
57
bpm, SD 4
Invasive CA: Details NS 
P
revalence of significant CAD
: NS
Cut-
off: 
50% stenosis
Segments (n
= 915): 
Sensitivity: 100%
Specificity: 97%
PPV
: 55%
NPV
: 100%
Image quality: 11 segments in five patients
showed severe calcifications resulting in an
insufficient assessment of the segment.
Because high-grade stenoses could not be
ruled out in these segments, they were
classified as severely stenotic 
CT interobserver agreement: NS
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2Health Technology Assessment 2008; Vol. 12: No. 17
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T
ABLE 22
Diagnostic studies: abstracts (cont’d)
Study
, design and methods
P
articipants
T
ests
Outcomes summary
a
Makaryus (2006a) and Makaryus (2006b) have been treated as two separate studies, although their patients are drawn from the sam
e patient population (n
= 374) and there may
also be some overlap of patients between the studies. Makaryus (2006a) assessed the accuracy of 64-slice CT for assessing signi
ficant coronary stenoses in comparison with
conventional CA in patients suspected of having CAD or who had experienced recurrent symptoms after prior coronary intervention
s and whose 64-slice CT results prompted
conventional CA investigation. In Makaryus (2006b) the patient population consisted of those with a history of CABG and the stu
dy assessed the accuracy of 64-slice CT compared
with conventional CA in assessing graft occlusion in bypass grafts. 
Sirol, 2006
102
Aim: T
o evaluate the diagnostic accuracy of
64-slice spiral CT angiography for the
detection of significant coronary stenoses
in a non-selected population of cardiac
patients typically seen by a cardiologist on
consultation 
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). Significant stenosis
was defined as >50% stenosis 
Method of recruitment
: NS 
P
eriod: NS 
Country: Germany 
Enrolled: NS
Analysed: 38
Age (years): Mean 59, SD 14 
Gender: M 24, F 14
P
revious PCI: NS
P
revious CABG: NS, 19 patients had
prior stent implantation or CABG
Indications for testing
: NS
Inclusion criteria: NS
Ex
clusion criteria: NS 
64-Slice CT
: NS
R
etrospective ECG gating: Y
es
R
otation time: 330 ms
Slice thickness: 0.6 mm
T
otal scan time
: NS
T
otal e
xamination time: NS
R
adiation dose: NS
Dose modulation used: NS
Use of drugs to limit heart rate
:
10–15
mg i.v
. metoprolol immediately
,
before the scan if heart rate was >70
bpm
Heart rate during CT scan: Mean
61
bpm, SD 7
Invasive CA: Quantitative CA was used 
P
revalence of significant CAD
: 20%
(103/521 evaluable segments) 
Cut-
off
: >50% stenosis
Segments (n
= 521), patients (n
NS): 
Sensitivity: 75%, 75%
Specificity: 77%, 89%
PPV
: 88%, 88%
NPV
: 94%, 76%
Image quality: 11.1% of the segments
were not evaluable due to the presence of
calcification (4.9%), stents (3.4%) or
motion artefacts (2.6%) 
CT interobserver agreement: NS
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2
W
ang, 2006,
103
Aim: T
o evaluate the diagnostic accuracy of
64-slice spiral CT angiography for the
assessment of coronary artery stenosis 
Study design: Non-randomised
comparative study in which patients
received both MSCT and invasive CA
(reference standard). Significant stenosis
was defined as >50% stenosis. Image
quality was assessed using a three-point
grading scale from excellent (1) to non-
assessable (3) 
Method of recruitment
: NS 
P
eriod: NS 
Country: China 
Enrolled: 100 
Analysed: 48
Age (years): NS
Gender: NS 
P
revious PCI: NS
P
revious CABG: NS
Indications for testing
: NS 
Inclusion criteria: P
atients with suspected
obstructive coronary stenoses
Ex
clusion criteria: NS 
64-Slice CT
: Sensation 64, Siemens
R
etrospective ECG gating: NS 
R
otation time: NS 
Slice thickness: NS 
T
otal scan time
: Mean 11.9 s, SD 0.9 
T
otal e
xamination time
: NS 
R
adiation dose: NS 
Dose modulation used: NS 
Use of drugs to limit heart rate
:
P
atients with a heart rate >70 bpm
received oral -blockers before the scan
Heart rate during CT scan: Mean
61
bpm, SD 8 
Invasive CA: Details NS 
P
revalence of significant CAD
: NS
Cut-
off
: >50% stenosis
Arteries (n
= 192): 
Sensitivity: 95%
Specificity: 93%
PPV
: 86%
NPV
: 98%
Image quality: 1.2, SD 0.47. Visibility of
distal arteries and small branches: LAD
distal 92%, LCX distal 98%, first obtuse
marginal 93%, cone branch 86% 
CT interobserver agreement: NS
CT intraobserver agreement: NS
F
ryback and Thornbury grading: Level 2 Appendix 5
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P
rognostic study: full text 
Study
, design and methods
P
articipants
T
ests
Outcomes summary
Hoffmann, 2006
55
Aim: In patients who were being admitted
for chest pain and who had negative initial
cardiac biomarkers and a non-diagnostic
ECG on presentation, to examine whether
CT angiography characteristics were
associated with risk of A
CS and whether
they provided incremental value to
standard cardiovascular risk factors and
standard clinical risk assessment 
Study design: P
rospective observational
cohort study with multivariate regression
analysis performed to determine whether
information on the extent of coronary
atherosclerotic plaque added incremental
value to information available at initial
triage to predict A
CS in patients who had
any atherosclerotic plaque on MSCT 
Method of recruitment
: Consecutive
P
eriod: May to July 2005
Follow
-up: Mean 5.2 months (SD 0.3)
Country: USA 
Enrolled: 106 
Analysed: 103
Age (years): Mean 54, SD 12
Gender: M 62; F 41
P
revious PCI: NS 
P
revious CABG: NS
Indications for testing
: Adults with acute
chest pain in whom initial ED evaluation
was inconclusive 
Inclusion criteria: Age >18 years,
>5
minutes of chest pain within the
previous 24 hours, no or non-diagnostic
ECG changes, normal initial cardiac
biomarkers, sinus rhythm, ability to
perform a breath-hold of 10–15 seconds 
Ex
clusion criteria: Elevated troponin-l or
creatine kinase-MB levels in the initial
blood sample obtained in the emergency
department, new diagnostic ECG changes
(ST
-segment elevation or depression
>1
mm or T
-wave inversion >4 mm in
more than two anatomically contiguous
leads), haemodynamic or clinical instability
,
known allergy to iodinated contrast agent,
serum creatinine >1.3
mg/dl, metformin
treatment, hyperthyroidism, inability to
provide informed consent, perceived
interference with standard clinical care of
patients 
64-Slice CT
: Sensation 64, Siemens,
Germany
R
etrospective ECG gating: Y
es
R
otation time: 330 ms
Slice thickness: 0.6 mm
T
otal scan time
: 13.6 (SD 2.2) s 
T
otal e
xamination time: Including patient
preparation 12 (SD 1) minutes
R
adiation dose: 6–11 mSv
Dose modulation used: Y
es
Use of drugs to limit heart rate: All
patients with a heart rate >60
bpm
received a -blocker (i.v
. metoprolol,
5–20
mg) unless their systolic blood
pressure was <100 mmHg or other
contraindications were present 
Heart rate during CT scan: NS
Invasive CA: NS 
Of the 103 patients, 14 were diagnosed
with A
CS (five with an acute MI and nine
with unstable angina pectoris). In
multivariate logistic regression analyses both
initial models containing either traditional
risk factors or the categorised clinical
estimates of probability of A
CS did not
predict A
CS (LR 8.41, 
p
= 0.13; LR 1.94,
p
=
0.38). Adding the extent of coronary
atherosclerotic plaque on 64-slice CT as a
continuous variable provided incremental
information and improved both the model
with traditional risk factors (LR 23.27,
p
=
0.0007) and the model with the
categorised clinical estimates of probability
of A
CS (LR 19.1, 
p
=
0.0003) 
In 81 (91%) of 89 patients diagnosed as not
having an A
CS during hospitalisation,
telephone follow
-up was conducted at a
mean of 5.2 months (SD 0.3) after hospital
discharge, with no patient having suffered a
major cardiovascular event 
F
ryback and Thornbury grading: Level 3 Health Technology Assessment 2008; Vol. 12: No. 17
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T
ABLE 24
P
rognostic studies: abstracts 
Study
, design and methods
P
articipants
T
ests
Outcomes summary
continued
Auseon, 2006
105
Aim: T
o analyse the first year of use of
cardiac multidetector CT in a major
university hospital and determine its impact
on invasive angiographic procedures to
diagnose and treat atherosclerotic heart
disease 
Study design: The findings from 1056
cardiovascular MSCT examinations were
recorded along with subsequent cardiac
catheterisations and cardiac surgeries. In
addition, the yearly procedural volumes in
the cardiac catheterisation laboratories
were tabulated and assessed for change
after the introduction of MSCT
Method of recruitment
: NS
P
eriod: 2005 calendar year
Follow
-up: NS
Country: USA 
Enrolled: NS 
Analysed: 1056
Age (years): NS
Gender: NS
P
revious PCI: NS
P
revious CABG: NS
Indications for testing
: NS 
Inclusion criteria: NS
Ex
clusion criteria: NS 
64-Slice CT
: NS
R
etrospective ECG gating: NS
R
otation time: NS
Slice thickness: NS
T
otal scan time
: NS
T
otal e
xamination time
: NS
R
adiation dose: NS
Dose modulation used: NS
Use of drugs to limit heart rate
: NS
Heart rate during CT scan: NS
Invasive CA: Details NS 
After MSCT
, 94/1056 (8.9%) patients
subsequently went on to require an invasive
diagnostic CA, of whom 69% were found
to have disease in the native coronary
arteries, 29% in both native vessels and
pre-existing bypass grafts and 2% in
peripheral arteries. 24 of these patients
went on to have a cardiovascular operative
procedure. 23 patients required PCI in the
coronary (92%), carotid (4%) and renal
arteries (4%). Of the 21 coronary
interventions, 47.6% had only native vessel
disease and 52.4% also had prior bypass
grafts 
A
verage yearly increase in (a)
diagnostic cardiac volume and (b) PCIs
:
2000–2004: 8.7%, 15.2% 
2005 (64-slice CT): 7%, 15% 
F
ryback and Thornbury grading: Level 4
Danciu, 2006
106
Aim: T
o review the initial experience with
64-slice CT angiography used in day
-to
-day
practice in a single 20-physician cardiology
group 
Study design: All records of studies
performed during the first 6 months of 
64-slice CT usage were reviewed. Charts
were abstracted for demographic data,
referral patterns and indications, prior
cardiac testing, results of 64-slice CT and
clinical decisions based on these. 
17-Segment AHA model. Short-term
follow
-up was obtained in all patients 
Enrolled: NS
Analysed: 486
Age (years): Mean 62, SD 12
Gender: M 282; F 204
P
revious PCI: NS
P
revious CABG: NS
Indications for testing
: Abnormal stress
test 228, unexplained symptoms after
stress test 170, high risk for CAD 46,
cardiomyopathy 16, other 26, including
congenital heart disease and post-
transplant 
Inclusion criteria: NS
Ex
clusion criteria: NS 
64-Slice CT
: NS
R
etrospective ECG gating: NS
R
otation time: NS
Slice thickness: NS
T
otal scan time
: NS
T
otal e
xamination time: NS
R
adiation dose: NS
Dose modulation used: NS
Use of drugs to limit heart rate
: NS
Heart rate during CT scan: NS
Invasive CA: Details NS 
CT ruled out CAD in 30% of patients
without prior known disease. Invasive CA
was recommended in 88 patients (18%)
and saved in 398 patients (82%). CT missed
six moderate stenoses, but no severe
stenosis, and overestimated six lesions. 
51 patients (10.5%) had revascularisation,
by stent (n
= 40, 8.5%) or CABG (n
= 11,
2%). During 300 patient-years of follow
-up
two hospitalisations for minor CAD
-related
issues were noted in the medically treated
patients 
Image quality: Adequate diagnostic quality
was achieved in 99% of cases. All 17 AHA
segments were seen in 89.5% of patients.
All vessels were analysed in 98% of Appendix 5
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P
rognostic studies: abstracts (cont’d)
Study
, design and methods
P
articipants
T
ests
Outcomes summary
continued
Method of recruitment
: NS
P
eriod: NS
Follow
-up: NS 
Country: USA 
patients. Three cases required rescanning
because of artefact 
F
ryback and Thornbury grading: Level 4 
Gallagher
, 2005
107
Aim: T
o compare the accuracy of MSCT
with stress MPI in low
-risk ED chest pain
patients
Study design: P
rospective cross-sectional
study
. All patients received rest/stress MPI
and 64-slice CT
. P
atients with positive MPI
(inducible ischaemia or submaximal heart
rate response) and/or positive MSCT
(calcium score >400, stenosis >50%, or
uninterpretable images defined by severe
calcification or motion artefacts) were
considered for catheterisation. P
atients with
negative results were discharged. 30-Day
MA
CE were identified by follow
-up
telephone calls and chart review
. R
eference
outcomes were defined as A
CS,
revascularisation, coronary stenosis >50%
and 30-day MA
CE (death, acute MI,
hospitalisation for angina or heart failure)
Method of recruitment
: NS
P
eriod: NS
Follow
-up: 30 days
Country: USA 
Enrolled: 97 
Analysed: 93
Age (years): NS
Gender: NS
P
revious PCI: NS
P
revious CABG: NS
Indications for testing
: NS 
Inclusion criteria: ED chest pain patients
identified as low or very low risk
(R
eilly/Goldman criteria) 
Ex
clusion criteria: P
ositive cardiac
enzymes or ECGs, known CAD, elevated
creatinine, or contraindications to
iodinated contrast or 
-blockers 
64-Slice CT
: NS
R
etrospective ECG gating: NS
R
otation time: NS
Slice thickness: NS
T
otal scan time
: NS
T
otal e
xamination time: NS
R
adiation dose: NS
Dose modulation used: NS
Use of drugs to limit heart rate
: NS
Heart rate during CT scan: NS
Invasive CA: Details NS 
MSCT and MPI were both negative in 52
patients, who were subsequently discharged
without undergoing invasive CA 
During the 30-day follow
-up 13 patients
underwent cardiac catheterisation, seven
had coronary stenoses >50% (six required
coronary revascularisation). There were no
additional 30-day adverse events 
F
ryback and Thornbury grading: Level 4Health Technology Assessment 2008; Vol. 12: No. 17
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P
rognostic studies: abstracts (cont’d)
Study
, design and methods
P
articipants
T
ests
Outcomes summary
MA
CE, major adverse cardiac events.
R
ubinshtein, 2005
108–110
Aim: T
o examine the role of 64-slice CT
angiography in the emergency room
assessment of patients presenting with
chest pain of uncertain aetiology 
Study design: MSCT was performed and
presumptive diagnosis, decision to
hospitalise and intended management
(intensive therapy/early intervention vs
medical management) were made and
recorded. Following MSCT
, change in
diagnosis, need for early intervention and/or
hospitalisation were noted 
Method of recruitment
: NS
P
eriod: NS
Follow
-up: 30 days
Country: Israel 
Enrolled: NS 
Analysed: 40
Age (years): Mean 56, SD 10.7
Gender: M 26; F 14
P
revious PCI: NS
P
revious CABG: NS
Indications for testing
: NS 
Inclusion criteria: Emergency room
patients presenting with chest pain of
uncertain aetiology
Ex
clusion criteria: NS 
64-Slice CT
: Brilliance 64, Philips
R
etrospective ECG gating: NS
R
otation time: NS
Slice thickness: NS
T
otal scan time
: NS
T
otal e
xamination time
: NS
R
adiation dose: NS
Dose modulation used: NS
Use of drugs to limit heart rate
: NS
Heart rate during CT scan: NS
Invasive CA: Details NS 
P
ain of cardiac origin: 
Before MSCT
: 28/40 (70%)
After MSCT
: 14/40 (35%)
Change in diagnosis/management: 14/28
(50%)
p-
V
alue: 0.002
Hospitalisation recommended:
Before MSCT
: 34/40 (85%)
After MSCT
: 19/40 (48%)
Change in diagnosis/management: 15/34
(44%)
p-
V
alue: 0.0004
Early intervention planned:
Before MSCT
: 24/40 (60%)
After MSCT
: 9/40 (23%)
Change in diagnosis/management: 17/40
(43%)
p-
V
alue: 0.0007
In 15 patients discharged from the
emergency room as a result of
negative/low
-risk MSCT findings, there
were no adverse cardiac events at 30-day
follow
-up 
F
ryback and Thornbury grading: Level 4Health Technology Assessment 2008; Vol. 12: No. 17
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Quality assessment results
Study Q1
Q2
Q3
Q4
Q5
Q6
Q7
Q8
Q9
Q10
Q11
Q12
Q13
Q14
Ehara, 2006a
46
++++++++++++++
Fine, 2006a
49
++++++++
?
+++
–
–
Ghostine, 2006
52
–
+++++++++++
–
+
Hoffmann, 2006
55
–+
+
+
a
+
a
++
?
+
–
++++
Johnson, 2007
56
–+–
+
a
+
a
+++
?
++++
–
Leber
, 2005
58
++++++
?
?
?
+++
–
+
Leschka, 2005
59
+++++++++++++
–
Meijboom, 2006
65
–
+++++++
?
–
++++
Mollet, 2005
66
++++++++
?
++++
–
Nikolaou, 2006
71
++++++++++++++
Ong, 2006
75
++++++++
?
+++++
P
ache, 2006
77
–
++++++
?
?
+++
–
+
Plass, 2006
79
–
+
?
++++
?
+++++
–
Pugliese, 2006a
83
–
+++++++
?
–
++++
R
aff
, 2005
85
++++++++++++
–
+
Rist, 2006
86
–
+++++++
?
+++++
Rixe, 2006
89
–
+++++
?
+++++
–
+
R
opers, 2006a
93
+++++++
?
++++
–
–
R
opers, 2006b
94
–
++++++
?
++++
–
+
Schuijf
, 2006
100
++++++++
?
+++
–
+
Sheth, 2006
101
–
+
?
+++
–
 
b
+?+
+
–
+
–
+, Y
es to the question; –, no to the question; ?, unclear
.
a
In the study by Hoffmann and colleagues
55
eight of 103 patients received 64–slice CT and invasive CA and in the study by Johnson and colleagues
56
20 of 55 patients received
64–slice CT and invasive CA. Both studies were checked Y
es for Q4 and Q5 as if only some patients in the studies received both 
tests, then it was only those who were considered
to be the patient sample and included in the review
. 
b
64–Slice CT readers were given the segment in which severe stenosis was located on invasive CA, but were unaware of other invas
ive CA data. Health Technology Assessment 2008; Vol. 12: No. 17
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Studies included in the pooled estimates for analysis
Study 
Level of analysis
P
atient
Segment
Left main artery
LAD artery
P
ro
ximal LAD artery
LCX artery
RCA
Stent
CABG
F
ull-text studies
Ehara, 2006
46
✓
✓
✓
✓✓✓
✓
Ghostine, 2006
52
✓
✓
✓
✓✓✓
✓
Hoffmann, 2006
55
✓
Leber
, 2005
58
✓
✓
Leschka, 2005
59
✓
✓
✓✓✓
✓
Meijboom, 2006
65
✓✓
✓
✓
✓
Mollet, 2005
66
✓✓
Nikolaou, 2006
71
✓✓
✓
✓
✓
✓
Ong, 2006
75
✓
✓
✓✓✓
✓
P
ache, 2006
77
✓
✓
Plass, 2006
79
✓✓
Pugliese, 2006a
83
✓
✓
✓✓✓
✓
R
aff
, 2005
85
✓✓
Rist, 2006
86
✓
Rixe, 2006
89
✓
R
opers, 2006a
93
✓✓
R
opers, 2006b
94
✓✓
✓
Schuijf
, 2006
100
✓✓
✓
Abstracts
Becker
, 2006
39
✓
Ehara, 2006b
45
✓
Hausleiter
, 2005
53
✓
Malagutti, 2006
62
✓
✓
Oncel, 2006
72
✓
Onuma, 2006
76
✓
R
ubinshtein, 2006a
95
✓
R
ubinshtein, 2006b
96
✓
Savino, 2006
97
✓✓
Schlosser
, 2006
99
✓Health Technology Assessment 2008; Vol. 12: No. 17
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64-Slice or higher CT diagnostic studies: full text
Study 
Cut-
off
, prevalence
Unit of analysis
No. 
TP
FP
FN
TN
Sens. 
Spec. 
PPV 
NPV
analysed
(%)
(%)
(%)
(%)
continued
Ehara,
2006a
42–44,46
(patients with
suspected and
proven CAD,
including 46 
post-PCI)
>50% reduction of
minimal lumen
diameter
P
revalence: 
91% (61/67)
Not evaluated:
3% (2/69) patients
8% (82/966) segments
All coronary artery segments
884
275
35
29
545
90
94
89
95
RCA overall
265
90
9
1
0
156
90
95
91
94
RCA proximal
65
27
1
3
34
96
92
90
97
RCA mid
66
28
2
3
33
93
92
90
94
RCA distal
68
23
5
2
38
82
95
92
88
P
osterior descending artery
66
12
1
2
51
86
98
92
96
Left main trunk
64
19
0
2
43
100
96
90
100
LAD overall
313
102
8
1
0
193
93
95
91
96
LAD proximal
65
42
2
2
19
95
90
95
90
LAD mid
60
18
0
3
39
100
93
86
100
LAD distal
64
2
1
0
61
67
100
100
98
First diagonal
62
25
2
3
32
93
91
89
94
Second diagonal
62
15
3
2
42
83
95
88
93
LCX overall
242
64
11
14
153
85
92
82
93
LCX proximal
62
19
1
4
38
95
90
83
97
LCX distal
64
27
5
8
24
84
75
77
83
First obtuse marginal artery
64
14
3
1
46
82
98
93
94
Second obtuse marginal artery
52
4
2
1
45
67
98
80
96
P
atients
67
59
1
1
6
98
86
98
86
Fine, 2006a
47,49
(all patients with
suspected CAD)
>50% stenosis
P
revalence: NS
Not evaluated:
6% (4/66) patients
Arteries
NS
NS
NS
NS
NS
95
96
97
92Health Technology Assessment 2008; Vol. 12: No. 17
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64-Slice or higher CT diagnostic studies: full text (cont’d)
Study 
Cut-
off
, prevalence
Unit of analysis
No. 
TP
FP
FN
TN
Sens. 
Spec. 
PPV 
NPV
analysed
(%)
(%)
(%)
(%)
continued
Ghostine,
2006
51,52
(all patients
LBBB) 
>50% stenosis
P
revalence: 
44% (29/66)
Not evaluated:
0% (0/66) patients
0% (0/990) segments
All segments
990
68
7
2
6
889
72
99
91
97
Left main
66
5
0
0
61
100
100
100
100
LAD
330
37
0
5
288
88
100
100
98
LAD proximal
66
15
0
1
50
94
100
100
98
LAD mid
66
16
0
3
47
84
100
100
94
LAD distal
66
0
0
0
66
100
100
First diagonal
66
6
0
1
59
86
100
100
98
Second diagonal
66
0
0
0
66
100
100
LCX
264
13
3
9
239
59
99
81
96
LCX proximal
66
5
3
0
58
100
95
63
100
LCX distal
66
3
0
2
61
60
100
100
97
First obtuse marginal
66
4
0
4
58
50
100
100
94
Second obtuse marginal
66
1
0
3
62
25
100
100
95
RCA
330
13
4
12
301
52
99
76
96
RCA proximal
66
2
1
2
61
50
98
67
97
RCA mid
66
7
3
3
53
70
95
70
95
RCA distal
66
2
0
1
63
67
100
100
98
Right posterior descending
66
1
0
3
62
25
100
100
95
P
osterolateral artery
66
1
0
3
62
25
100
100
95
P
atients
66
28
2
1
35
97
95
93
97
Hoffmann,
2006
55
(eight of 103
patients with
acute chest pain
received CA)
50% stenosis
P
revalence:
63% (5/8)
Not evaluated:
0% (0/8) patients
P
atients
8
5003
1
0
0
1
0
0
1
0
0
1
0
0
Johnson, 2007
56
(all patients with
acute chest pain)
>50% stenosis
P
revalence:
85% (17/20)
Not evaluated:
0% (0/20) patients
P
atients
20
94
77
84
91Appendix 8
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64-Slice or higher CT diagnostic studies: full text (cont’d)
Study 
Cut-
off
, prevalence
Unit of analysis
No. 
TP
FP
FN
TN
Sens. 
Spec. 
PPV 
NPV
analysed
(%)
(%)
(%)
(%)
continued
Leber
,
2005
57,58a
(all patients with
stable angina
pectoris,
including ten
post-PCI)
>50% stenosis
P
revalence:
42% (25/59)
Not evaluated:
7% (4/59) patients
8% (74/885) segments
All segments
798
59
23
16
700
79
97
72
98
P
atients
55
22
NS
3
NS
8
8
NS
NS
NS
Leschka, 2005
59
(patients with
suspected CAD
or prior to
CABG)
Narrowing of the
coronary lumen
>50%
P
revalence:
70% (47/67)
Not evaluated:
0% (0/67) patients
0% (0/1005) segments
All vessel segments
1005
165
24
11
805
94
97
87
99
Left main 
67
6
0
0
61
100
100
100
100
LAD (proximal, middle, distal)
201
54
7
3
137
95
95
89
98
LAD proximal
67
28
0
0
39
100
100
100
100
LAD middle
6
7
2
5
5
2
3
5
9
3
8
8
8
3
9
5
LAD distal
67
1
2
1
63
50
97
33
98
LCX (proximal, distal)
134
32
8
2
92
94
92
80
98
LCX proximal
67
18
5
0
44
100
90
78
100
LCX distal
67
14
3
2
48
88
94
82
96
Left posterior descending artery
67
0
0
1
66
0
100
NA
99
Right posterior descending artery
67
2
0
0
65
100
100
100
100
RCA (proximal, middle, distal)
201
41
6
3
151
93
96
87
98
RCA proximal
67
18
0
0
49
100
100
100
100
RCA middle
67
19
4
1
43
95
91
83
98
RCA distal
67
4
2
2
59
67
97
67
97
Diagonal branch 1
6
7
7
1
2
57
78
98
88
97
Diagonal branch 2
6
7
8
0
0
59
100
100
100
100
Obtuse marginal branches
67
2
0
0
65
100
100
100
100
P
osterolateral branches
67
13
2
0
52
100
96
87
100
>75% stenosis
Not evaluated:
As above
All segments
798
28
11
7
752
80
99
72
99
P
atients
45
NS
3
NS
1
7
NS
8
5
NS
NS
Stenosis that
subsequently required
either PCI or CABG
P
atients
18
17
1
9
4
In-stent restenosis
>50%
Stents
13
2425
5
0
5
6
3
3
7
1Health Technology Assessment 2008; Vol. 12: No. 17
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T
ABLE 27
64-Slice or higher CT diagnostic studies: full text (cont’d)
Study 
Cut-
off
, prevalence
Unit of analysis
No. 
TP
FP
FN
TN
Sens. 
Spec. 
PPV 
NPV
analysed
(%)
(%)
(%)
(%)
continued
Meijboom,
2006
64,65
(all patients
referred for
cardiac valve
surgery)
50% stenosis
P
revalence:
26% (18/70)
Not evaluated:
0% (0/70) patients
0% (0/280) arteries
0% (0/1003) segments
All segments
1003
34
18
2
949
94
98
65
100
Segments: calcium score 0–10
338
0
0
0
338
100
100
Segments: calcium score 11–400
465
15
7
0
443
100
98
68
100
Segments: calcium score 401–1000
146
16
5
1
124
94
96
76
99
Segments: calcium score >1000
54
3
6
1
44
75
88
33
98
Arteries
280
26
8
0
246
100
97
76
100
RCA
70
10
2
0
58
100
97
83
100
Left main
70
0
0
0
70
100
100
LAD
70
10
6
0
54
100
90
63
100
Circumflex
70
6
0
0
64
100
100
100
100
P
atients
70
18
4
0
48
100
92
82
100
P
atients with angina pectoris
21
8
1
0
12
100
92
89
100
P
atients with no angina pectoris
49
10
3
0
36
100
92
77
100
P
atients with aortic stenosis
31
9
3
0
19
100
86
75
100
P
atients with no aortic stenosis
39
9
1
0
29
100
97
90
100
Mollet,
2005
40,66,67
(patients with
atypical chest
pain, stable or
unstable angina
pectoris, or non-
ST segment MI)
50% stenosis
P
revalence: 
76% (39/51)
Not evaluated:
2% (1/52) patients
18% (159/884)
segments (of which
142 could not be
visualised on
conventional
angiogram)
All segments
725
93
30
1
601
99
95
76
100
P
roximal segments
204
NS
NS
NS
NS
100
97
83
100
Mid segments
142
NS
NS
NS
NS
97
94
81
99
Distal segments
121
NS
NS
NS
NS
100
97
73
100
Side branches
258
NS
NS
NS
NS
100
94
65
100
Left main 
51
NS
NS
NS
NS
100
100
100
100
LAD
230
NS
NS
NS
NS
97
92
69
99
LCX
235
NS
NS
NS
NS
100
97
83
100
RCA
209
NS
NS
NS
NS
100
95
77
100
P
atients
51
38
1
0
12
100
92
97
100Appendix 8
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T
ABLE 27
64-Slice or higher CT diagnostic studies: full text (cont’d)
Study 
Cut-
off
, prevalence
Unit of analysis
No. 
TP
FP
FN
TN
Sens. 
Spec. 
PPV 
NPV
analysed
(%)
(%)
(%)
(%)
continued
Nikolaou,
2006
69–71
(patients with
suspected or
known CAD)
>50% stenosis
P
revalence:
57% (39/68)
Not evaluated:
6% (4/72) patients
10% (97/1020)
segments
All segments
923
97
43
21
762
82
95
69
97
Left main
68
4
0
0
64
100
100
100
100
LAD
311
47
19
13
232
78
92
71
95
RCA
251
26
9
4
212
87
96
74
98
LCX
293
20
15
4
254
83
94
57
98
All patients
68
38
6
1
23
97
79
86
96
P
atients with known CAD 
29
NS
NS
NS
NS
100
75
85
100
P
atients with suspected CAD
39
NS
NS
NS
NS
95
82
88
93
>75% stenosis
All segments
56
48
NS
8
N
S
8
6
N
S
N
S
N
S
Left main
3
3
NS
0
NS
100
NS
NS
NS
L
A
D
3
0
2
5N
S
5N
S
8
3N
SN
SN
S
R
C
A
1
3
1
2N
S
1N
S
9
2N
SN
SN
S
LCX
10
8
NS
2
NS
80
NS
NS
NS
Ong, 2006
74,75
b
(all patients with
ischaemic heart
disease)
Diseased segments
were graded as 1 =
none or mild stenosis,
or 2 = moderate to
severe stenosis 50%
P
revalence (patients
with significant
lesions):
73% (98/134)
Not evaluated:
10% (143/1474)
segments
All segments (all patients)
1331
185
45
32
1069
85
96
80
97
Left main
128
5
0
0
123
100
100
100
100
P
roximal LAD
125
39
7
4
75
91
91
85
90
Mid LAD
122
38
7
1
76
97
92
84
99
Distal LAD
112
4
1
0
107
100
99
80
100
Main diagonal branch
115
20
2
4
89
83
98
91
96
LCX overall
256
18
14
7
217
72
94
56
97
P
roximal circumflex
129
12
8
3
106
80
93
60
97
Distal circumflex
127
6
6
4
111
60
95
50
97
Main obtuse marginal
113
5
2
7
99
42
98
71
93
RCA overall
360
56
12
9
283
86
96
82
97
P
roximal RCA
128
37
3
1
87
97
97
93
99
Mid RCA
117
9
7
6
95
60
93
56
94
Distal RCA
115
10
2
2
101
83
98
83
98
All segments (patients with calcium 
700
64
12
5
619
93
98
84
99
score <142 A
S
)
Left main
65
0
0
0
65
100
100
P
roximal LAD
63
13
3
0
47
100
94
81
100
Mid LAD
63
16
1
1
45
94
98
94
98
Distal LAD
61
1
0
0
60
100
100
100
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T
ABLE 27
64-Slice or higher CT diagnostic studies: full text (cont’d)
Study 
Cut-
off
, prevalence
Unit of analysis
No. 
TP
FP
FN
TN
Sens. 
Spec. 
PPV 
NPV
analysed
(%)
(%)
(%)
(%)
continued
Main diagonal branch 
63
10
0
1
52
91
100
100
98
LCX overall
132
2
3
1
126
67
98
40
99
P
roximal circumflex
6
6
2
2
1
61
67
97
50
98
Distal circumflex
66
1
6
5
9
9
100
Main obtuse marginal
61
1
1
1
58
50
98
50
98
RCA overall
192
21
4
1
166
95
98
84
99
P
roximal RCA
66
16
0
0
50
100
100
100
100
Mid RCA
63
2
3
1
57
67
95
40
98
Distal RCA
63
3
1
0
59
100
98
75
100
All segments (patients with calcium 
631
121
33
27
450
82
93
79
94
score 
142 A
S)
Left main
63
5
0
0
58
100
100
100
100
P
roximal LAD
62
26
4
4
28
87
88
87
88
Mid LAD
59
22
6
0
31
100
84
79
100
Distal LAD
51
3
1
0
47
100
98
75
100
Main diagonal branch 
52
10
2
3
37
77
95
83
93
LCX overall
124
16
11
6
9
1
7
3
8
9
5
9
9
4
P
roximal circumflex
6
3
1
0
6
2
4
5
8
3
8
8
6
3
9
6
Distal circumflex
61
6
5
4
46
60
90
55
92
Main obtuse marginal
52
4
1
6
41
40
98
80
87
RCA overall
168
35
8
8
117
81
94
81
94
P
roximal RCA
62
21
3
1
37
95
93
88
97
Mid RCA
54
7
4
5
38
58
90
64
88
Distal RCA
52
7
1
2
42
78
98
88
95
P
ache, 2006
77
(all patients post
CABG)
>50% stenosis
P
revalence:
77% (24/31)
Not evaluated:
0% (0/93) grafts
All grafts
93
45
5
1
42
98
89
90
98
Arterial grafts
22
5
4
1
12
83
75
56
92
V
enous grafts
71
40
1
0
30
100
97
98
100
P
atients
31
24
2
0
5
100
71
92
100Appendix 8
132
T
ABLE 27
64-Slice or higher CT diagnostic studies: full text (cont’d)
Study 
Cut-
off
, prevalence
Unit of analysis
No. 
TP
FP
FN
TN
Sens. 
Spec. 
PPV 
NPV
analysed
(%)
(%)
(%)
(%)
continued
Plass, 2006
79,80
(patients with
CAD and
patients with
valve disease)
>50% stenosis
P
revalence:
80% (40/50)
3% (17/550) segments
rated not assessable
but included in the
analysis: three
significant lesions
missed with CT in
unassessable segments
were classed as FN
All segments
550
111
18
17
404
87
96
86
96
Segments classed as reliable
506
106
11
8
381
93
97
91
98
Segments – valvular disease patients
110
1
109
99
P
atients
50
40
1
0
9
100
90
98
100
P
atients with valvular disease
10
1
9
90
Pugliese,
2006a
83
(all patients with
stable angina
pectoris)
50% stenosis
P
revalence:
71% (25/35)
Not evaluated:
0% (0/35) patients
0% (0/494) segments
All segments
494
66
19
1
408
99
96
78
100
RCA, posterior descending artery
, 
138
20
5
0
113
100
96
80
100
posterolateral artery
RCA
90
17
4
0
69
100
95
81
100
RCA 1
35
10
1
0
24
100
96
91
100
RCA 2
28
5
1
0
22
100
96
83
100
RCA 3
27
2
2
0
23
100
92
50
100
P
osterior descending artery
27
1
0
0
26
100
100
100
100
Distal RCA/posterolateral artery
21
2
1
0
18
100
95
67
100
Left main
35
0
3
5
100
100
LAD, diagonal branches
156
25
9
1
121
96
93
74
99
LAD
101
18
3
1
79
95
96
86
99
LAD 1
35
8
1
0
26
100
96
89
100
LAD 2
33
9
2
1
21
90
91
82
95
LAD 3 
33
1
0
0
32
100
100
100
100
Diagonal branches 
55
7
6
0
42
100
88
54
100
Diagonal branch 1 
33
6
5
0
22
100
81
55
100
Diagonal branch 2 
22
1
1
0
20
100
95
50
100
LCX, MO
, intermediate branch
165
21
5
0
139
100
97
81
100
LCX
92
10
2
0
80
100
98
83
100
LCX 1
35
4
0
0
31
100
100
100
100
LCX 2
34
5
2
0
27
100
93
71
100
LCX 3
23
1
0
0
22
100
100
100
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T
ABLE 27
64-Slice or higher CT diagnostic studies: full text (cont’d)
Study 
Cut-
off
, prevalence
Unit of analysis
No. 
TP
FP
FN
TN
Sens. 
Spec. 
PPV 
NPV
analysed
(%)
(%)
(%)
(%)
continued
MO
60
9
2
0
49
100
96
82
100
MO 1
35
7
2
0
26
100
93
78
100
MO 2
25
2
0
0
23
100
100
100
100
Intermediate branch
13
2
1
0
10
100
91
67
100
P
atients
35
25
1
0
9
100
90
96
100
Rist, 2006
86
(all patients post-
PCI)
50% restenosis
Not evaluated:
2% (1/46) stents
Stents
45
6
3
2
34
75
92
67
94
Stenosis proximal <3 mm to stent
45
3
2
1
39
75
95
60
98
Stenosis distal to stent
45
2
6
1
36
67
86
25
97
Significant disease, not occluded
4
2
67
Occluded
Stents
2
0
100
R
aff
, 2005
85
(all patients with
suspected CAD)
>50% stenosis
P
revalence:
57% (40/70)
Not evaluated:
0% (0/70) patients
0.4% (1/280) arteries
12% (130/1065)
segments
Segments
935
79
41
13
802
86
95
66
98
Calcium rating: segments: none
709
27
14
8
660
77
98
66
99
Calcium rating: segments: mild
89
13
5
2
69
87
93
72
97
Calcium rating: segments: moderate
48
11
6
1
30
92
83
65
97
Calcium rating: segments: severe
88
28
16
2
4
2
9
3
7
2
6
4
9
5
Arteries
279
63
16
6
194
91
92
80
97
Calcium rating: arteries: none
172
22
3
3
144
88
98
88
98
Calcium rating: arteries: mild
36
10
4
1
21
91
84
71
95
Calcium rating: arteries: moderate
30
10
3
1
16
91
84
77
94
Calcium rating: arteries: severe
40
21
6
1
12
95
67
78
92
P
atients
70
38
3
2
27
95
90
93
93
Calcium score 0–100
35
15
1
1
18
94
95
94
95
Calcium score 101–400
17
9107
1
0
0
8
8
9
0
1
0
0
Calcium score 401–1804
18
14
1
1
2
93
67
93
67
BMI normal (<25 kg/m
2
)
1
0
5005
1
0
0
1
0
0
1
0
0
1
0
0
BMI overweight (25–29.9 kg/m
2
)
25
14
1
0
10
100
91
93
100
BMI obese (30 kg/m
2
)
3
5
1
9
2
21
29
08
69
08
6
Heart rate <70 bpm
54
31
1
1
21
97
95
97
95
Heart rate 71–85 bpm
15
7215
8
8
7
1
7
8
8
3
Heart rate >85 bpm
1
0
1
100
100Appendix 8
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T
ABLE 27
64-Slice or higher CT diagnostic studies: full text (cont’d)
Study 
Cut-
off
, prevalence
Unit of analysis
No. 
TP
FP
FN
TN
Sens. 
Spec. 
PPV 
NPV
analysed
(%)
(%)
(%)
(%)
continued
Rix
e 2006
87–89
(all patients post-
PCI)
50% restenosis
Not evaluated:
42% (43/102) stents
48% (31/64) patients
Stents
59
6
1
1
51
86
98
86
98
Stents 
3.0 mm
25?
100
100
100
100
Stents 3.0 mm
33
83
96
83
96
Stents <3.0 mm
1
0
1
100
100
P
atients
33
83
46
10
96
R
opers,
2006a
90,92,93
(all patients with
suspected CAD)
50% stenosis
P
revalence:
32% (26/81)
Not evaluated:
4% (45/1128)
segments
4% (15/336) arteries
4% (3/84) patients
Segments
1083
39
31
3
1010
93
97
56
100
Arteries
321
36
20
2
263
95
93
64
99
P
atients
81
25
5
1
50
96
91
83
98
R
opers,
2006b
91,94
(all patients post-
CABG) 
> 50% stenosis
Occluded
50–99% stenosis
>50% stenosis
P
revalence:
72% (36/50)
Not evaluated:
0% (0/138) bypass
grafts
9% (55/621) native
segments
7% (29/407) non-
grafted arteries and
run-
off vessels distal to
bypass graft
anastomoses
0% (0/50) patients
Bypass grafts
138
54
5
0
79
100
94
92
100
Bypass grafts
138
38
0
0
100
100
100
100
100
Bypass grafts classed as patent by CA
100
16
5
0
79
100
94
76
100
Segments (evaluable)
566
87
111
14
354
86
76
44
96
Segments (unevaluable classed as positive)
621
97
156
14
354
87
69
38
96
Non-grafted arteries and run-
off vessels 
378
38
32
6
302
86
90
54
98
distal to bypass graft anastomoses
Non-grafted arteries and run-
off vessels 
407
42
57
6
302
88
84
42
98
distal to bypass graft anastomoses 
(unevaluable classed as positive)
P
atients: bypass grafts
50
31
2
0
17
100
89
94
100
P
atients: non-grafted arteries and the 
33
18
2
1
12
95
86
90
92
distal run-
off vessels
P
atients: non-grafted arteries and the 
50
35
2
1
12
97
86
95
92
distal run-
off vessels (unevaluable 
classed as positive)Health Technology Assessment 2008; Vol. 12: No. 17
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T
ABLE 27
64-Slice or higher CT diagnostic studies: full text (cont’d)
Study 
Cut-
off
, prevalence
Unit of analysis
No. 
TP
FP
FN
TN
Sens. 
Spec. 
PPV 
NPV
analysed
(%)
(%)
(%)
(%)
MO
, marginal obtuse branch. 
a
Non-evaluable segments: four of 59 (60 segments) patients had CT angiograms that were severely affected by motion artefacts. P
o
tentially evaluable segments from 59 patients =
885, – 60 segments = 825, – 14 distally located segments not evaluable because of an occlusion of four vessels = 811, – 13 segm
ents containing a stent that were separately
analysed = 798. Therefore, 10% (87/885) of segments were not evaluated. 
b
The data for LCX overall were calculated by adding the true positives, false positives, false negatives and true negatives for 
proximal circumflex and distal circumflex. The data for
RCA overall were calculated by adding the true positives, false positives, false negatives and true negatives for proximal RCA,
 mid RCA and distal RCA. 
P
atients: bypass grafts, distal run-
off 
33
18
2
1
12
95
86
90
92
vessels and non-grafted coronary arteries
P
atients: bypass grafts, distal run-
off 
50
35
2
1
12
97
86
95
92
vessels and non-grafted coronary 
arteries (unevaluable classed as positive)
Schuijf
, 2006
100
(patients
scheduled for
invasive CA)
50% stenosis
P
revalence:
52% (31/60)
Not evaluated:
1% (12/854) segments
0.4% (1/240) arteries
2% (1/61) patients 
Segments
842
62
14
11
755
85
98
82
99
Arteries
239
46
7
7
179
87
96
87
96
P
atients
60
29
1
2
28
94
97
97
93
Stented segments
44
3
0
0
41
100
100
100
100
Sheth, 2006
101
[all patients with
significant
(>70%)
stenosis] 
Lesions with 1
feature of complexity
Segments with lesions that were 
>70% stenosed
55
23
5
3
24
88
83
82
89
Lesions with severe
calcium
Lesions totally occluded
Ostial lesions
Bifurcation lesions
P
revalence of stenosis
>70%:
100% (29/29)
Not evaluated:
15% (10/65) segments
55
5
7
0
43
100
86
42
100
49
13
1
1
34
93
97
93
97
49
3
1
2
43
60
98
75
96
49
4
0
1
44
80
100
100
98Appendix 8
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T
ABLE 28
64-Slice or higher CT diagnostic studies: abstracts 
Study 
Cut-
off
, prevalence
Unit of analysis
No. 
TP
FP
FN
TN
Sens. 
Spec. 
PPV 
NPV
analysed
(%)
(%)
(%)
(%)
continued
Beck, 2006
37,38
(all patients with
suspected CAD)
>50% stenosis
Segments
1326
NS
NS
NS
NS
90
99
95
98
Ehara, 2006b
45
(all patients post-
PCI)
>50% stenosis
Not evaluated:
12% (15/128)
Stented segments
113
21
9
1
82
95
90
70
99
P
atients
80?
89
87
71
96
Hausleiter
,
2005
53
(all patients post-
CABG)
50% stenosis
CABGs
130
34
2
1
93
97
98
94
99
Graft anastomosis
142
10
0
100
R
un-
off vessels of grafts
NS
NS
NS
NS
NS
100
98
80
100
Fine, 2006b
48
(three groups of
high-risk patients:
diabetes,
metabolic
syndrome,
comparison
group) 
Subclinical disease
(lesions <70%),
clinically significant
disease (lesions
>70%)
P
revalence (lesions
>70%): 
41% diabetes, 33%
metabolic syndrome,
15% comparison
group 
Diabetes group
101 
NS
NS
NS
NS
87
94
87
94
Metabolic syndrome group
in total
NS
NS
NS
NS
91
94
87
94
Comparison group
NS
NS
NS
NS
91
98
93
98
Becker
, 2006
39
(all patients with
acute chest pain)
Significant CAD
P
revalence:
59% (117/199)
P
atients
199
113
17
4
6
5
9
7
7
9
8
7
9
4Health Technology Assessment 2008; Vol. 12: No. 17
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T
ABLE 28
64-Slice or higher CT diagnostic studies: abstracts (cont’d)
Study 
Cut-
off
, prevalence
Unit of analysis
No. 
TP
FP
FN
TN
Sens. 
Spec. 
PPV 
NPV
analysed
(%)
(%)
(%)
(%)
continued
Makaryus,
2006a
61
a
(patients with
suspected CAD
or recurrent
symptoms after
prior coronary
interventions)
>50% stenosis
Unclear
NS
8
N
S
2
NS
88%
97%
NS
NS
Makaryus
2006b
60
a
(all patients post-
CABG)
> 50% stenosis
Bypass grafts
43
NS
NS
NS
NS
90%
97%
NS
NS
Malagutti,
2006
62,63
(all patients post-
CABG and
symptomatic)
>50% stenosis
P
revalence:
96% (50/52)
Grafted segments
182
71
4
1
106
99
96
95
99
Obstructed run-
offs
8
1
89
Non-grafted coronary branches
288
62
32
2
192
97
86
66
99
P
atients
52
50
1
0
1
100
50
98
100
Graft disease
52
36
1
0
15
100
94
97
100
Distal run-
off disease
51
7
6
1
37
88
86
54
97
Non-grafted CAD
47
28
8
0
11
100
58
78
100
Motoyama,
2006
68
(type of patients
NS)
>50% stenosis
Segments with severe calcification 
101
NS
NS
NS
NS
100
96
73
100
excluded 
Segments with severe calcification 
101
NS
NS
NS
NS
100
90
61
100
assumed as stenosis
Oncel, 2006
72,73
(all patients post-
PCI)
>50% stenosis 
Coronary stents
43
23
1
2
17
92
94
96
89
Onuma, 2006
76
(type of patients
NS)
>50% stenosis
Segments
430
51
4
3
372
94
99
93
99Appendix 8
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T
ABLE 28
64-Slice or higher CT diagnostic studies: abstracts (cont’d)
Study 
Cut-
off
, prevalence
Unit of analysis
No. 
TP
FP
FN
TN
Sens. 
Spec. 
PPV 
NPV
analysed
(%)
(%)
(%)
(%)
continued
Pinto, 2006
78
(all patients post-
PCI)
In-stent restenosis
Coronary stents
30?
3
0
100
Pugliese,
2006b
81,82
(all patients with
suspected CAD)
Cut-
off not defined
Not evaluated:
0% (0/N
NS)
segments >2 mm
diameter
74% (n/N
NS)
coronary branches
<2
mm diameter
Segments >2 mm diameter
99
96
80
99
Segments >2 mm diameter plus 
99
95
76
99
assessable segments < 2 mm 
diameter
Pugliese,
2006c
84
(patients with
unstable angina
or suspected
acute MI)
One or more vessel
disease
P
revalence:
96% (24/25)
P
atients
25
24
0
0
1
100
100
100
100
R
ubinshtein,
2006a
50,95
(all patients with
chest pain and
negative/equivocal
ETT)
MSCT
: 
50% stenosis
P
revalence:
30% (40/133)
ETT
: equivocal
(<1
mm horizontal, or
upsloping, ST segment
depression)
P
revalence:
30% (40/133)
P
atients, MSCT 64-slice
133
40
4
0
89
100
96
91
100
P
atients, ETT
133
22
35
18
58
55
62
39
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T
ABLE 28
64-Slice or higher CT diagnostic studies: abstracts (cont’d)
Study 
Cut-
off
, prevalence
Unit of analysis
No. 
TP
FP
FN
TN
Sens. 
Spec. 
PPV 
NPV
analysed
(%)
(%)
(%)
(%)
a
Makaryus (2006a) and Makaryus (2006b) have been treated as two separate studies, although their patients are drawn from the sam
e patient population (n
= 374) and there may
also be some overlap of patients between the studies. Makaryus (2006a) assessed the accuracy of 64-slice CT for assessing signi
ficant coronary stenoses in comparison with
conventional CA in patients suspected of having CAD or who had experienced recurrent symptoms after prior coronary intervention
s and whose 64-slice CT results prompted
conventional CA investigation. In Makaryus (2006b) the patient population consisted of those with a history of CABG and the stu
dy assessed the accuracy of 64-slice CT compared
with conventional CA in assessing graft occlusion in bypass grafts. 
R
ubinshtein,
2006b
96
(patients with
low
-grade
reversible
perfusion defects
on SPECT)
>50% stenosis
P
revalence:
23% (9/40)
V
essels
51
10
5
0
36
100
88
67
100
P
atients
40
9
5
0
26
100
84
64
100
Savino,
2006
41,54,97,104
(all patients with
suspected CAD)
>50% stenosis
P
revalence:
35% (19/55)
Not evaluated:
0% (0/55) patients
Segments
826
50
22
11
743
82
97
69
99
Arteries
165
32
11
4
118
89
91
74
97
P
atients
55
19
6
0
30
100
83
76
100
W
ang, 2006
103
(all patients with
suspected CAD)
>50% stenosis
Arteries
192
56
9
3
124
95
93
86
98
Sirol, 2006
102
(patients with
suspected and
known CAD)
>50% stenosis
Not evaluated:
11% (65/586)
segments
Segments
521
75
97
88
94
P
atients
38
75
89
88
76
Schlosser
,
2006
98,99
(all patients with
suspected CAD) 
50% stenosis
Segments
915
34
28
0
853
100
97
55
100Health Technology Assessment 2008; Vol. 12: No. 17
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Appendix 9
Illustrative longer term modelling
LRTN
No MI
MI
Dead
HRTP
LRTN
MRPTCA
MRCABG Revasc.
No revasc.
CABG
PTCA
MRTP
No MI
MI
Dead
HRTP
MRTP
MRPTCA
MRCABG Revasc.
No revasc.
CABG
PTCA
MRPTCA
No MI
MI
Dead
HRPTCA
MRPTCA
MRCABG
No MI
MI
Dead
HRCABG
MRCABG
HRTP
No MI
MI
Dead
HRTP
HRTP
HRPTCA
HRCABG Revasc.
No revasc.
CABG
PTCA
HRPTCA
No MI
MI
Dead
HRPTCA
HRPTCA
HRPTCA2 2nd revasc.
No revasc.
PTCA
FIGURE 19 Longer term modelling. FN, false negative; HR, high risk; LR, low risk; MR, medium risk; Rediag., rediagnosis; Revasc.,
revascularisation; TN, true negative; TP , true positive. Appendix 9
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HRCABG
No MI
MI
Dead
HRCABG
HRCABG
HRCABG 2nd revasc.
No revasc.
CABG
HRPTCA2
No MI
MI
Dead
HRPTCA2
HRPTCA2
HRCABG
No MI
MI
Dead
HRCABG
HRCABG
HRFN
No MI
MI
Dead
HRTP
HRFN
HRTP Rediag.
No rediag.
MRFN
No MI
MI
Dead
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MRFN
MRTP Rediag.
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Appendix 10
Long-term model variables 
TABLE 29 Long-term model variables
Discount rates
Costs 3.50%
Benefits 3.50%
Cohort
Cohort age 50
% Male 100%
Utilities
Low risk 0.87
Medium risk 0.81
High risk 0.67
MI –0.10
Revascularisation –0.10
Medication and other ongoing costs
Low risk £0
Medium risk £350
High risk £350
General mortality multipliers
Medium risk 2.3
High risk 3.6
Procedure mortality rates
PTCA 3.10%
CABG 0.75%
Likelihood of HR second revascularisation
From HR-PTCA 2.50%
From HR-CABG 2.50%
MI relative risk
PTCA 17.00%
CABG 40.00%
MI fatality rate
Fatal male 44.84%
Fatal female 51.08%
MI rates  Cost
Low risk 2.50% £1055
Med risk 5.00% £1055
High risk 9.00% £1055
Revascularisation rates Base PTCA CABG PTCA CABG
Low risk 5% 90.00% 10.00% £3141 £6320
Med risk 50% 61.00% 39.00% £3141 £6320
High risk 100% 10.00% 90.00% £3141 £6320
Source: Mowatt et al. (2004).113Health Technology Assessment 2008; Vol. 12: No. 17
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